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Inherited eye diseases are an important contributor to the burden of childhood 
blindness globally. These conditions are often associated with significant phenotypic 
and genetic heterogeneity and are extremely difficult to study in a general population 
setting. This thesis details the study of inherited eye diseases in genetically isolated 
populations including the North American Amish and rural Pakistani and Palestinian 
communities. Here, an enrichment of disease-causing founder mutations arising from 
common ancestry, characteristic marriage patterns and geographical isolation, 
combined with the often large family sizes typical of families in these regions, enables 
powerful genomic studies to identify pathogenic sequence variants. As well as 
providing an important opportunity to learn about the genetic causes of inherited eye 
diseases, these studies also provide desperately required healthcare benefits for the 
families and populations involved.  
 
Chapter 3 describes studies of oculocutaneous albinism (OCA) in 40 Amish and 
Pakistani families. Results from comprehensive clinical, genomic and functional 
studies, initiated by a search for the cause of OCA in a number of Amish families, 
provide strong evidence for the pathogenicity of two common TYR gene variants 
[p.(Ser192Tyr) and p.(Arg402Gln)] when inherited in cis. These variants were 
previously considered gene polymorphisms although this has been heavily debated in 
many studies, and these variants are currently variably reported and even potentially 
excluded by clinical testing laboratories. The findings reported in this thesis have 
important diagnostic implications by helping clarify the contribution of these variants 
to the OCA phenotype, and by promoting the reporting the TYR 
p.(Ser192Tyr)/p.(Arg402Gln) in cis haplotype as a pathogenic allele. This will likely 
increase the molecular diagnoses in albinism patients with missing heritability by 25-
50%. This chapter also entails a comprehensive investigation involving genetic studies 
alongside an exhaustive literature review of all published OCA genetic causes in 
Pakistani families, including cross-referencing with established genomic databases to 




Chapter 4 entails clinical and genomic findings in four families with phenotypic features 
highly suggestive of a ciliopathy disorder. Findings include identification of novel 
SCAPER and BBS5 variants, enabling a more precise definition of the SCAPER 
clinical phenotype. This work also consolidates an INPP5E c.1879C>T; p.(Gln627*) 
variant, a likely pathogenic founder alteration present in Northern Pakistan, as a cause 
of MORM syndrome.  
 
Chapter 5 documents studies of families with rare and ultra-rare inherited ocular 
diseases in Pakistani and Palestinian communities. This includes consolidating SDHD 
dysfunction as a cause of mitochondrial disease through investigations of an extended 
Palestinian family, facilitating a clearer delineation of the variable ocular (and non-
ocular) phenotypical features. Alongside this, the identification of novel and known 
variants in ALDH1A3, FYCO1, TDRD7, CYP1B1, ATOH7, LRP5, FRMD7 and HPS1 
in Pakistani communities contributes to an improved knowledge of the genetic 
spectrum and frequencies of various forms of inherited eye diseases regionally. 
 
The comprehensive OCA and BBS datasets provide notably improved knowledge, as 
well as a centralised repository, of the genetic spectrum and regional frequencies of 
the molecular causes of these conditions in the Amish and in Pakistan. Ultimately, 
these findings will greatly facilitate the establishment of robust cost-effective accurate 
diagnostic genetic testing, clinical management and counselling efforts. Together the 
work of this thesis describes data of scientific importance, and highlights the immense 
value of translational community research studies to deliver clinical benefits locally and 
globally in the field of inherited eye diseases.  
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1.1 Anatomy of the eye 
 
The eye is a highly specialised sensory organ which enables visual function through 
photoreception and phototransduction. Light from the environment is absorbed by 
specialised rod and cone photoreceptors in the retina, which converts light stimulus 
into nerve action potentials. These electrical impulses are transmitted via bipolar cells 
to ganglion cells, whose long axonal fibres converge to form the optic nerve, optic 
chiasm and optic tract. This neural information is subsequently relayed to the visual 
cortex in the brain, where it is processed and consciously appreciated as vision. Other 
structures in the eye serve to support this basic physiological process, either by 
helping to focus and transmit light to the retina, such as the cornea, lens, iris and ciliary 
body, or to nourish and support the tissues of the eye, such as the choroid, aqueous 
outflow system, and the lacrimal apparatus. 
 
In humans, the eye is roughly spherical in shape with an approximate diameter of 23 
mm. It is made up of three basic layers of tissue; the outer fibrous corneoscleral layer, 
the middle uveal layer, and the inner retinal layer (Figure 1.1). The cornea and sclera 
together form a tough fibrous envelope that protects and supports the ocular tissues. 
The sclera is opaque and provides structural support for attachment of the extraocular 
muscles, whilst anteriorly, the transparent cornea serves as the principle refracting 
medium of the eye and roughly focuses an image onto the retina. The border of the 
cornea and the sclera is known as the limbus. The middle layer, the uvea or uveal 
tract, is composed of the choroid, the ciliary body and the iris. The choroid is a thin, 
heavily pigmented, vascular connective tissue that lies between the sclera and the 
retina. It nourishes and supports the outer retinal layer, and aids vision by absorption 
of scattered light. Anteriorly, the choroid merges with the ciliary body, which is a 
circumferential thickening of the uvea lying beneath the limbus. It consists of the ciliary 
epithelium and the ciliary muscle, which are important in aqueous humour production 




The eye is divided into two segments by the ciliary body, zonules and lens. The smaller 
anterior segment is filled with aqueous humour, which is secreted by the ciliary 
epithelium, and helps maintain the intraocular pressure within the eye as well as 
providing nutrition to the avascular cornea and lens. The larger posterior segment 
contains the transparent viscoelastic vitreous gel that helps maintain the shape of the 
eye. The heavily pigmented iris lies anterior to the ciliary body and lens, and contains 
a central aperture, the pupil. The iris incompletely divides the anterior segment into 
the larger anterior chamber and the smaller posterior chamber, which communicate 
through the pupil. The contractile iris acts as an adjustable diaphragm by altering the 
pupil size, thereby regulating the amount of light reaching the retina. The crystalline 
lens is a transparent, biconvex structure that is attached to the ciliary body via radially 
arranged suspensory ligaments or zonules. Changes in the tone of the ciliary muscle 
alters the tension of the zonules, resulting in changes to the shape of the naturally 
elastic lens. This then changes the refractive power of the lens, facilitating 
accommodation by allowing the eye to focus from distant to near images. 
 
The innermost layer of the eye is the photosensitive retina, which consists of two 
primary layers, an inner neurosensory retina, and an outer retinal pigment epithelium 
(RPE). The retina terminates anteriorly behind the ciliary body in a scalloped line 
known as the ora serrata. The macula is an oval-shaped pigmented area near the 
center of the retina, and this area is responsible for central high-acuity and colour 
vision. The visual axis of the eye passes through the fovea centralis, a depression in 
the center of the macula where cone photoreceptors are concentrated at the maximum 
density to the exclusion of rod photoreceptors. The optic nerve is formed by 
convergence of retinal ganglion cell (RGC) axons at the optic disc and exits the eye 






Figure 1.1 Anatomy of the human eye 
Abbreviations: AC, anterior chamber; RPE, retinal pigment epithelium. Adapted from Koeppen 
et al (1), created with BioRender. 
 
1.2 Ocular development and malformations 
 
1.2.1 General ocular development 
 
The adult eye is a complex organ with multiple tissue components and cell types, each 
with diverse yet specific functions. The development of the eye can be empirically 
subdivided into three phases. The first phase involves induction through localised 
signalling and regional specification to form the major morphological structures of the 
eye. The second phase involves cellular differentiation and maturation of these 
structures to form the functional eye. The third phase then involves the formation of 
neuronal connections between the retina and the visual processing centre in the brain 
(2). Normal ocular development is a coordinated multi-step process that is regulated 
through a complex interaction of signalling molecules and transcription factors 
encoded for by a cascade of genes that are activated in specific cell types in a specific 
order. Vision and ocular development genes are highly conserved, suggesting similar 
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genetic developmental programs across species. One such gene is PAX6, which 
encodes a transcription factor that is a key regulator of several ocular developmental 
processes (3). The amino acid sequence of the human Pax6 protein is identical to the 
mouse protein (4) and shares 97% sequence identity to the zebrafish protein (5). 
Mutation of the PAX6 gene in humans causes aniridia, characterised by partial or 
complete absence of iris tissue (6), whilst mutations in the mouse Pax6 gene, known 
as small-eye (Sey), cause iris hypoplasia and other ocular defects similar to human 
aniridia (7). Developmental eye anomalies such as anophthalmia and microphthalmia 
can also be caused by pathogenic mutations in a number of other ocular 
developmental genes including SOX and OTX2 (8). 
 
The developing embryo consists of three germinal layers: the ectoderm, the 
mesoderm and the endoderm. The ectoderm then differentiates in the outer surface 
ectoderm and the inner neuroectoderm. Developing vertebrate embryos also have a 
multipotent stem cell population, the neural crest cells, which migrate and can 
differentiate into diverse cell types. Ocular and orbital tissues develop from the 
neuroectoderm, with contributions from the surface ectoderm, mesoderm, and 
significantly from the neural crest cells. Neural crest cells also give rise to many facial 
and skull structures, and therefore ocular and craniofacial anomalies are often seen in 
syndromes such as Goldenhar syndrome and CHARGE syndrome that arise from 
neural crest maldevelopment (9). 
 
In humans, eye development begins during gastrulation, when the eye field, or the 
eye-forming region, is induced within the anterior part of the neural plate (derived from 
neuroectoderm). The eye field later splits along the midline during neurulation, and the 
optic grooves develop, which later form the right and left optic vesicles (Figure 1.2). A 
key inductive signal in this process is the sonic hedgehog protein encoded for by the 
SHH gene, and failure of this process results in a midline defect known as 
holoprosencephaly, associated with wide ocular phenotypic variability ranging from 





Figure 1.2 Development of the optic vesicles 
(A) Transverse section through developing forebrain at day 22 showing development of the 
optic grooves.  
(B) Transverse section through developing forebrain at week 4; contact between the 
neuroepithelium of the optic vesicles and the surface ectoderm induces the formation of the 
lens placode.  
Adapted from Lamb (11). 
 
The optic vesicles interact with and induce the overlying surface ectoderm to thicken 
into the lens placode. The distal part of the optic vesicle then invaginates, forming a 
bilayered optic cup. The inner layer of the optic cup will form the neural retina, whilst 
the outer layer differentiates into the RPE (Figure 1.3). Invagination of the optic cup 
occurs asymmetrically, with a groove, the optic fissure, developing from the ventral 
side of the optic cup into the optic stalk. This fissure facilitates the entry of hyaloid 
vessels that supply nutrients to the inner layer of the optic cup and the lens vesicle 
during ocular development. Closure of this fissure occurs around week 5 of gestation, 
and starts in the centre of the fissure, before “zipping up” both anteriorly and 
posteriorly. The optic fissure closes by week 6, establishing the basic structure of the 
eye; incomplete closure results in a coloboma, an ocular malformation that can affect 
one or several structures in the eye including the iris, choroid, retina or optic disc. 
Colobomas are most commonly located in the inferonasal quadrant of the eye, which 





Figure 1.3 Development of the lens vesicle and optic cup 
(A) Development of the optic vesicle and localised thickening of the surface ectoderm to form 
of the lens placode.  
(B) Invagination of the lens vesicle into the optic cup. 
(C) Lens pit deepens and detaches from the ectoderm to form a lens vesicle; invagination of 
the optic vesicle forms a bilayered optic cup which will eventually develop into the neural retina 
and retinal pigment epithelium (RPE) layers of the retina. Adapted from Erskine et al (13) 
 
In parallel to the development of the optic cup, the lens placode invaginates into the 
optic cup, forming a shallow depression known as the lens pit. The lens pit deepens, 
closes anteriorly and detaches from the surface ectoderm, forming the lens vesicle 
(Figure 1.3). Delayed or incomplete separation of the lens vesicle from the surface 
ectoderm can result in an ocular malformation known as Peters anomaly, associated 
with central or paracentral corneal opacities (leukoma), absence of the adjacent 
posterior corneal stroma, corneal endothelium and descemet’s membrane, and a 
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variable degree of iris and lenticular adhesions to the posterior cornea. Most cases of 
Peters anomaly are sporadic without an identified genetic cause, although some cases 
have been associated with mutations in MAF, FOXC1, FOXE3, PITX2 and PAX6 (14). 
 
As the optic vesicles extend outward, their proximal attachment to the developing 
forebrain becomes the optic stalk. Growth of RGC axons into the optic stalk in week 7 
leads to the formation of the optic nerve, connecting the eye with the visual centres of 
the brain (12). 
 
1.2.2 Development of the lens 
 
The lens vesicle is a symmetrical unicellular epithelial structure that is almost spherical 
in shape, and surrounded by a basal lamina layer that will eventually form the lens 
capsule. Growth factors from the developing neural retina induce the posterior cells of 
the lens vesicle to elongate, forming the primary lens fibres. The base of each 
elongating lens cell remains anchored to the basal lamina posteriorly, whilst their 
apices grow anteriorly, thereby filling the central cavity of the lens vesicle. The anterior 
lens epithelial cells migrate from the central to the equatorial regions of the lens 
vesicle, where they undergo mitosis and differentiate to form secondary lens fibres. 
These surround the primary lens fibres in concentric layers in a process that continues 
into adulthood, resulting in an ellipsoid-shaped lens. Differentiated lens fibre cells no 
longer contain nuclei or mitochondria, and accumulate specialised proteins known as 
crystallins, leading to lens transparency.  
 
Lens development is a complex and delicate process and susceptible to disruption, 
resulting in congenital lens opacities or cataracts. Over half of all congenital cataracts 
are idiopathic (15); identified causes of congenital cataracts include genetic 
aetiologies, intrauterine infections and teratogen exposure. Congenital cataracts due 
to genetic aetiologies can be isolated (with autosomal dominant, autosomal recessive 
and X-linked inheritance patterns described), associated with other ocular anomalies 
such as aniridia, anterior segment dysgenesis, persistent foetal vasculature, and 
posterior lenticonus, or associated with a number of chromosomal abnormalities, 
genetic syndromes or metabolic diseases (16). Inherited congenital cataracts have 
been associated with pathogenic variants in genes encoding lens proteins including 
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crystallins (CRYAA, CRYAB, CRYBA1, CRYBA2, CRYBA4, CRYBB1, CRYBB2, 
CRYBB3, CRYGB, CRYGC, CRYGD and CRYGS), cytoskeletal structural proteins 
(BFSP1 and BFSP2) and membrane proteins (GJA3, GJA8, MIP, LIM2, EPHA2, and 
DNMBP), as well as the transcription factors FOXE3, PITX3, HSF4 and MAF (17).  
 
1.2.3 Development of the cornea, iris and ciliary body 
 
After separation of the lens vesicle, the surface ectoderm reforms. The underlying lens 
vesicle then induces the overlying surface ectoderm to differentiate into the corneal 
epithelium. Neural crest cells migrate to this region in three waves. The first wave of 
cells migrate into the space between the surface ectoderm and the anterior surface of 
the lens and give rise to the corneal endothelium and trabecular meshwork. A second 
wave of cells then migrates between the corneal epithelium and endothelium to form 
the corneal stroma. Later, a third wave of cells migrate to the space between the 
corneal endothelium and the anterior edge of the optic cup, contributing to the ciliary 
body and iris stroma (18). The iris and ciliary body also develop from the margins of 
the optic cup under inductive influences from the developing lens, with the optic cup 
margin ultimately forming the pupil margin.  
 
FOXC1 and PITX2 are genes that encode transcription factors with critical roles in 
regulating the process of neural crest cell migration in the developing eye. Both Foxc1 
and Pitx2 are co-expressed in periocular mesenchyme (derived from neural crest cells 
and mesoderm mesenchyme) in the developing mouse eye, and physically interact 
through crucial functional domains (19). In humans, mutations in FOXC1 or PITX2 
cause Axenfeld-Rieger syndrome, an autosomal dominant disorder characterised by 
anterior segment dysgenesis and systemic abnormalities. Ocular features of Axenfeld-
Rieger syndrome mainly affect the iris, cornea and anterior chamber angle, structures 
that are derived from the periocular mesenchyme, and include iris hypoplasia, 
corectopia, polycoria, posterior embryotoxon, and iris strands connecting the 





1.2.4 Development of the retina and RPE  
 
All retinal tissues develop from the bilayered optic cup, with the neural retina 
developing from the inner layer of the optic cup, whilst the outer layer forms the RPE. 
As a result of the invagination process, the apical surface of the neural retina lies 
adjacent to the apical surface of the RPE, with a potential space between the two 
layers derived from the cavity of the optic cup; this intra-retinal space later disappears 
as the two layers fuse. There are no real anatomic junctions formed between the cells 
in apposition in the two layers (photoreceptors of the neural retinal and RPE cells) 
(21). Therefore, whilst this interaction between the layers is crucial for the functional 
maintenance of the photoreceptors, the attachment between layers remains weak, and 
can be overcome by a number of mechanisms, resulting in a retinal detachment and 
re-establishment of the potential intraretinal space between these two layers. 
 
Differentiation of the retinal layers and cell types proceeds in a highly regulated 
manner, starting at the posterior pole and proceeding peripherally in a concentric 
manner; a gradient of retinal differentiation can therefore be seen within an individual 
eye. Retinal vasculature follows the same concentric pattern of development, arising 
from the hyaloid circulation at the optic disc and spreading peripherally, first reaching 
the nasal periphery at 8 months gestation, whilst the temporal periphery is not 
completely vascularised till shortly after birth at full term. As such, temporal retinal 
vascularisation may not be fully developed in premature infants, explaining the greater 
susceptibility of the temporal retina to retinopathy of prematurity, a retinal 
vasoproliferative disorder affecting premature neonates (22). Congenital anomalies in 
retinal vascular development are also associated with inherited ocular diseases such 
as familial exudative vitreoretinopathy (FEVR), characterised by incomplete 
vascularisation of the peripheral retina and poor vascular differentiation, which can 
lead to complications such as the development of fibrovascular membranes resulting 
in vitreoretinal traction, retinal folds and retinal detachment, and potentially profound 
vision loss. Mutations in at least 10 genes have been associated with the FEVR 
phenotype including NDP, FZD4, LRP5, TSPAN12, ZNF408, CTNNB1, KIF11, 
RCBTB1, JAG1 and ATOH7 (23, 24); of these, NDP, FZD4, LRP5 and TSPAN12 have 
been shown to play a role in the Norrin/Frizzled4 signalling pathway, suggesting a 




The primitive neural retina consists of two zones, an inner non-nucleated ‘marginal 
zone’ and an outer nucleated ‘primitive zone’. At around week 7 of gestation, newly 
formed cells from the mitotically active primitive zone migrate into the marginal zone 
to form the inner neuroblastic layer; the outer nucleated zone is now known as the 
outer neuroblastic layer. The inner neuroblastic layer eventually gives rise to the Müller 
cells, ganglion cells and amacrine cells, whilst the outer neuroblastic layer gives rise 
to bipolar cells, horizontal cells and primitive photoreceptor cells. The inner and outer 
neuroblastic layers are surrounded by the internal and external limiting membranes 
respectively, which form when the cells within these layers cease to proliferate and 
start differentiating. Lamination of the neural retina occurs at approximately 8-12 
weeks of gestation, with ganglion cells being the first cells to differentiate. Later, Müller 
cells, amacrine cells, bipolar cells, horizontal cells, and photoreceptors are formed, 
and their cell bodies and synaptic connections contribute to the nuclear and plexiform 
layers seen in the familiar 10-layered retinal structure (Figure 1.4).  
 
Each retinal cell type is not determined by an invariant cell lineage, instead, each 
retinal progenitor cell appears to have the potential to form any of the mature retinal 
neurons or glial cell types (25). This neural retinal development is driven by 
overlapping cascades of genetic programs that help determine cell lineages and 
commitment to specific cell fates, regulated by the temporal and spatial expression of 
transcription factors in the retina encoded by three major groups of genes; the basic 
helix-loop-helix (bHLH), the forkhead box (FOX) and the homeobox genes (26). 
Variants in retina-specific transcription factors such as NR2E3 are associated with 
primary retinal disorders (27), whilst variants in more widely expressed transcription 
factors can result in systemic disorders with ocular manifestations; for example, 
variants in NEUROD1, a bHLH transcription factor that functions in brain and pancreas 







Figure 1.4 Cell types and histologic layers in the adult human retina 
The internal limiting membrane (ILM) is the innermost boundary of the retina and is formed by 
the footplates of the Müller cells. The retinal nerve fibre layer (RNFL) is formed by the axons 
of the ganglion cells, whilst the ganglion cell layer (GCL) contains ganglion cell nuclei. The 
inner plexiform layer (IPL) is made up of the neuronal processes and synapses of bipolar, 
ganglion and amacrine cells, whilst the outer plexiform layer (OPL) is composed of the 
interconnections between the photoreceptor synaptic bodies and the horizontal and bipolar 
cells. The inner nuclear layer (INL) contains bipolar, amacrine, horizontal and Müller cell 
nuclei, whilst the outer nuclear layer (ONL) contains the cell bodies of the rod and cone 
photoreceptors. The external limiting membrane (ELM) is the outermost layer of the 
neurosensory retina; it is formed by the attachment sites of adjacent photoreceptors and Müller 
cells, and separates the photoreceptor inner segments and cell nuclei. The photoreceptor 
layer (PL) contains the inner and outer segments of the rod and cone photoreceptors. The 
retinal pigment epithelium (RPE) consists of a single layer of pigmented epithelial cells. 
Adapted from Koeppen et al (1), created with BioRender 
 
Photoreceptors arise from the outermost cells of the primitive neural retina. Cone 
photoreceptors develop first, followed by rod photoreceptors. The outer segments of 
photoreceptors, which are actually modified ciliated processes, consist of stacks of 
membranous discs containing opsin, a visual pigment that is key to initiation of the 
phototransduction cascade. These outer segments are in close contact with the RPE. 
Mutations in NRL and CRX, which encode transcription factors that regulate 
photoreceptor differentiation during retinal development, have been shown to retinal 




Development of the macula differs from the rest of the retina. The macula is first 
evident as a localised increase in ganglion cell density temporal to the optic disc. This 
is later followed by displacement of the ganglion cells and the formation of an area of 
localised thinning, the foveal depression. The foveal structure is still immature at birth, 
and it can take up to 15 - 45 months post-partum for the fovea to reach full histological 
maturity, where the inner nuclear and ganglion cell layers have receded to the margins 
of the fovea, leaving only densely packed cone photoreceptors in the foveal region 
(31). 
 
At birth, the ganglion cell layer at the fovea is still a single cell thick; in fact, full macula 
development is not complete till 4 months postpartum. In foveal hypoplasia, the fovea 
appears to be poorly developed or absent. This feature in isolation is rare, and is 
usually described in association with other ocular disorders such as albinism, aniridia, 
microphthalmia, retinopathy of prematurity, achromatopsia, optic nerve hypoplasia, 
FEVR and Stickler syndrome (32, 33). Studies of inherited disease phenotypes 
associated with foveal hypoplasia have identified a number of genes and molecular 
pathways critical for normal foveal development, including the PAX6 transcription 
factor and members of the Wnt signaling pathway (FZD4 and NDP) (34).  
 
The RPE develops from the outer layer of the optic cup, and is initially comprised of a 
single layer of ciliated pseudostratified columnar epithelial cells; the cilia later 
disappear as melanogenesis commences. The basement membrane of the RPE forms 
one of the five layers of the Bruch’s membrane, and tight junctions between the retinal 




1.2.5 Development of vitreous and hyaloid system  
 
The vitreous develops in the space between the inner layer of the optic cup and the 
lens vesicle in three distinct stages. At 5 weeks gestation, the lentoretinal space is 
occupied by the primary vitreous. This is derived from mesenchymal cells that have 
entered the optic cup via the optic fissure, as well as from lens surface ectoderm cells 
and neuroectoderm cells from the inner layer of the optic cup (35). The hyaloid artery, 
which is a branch of the primitive ophthalmic artery, enters the optic cup via the optic 
fissure and courses through the primary vitreous to reach the posterior lens surface, 
where it branches to form a network of capillaries, the tunica vasculosa lentis.  
 
The secondary vitreous is derived entirely from the neuroectoderm, and is composed 
of fine, organised fibrillary material (35). It is initially deposited at the posterior pole 
behind the primary vitreous, later extending to envelop the entire primary vitreous. 
Tertiary vitreous refers to a phase of development around the end of the third month, 
where distinct condensations of the secondary vitreous become evident at the lens 
equator, associated with the formation of lens zonules, and become firmly attached to 
the inner limiting membrane of the retina in the developing pars plana region, forming 
the vitreous base. The tertiary vitreous and zonular fibres are actually thought to be 
produced by the neuroectoderm of the developing ciliary body (35). 
 
During the 4th month of gestation, regression of the primary vitreous, the hyaloid 
vessels, and the tunica vasculosa lentis occurs. The course of the regressing hyaloid 
artery is evident in the adult vitreous as Cloquet’s canal, a narrow, fluid-filled central 
channel that extends from the optic disc posteriorly to the region of the degenerating 
tunica vasculosa lentis anteriorly. Failure of the hyaloid system to regress can result 
in developmental abnormalities of the vitreous such as a Mittendorf dot, Bergmeister’s 
papilla, persistent hyaloid artery, and persistent fetal vasculature (previously known as 
persistent hyperplastic primary vitreous) (35). The adult vitreous is a specialised 
extracellular matrix composed of hyaluronan, the major macromolecule, interwoven 
with collagen fibrils (composed of collagen types II, IX, and V/XI) (36). As such, 
inherited diseases resulting from mutations in genes affecting collagen or hyaluronan 
function, such Marfan syndrome (FBN1), Ehlers-Danlos syndrome (COL1A1, 
COL1A2, COL5A1 and COL5A2), Stickler syndrome (COL2A1, COL9A1, COL11A1), 
29 
 
Knobloch syndrome (COL18A1), Wagner syndrome (VCAN) and HYAL2 syndrome 
(HYAL2), also often display ocular features associated with vitreoretinal degeneration, 
including vitreous syneresis, vitreous traction, high myopia and retinal detachment (37, 
38).  
 
1.3 Genetic studies in communities 
 
The field of community genetics or genomics can be defined as “the art (application) 
and science (research) of the responsible and realistic application of health and 
disease-related genetics and genomics knowledge and technologies in human 
populations and communities to the benefit of individuals therein” (39). Communities 
can be defined by their geographical location, ethnic origins, or by their cultural, 
religious or socio-economic characteristics. Community genetics aims to bring about 
clinical benefits to individuals and families affected by genetic diseases, as well as to 
locate individuals within the wider community who may also be at risk of the same 
inherited conditions. Communities also benefit through liaison with support 
organisations and health authorities to ensure delivery of up-to-date genetic 
counselling, screening and clinical care to affected individuals.  
 
Our research team has established collaborations with scientists and healthcare 
professionals in several communities globally. There is a strong emphasis on 
translating the scientific insights arising from our research studies into improved 
healthcare outcomes for communities as well as affected individuals globally through 
new therapies and diagnostic strategies as well as refinement of genomic healthcare 
policy. This thesis focuses on inherited eye diseases in affected families from Amish, 
Pakistan and Palestinian communities. 
 
1.3.1 The Amish and Anabaptist communities 
 
The Amish are a distinct group of traditional rural-living Anabaptist Christians, known 
for their simple living, plain dress and separation from modern technologies and 
conveniences, whose roots can be traced back to the Protestant Reformation in 16th 
century Europe. One group of reformers, the Anabaptists, rejected infant baptism, 
believing instead that only adults who had confessed their faith should be baptised (or 
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re-baptised). They also advocated for separation of church and state. Due to these 
beliefs, Anabaptist groups were severely persecuted throughout Europe, with many 
fleeing to the mountains of Switzerland and southern Germany.  
 
One of the church leaders, a Swiss bishop named Jakob Ammann, sought to revitalise 
the Anabaptist movement by suggesting reforms of church practices that enforced 
closer links between church discipline and social practices. Amman proposed holding 
communion twice a year rather than once, as was the typical Swiss practice, and 
suggested that Christians, in obedience to Christ, should wash another’s feet in the 
communion service. To promote doctrinal purity and spiritual discipline, Ammann 
forbade the trimming of beards and the wearing of fashionable dress, teaching that 
church members should dress in a uniform manner. He also believed in a stricter 
interpretation of the doctrine of shunning or “Meidung”, a practice based on the New 
Testament command not to associate with a church member who was not repentful of 
his sinful conduct. Ammann taught that if a member of the church was 
excommunicated because of an unrepented sin, they should be completely shunned 
or avoided by all church members, including refusal of goods from the offending 
individual or refusing to share a meal with them. This practice was not intended to be 
a punishment but was instead meant as a lesson to help the individual realise the error 
of his ways and to seek forgiveness.  
 
These beliefs however caused a schism between Ammann’s followers and the other 
Anabaptists in Switzerland and Alsace, leading to an eventual split from the group in 
1693. Ammann’s followers were first called the “Amman-ish” group, later becoming 
known as the Amish. 
 
The Amish first began emigrating to North America in the early 18th century to escape 
persecution in Europe for their religious beliefs. The Amish had largely been landless 
tenant farmers in Europe, so the chance to own their own land was also an attractive 
proposition. They first settled near Lancaster County in Pennsylvania (“Penn’s 
woods”), attracted by the promise of religious freedom as part of William Penn’s “Holy 
Experiment” of religious tolerance, where a large community remains today. The first 
wave of Amish migration to the state was between 1736 and 1770 and comprised 




A second wave of Amish immigrants estimated to be around 3000 in number, occurred 
between 1815-1860. Compulsory military service was becoming commonplace in 
Europe, and this combined with the economic opportunities in North America, was a 
strong driving force to leave Europe and seek a new life in the “New World”. These 
Amish immigrants settled in new areas outside Pennsylvania, including Ohio, Indiana, 
Iowa and Illinois. The last Amish settlement in Europe disappeared in 1937; none 
remain in Europe today. 
 
Today, the Amish are found in 31 states in North America, the Canadian provinces of 
Manitoba, New Brunswick, Ontario, and Prince Edward Island, and the South 
American countries of Argentina and Bolivia. Nearly two-thirds still live in the three 
states where the first Amish settlements were established; Pennsylvania, Ohio and 
Indiana (40). All Amish people share common beliefs and practices, including adult 
baptism, non-violence, lay ministers, small local congregations with services held in 
the homes of members with no formal religious buildings, rural living and separation 
from the outside world, education only up to eighth grade, church-regulated and 
traditional plain style of dress, selective use of technology, use of horse-drawn 
transportation and speaking a German-derived dialect (41). There are however around 
40 different Amish affiliations, each comprising groups of church districts united by 
social and religious practices, differing with regards to types of dress, rules about 
technology and restrictions on participating in American society. 
 
Founder effect and inherited diseases in the Amish 
 
There is unfortunately a higher incidence of specific autosomal recessive genetic 
disorders, such as hereditary spastic paraplegia (42) and Ellis-van Creveld syndrome 
(a form of dwarfism) (43), among the Amish compared to the general population due 
to a phenomenon known as the “founder effect”. This refers to a loss of genetic 
variation that occurs when a new population is established by a very small number of 
individuals, or founders, from a larger population (Figure 1.5). Rare, recessive 
disease-causing mutations, if present in unaffected carrier, may then accumulate and 
become enriched in the population as it expands over subsequent generations, 
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leading to an increased frequency of certain otherwise rare autosomal recessive 




Figure 1.5 Ancestral bottleneck leading to founder effect 
 
The modern Amish community in America is descended from the few hundred 
German-Swiss settlers who immigrated to the United States in the 18th century, many 
of whom were already part of related family groups. This limited number of ancestors 
founded a rapidly expanding Amish population, now estimated to number >350,000 in 
North America (40). One of the driving forces behind this population growth is 
attributed to large family sizes, with an average of 7-9 children per family. The Amish 
tend to have limited geographical mobility due to their religious constraints on 
transportation, and they tend to observe strict endogamy, marrying only within the 
community, with little or no migration into the community. This geographical and 
sociological isolation further contributes to the unique genetic distinctiveness of the 
Amish, providing a unique opportunity for the study of rare inherited disorders and 
identification of causative disease genes (45). 
 
Genetic studies in the Amish are also aided by cultural and demographic 
characteristics of the community. The Amish keep extensive historical and 
genealogical records, enabling the construction of comprehensive family pedigrees. 
Large nuclear families (with low rates of non-paternity) are common, with a number of 
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unaffected as well as affected siblings with the same condition within each family, 
facilitating genetic analyses for identification of the causal disease variant. The impact 
of environmental factors on the expression of genetic diseases is minimised by the 
high standards of living, homogeneous lifestyles, and uniform socio-economic and 
occupational circumstances. Standards of medical care are relatively high, with 
extensive availability of medical records. The Amish also show an interest in illness 
and in the health of their relatives, with extensive sharing of health issues both locally 
and through publications such as “The Budget” newspaper, creating networks of 
knowledge about individuals with health problems. They also frequently provide home-
based care for children with birth defects or genetic disorders instead of 
institutionalisation (46-48). Whilst studies of rare inherited diseases in modern diverse 
populations are hampered by small numbers of affected individuals and genetic and 
environmental complexities, these factors enhance the visibility of genetic disorders 
within the Amish communities, greatly facilitating the discovery of genes responsible 
for these inherited conditions. 
 
Studies of inherited disorders present in the Amish were first undertaken in 1962 by 
the world-renowned geneticist Victor McKusick. These studies were inspired by an 
article written by a local family doctor, David Krusen, mentioning the frequent 
occurrence of achondroplasia among the Amish, as well as a manuscript entitled 
“Amish Society” by John Hostetler, which highlighted several characteristics of the 
Amish community that were advantageous to the study of genetic traits (47). The early 
studies on dwarfism in the Amish led to the recognition that the majority did not in fact 
have achondroplasia, and this instead led to the description of two separate forms of 
autosomal recessive dwarfism within the community; Ellis‐van Creveld syndrome, a 
previously recognised disorder, as well as cartilage-hair hypoplasia, a new form of 
metaphyseal chondrodysplasia (47).  
 
Over the next few decades, McKusick and his colleagues published over 30 reports of 
genetic disorders among the Amish (49). The work of McKusick led to the development 
and publication of the Mendelian inheritance in Man (MIM), first published in print as 
a trilogy of catalogues containing overviews of genes and genetic phenotypes for 
autosomal dominant, autosomal recessive and X-linked conditions (50). Print editions 
have since been superseded by an online version, the Online Mendelian of Inheritance 
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in Man or OMIM, providing a comprehensive and authoritative compendium of human 
genes and genetic phenotypes that is updated daily, and is a frequently used and 
invaluable resource in the field of medical genetics (51).  
 
The Amish are surprisingly open to participation in genetic studies, and this receptivity 
may stem from the initial approaches by physicians and geneticists who were 
genuinely interested in helping affected individuals in the community. For instance, in 
patients with Ellis‐van Creveld syndrome, arrangements were made for surgical repair 
of the associated cardiac defects and for orthopaedic correction of knee deformities. 
Researchers working with the community have also reported a willingness for families 
to participate in studies, even when their affected children may not necessarily benefit, 
because of the potential benefit to others, reflecting their generous and altruistic 
nature. 
 
The higher incidence of rare inherited disorders among the Amish places a significant 
social and financial burden on this community. Whilst community schemes are 
available to help with medical expenses, the rising costs of medical care means that 
many families experience difficulties in obtaining clinical investigations and treatments. 
The Windows of Hope (WoH) Project was established in 2000, and is a non-profit 
translational community genomics research program led by Professor Andrew Crosby 
and Dr Emma Baple (research supervisors). It aims to determine the clinical and 
molecular spectrum of inherited diseases within the Amish and other Anabaptist 
communities by facilitating collaborations between clinical specialities as well as 
research and diagnostic genomic laboratories. The project has assisted in the 
identification and description of the underlying genetic cause in a large number of 
inherited disorders, including 18 novel conditions amongst the Amish and Anabaptist 
communities. These findings have allowed numerous families to receive much-needed 
diagnoses for previously unrecognised conditions, leading to an improved 
understanding of the clinical course and associated features, thereby facilitating 
improved clinical and developmental outcomes for the affected individuals through 
early medical intervention and social support. 
 
To date, researchers have described over 250 separate genetic disorders among the 
Amish and other Anabaptist communities, collated into several community-specific 
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databases (52) (WoH Project Database, viewed at https://wohproject.com/). These 
include conditions that are completely new to medical science, and although a few 
disorders are unique to the Amish so far, most disease genes initially identified in the 
Amish have subsequently been shown to cause similar diseases in other populations 
worldwide, highlighting the global importance and relevance of studying inherited 
conditions in genetic isolates such as the Amish. There are also rare genetic disorders 
described in very small numbers of affected individuals identified in modern diverse 
populations, but present at increased frequency in the Amish communities due to an 
enrichment of disease-causing mutations. The larger numbers of affected individuals 
within the Amish communities facilitates the study of these rare genetic disorders, and 
may illuminate otherwise obscure biochemical pathways and enable a more 
comprehensive understanding of physiologic processes in human health and disease. 
This enhanced knowledge of the genetic and molecular mechanisms underpinning 
human disease may in turn lead to the development of new treatment strategies, 
thereby benefiting affected individuals worldwide. The increased numbers of affected 
individuals with a disease in a community also facilitates clinical studies to determine 
the clinical minutia of a condition, and to assess the efficacy of potential treatments as 
they are developed. 
 
1.3.2 Inherited diseases in Pakistan 
 
Pakistan is the 5th most populous country in the world, with a population exceeding 
216 million (53), and is comprised of four provinces (Punjab, Khyber-Pakhtunkhuwa 
or KPK, Sindh and Balochistan) and three territories (Islamabad Capital Territory, 
Gilgit-Baltistan and Azad Kashmir). The population of Pakistan is ethnically and 
linguistically diverse, with around 18 ethnicities (based on historical lineage, 
geographical origin, language and cultural practices) and over 60 spoken dialects (54). 
The major ethnic groups are Punjabi and Pashtun (also known as Pathan) in northern 
Pakistan and Sindhi, Saraiki, Muhajirs (the immigrants from India, mostly Urdu-
speaking) and Baloch in southern Pakistan (55). Social stratification is strongly based 
on ethnic and tribal groupings, with tribal groupings based on the biraderi or 
‘brotherhood’ system, a patrilineal kinship that transcends geographical boundaries 




There is a strong preference for endogamous marriage in Pakistan, where it is 
estimated that 40-60% of all marriages occur among relatives, particularly between 
first and second cousins (54, 55, 57). This arises in part due to the clan-orientated 
nature of the society, which values similarities in social group identity based on 
religion, ethnicity and tribal/clan affiliation (54). Cultural preferences for 
consanguineous marriages include the belief that the marriage will be more stable and 
secure with high fertility and lower divorce rates. There might already be existing family 
relationships between partners who are likely to have similar socioeconomic status 
and family customs, and there are financial benefits such as strengthening of the 
family business and maintenance of property within the family (55, 58). Most marriages 
still occur within the biraderi, with inter-biraderi marriages rare due to social 
stratification and limited social mixing (56). The frequency of autosomal recessive 
disorders is higher in populations with a high degree of endogamy, with Pakistan 
having one of the highest rates of genetic disorders in the world (59). The high rates 
of traditional intra-familial marriages, strong socio-cultural and ethnic divides, and 
geographical barriers and isolation has led to numerous genetically distinct 
communities, where there may be a high prevalence of specific inherited disorders 
due to the accumulation of regional founder variants (60, 61). These founder mutations 
often represent important causes of disease in a particular region, and knowledge of 
their presence, frequency and clinical outcomes will lead to enhanced knowledge of 
the genomic architecture of inherited diseases in Pakistan. This knowledge is of 
enormous value for local healthcare resource planning and will facilitate the design of 
community-specific hierarchical strategies for cost-effective genetic testing arrays to 
enable an accurate disease diagnosis to be achieved more rapidly, thus aiding the 
development of diagnostic and clinical care pathways and policies throughout Pakistan 
(59). This has led to the early development of specific genomic databases correlating 
disease mutation with clinical phenotype, geographic localisation and ethnicity or tribal 
affiliation within Pakistan (57). 
 
1.3.3 Inherited diseases in Palestine  
 
The Palestinians are a group of people who either live in, or originate from, historical 
Palestine, which formed the land bridge between the continents of Europe, Asia and 
Africa. Control of the region is strategic, and it remains one of the most contested 
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regions of the world today. Creation of the state of Israel in 1948 resulted in a 
displacement of a large proportion of the Palestinian Arab population, mainly to the 
West Bank and Gaza, but also to neighbouring Arab countries including Jordan, 
Lebanon and Syria. The Oslo accord of 1993 subsequently resulted in the 
establishment of Palestinian autonomy in the Occupied Palestinian Territories of the 
West Bank and Gaza. The global Palestinian population is now estimated to be 13.4 
million, with the Palestinian diaspora numbering 6.7 million; 5.0 million in the Occupied 
Palestinian Territories, and 1.6 million in Israel (62). The majority of Palestinian Arabs 
are Muslims (over 80%); other religious communities are smaller and include 
Christians and the Duze (63). 
 
Most of the Palestinian Arabs in Israel and in the territories under the Palestinian 
Authority live in villages or tribes that were founded by only a few individuals. With 
many Palestinians having large families (in 1993, the average number of offspring per 
woman in the West Bank and Gaza was 7.8) (64), there has been a natural expansion 
of the Arab population. Consanguineous marriages are common among the 
Palestinian Arab population, with over 40% of marriages occurring between relatives, 
and of these approximately half are between first cousins, most often involving children 
of brothers (65). Middle Eastern societies, and in particular the rural Arab populations, 
are characterised by close family relationships, and the preference for marrying 
relatives is a deeply rooted cultural trait. Although there appears to be evidence for a 
declining trend in consanguineous marriages amongst Palestinian Arabs (66-68), they 
remain prevalent within this population due to a number of political, economic and 
social factors that favour such marriages. Each village or tribe can therefore be 
considered a genetic isolate, where autosomal recessive diseases are relatively 
frequent, as the introduction of a new recessive mutation can lead to a relatively rapid 
appearance of several affected individuals in only a few generations. Whilst some 
inherited disorders such as thalassaemia and familial Mediterranean fever are 
prevalent throughout the Palestinian Arab population (69), the distribution of 
autosomal recessive diseases in general is not uniform, with many rare inherited 
diseases, including some novel diseases, specific to a single tribe or village due to this 
local founder effect (63). Inherited diseases are an important cause of childhood 
morbidity and mortality in these communities, however, particularly in the rural 
Palestinian areas, families often do not have access to advanced medical diagnostics 
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or assessment by trained specialists, and an accurate clinical diagnosis is often 
difficult to establish. A detailed knowledge of the distribution of genetic diseases in 
each village can therefore enable appropriate medical management as well as genetic 
counselling to be provided within the community (69). 
 
1.4 Inherited eye diseases 
 
Inherited eye diseases refer to a clinically and genetically heterogeneous group of 
disorders that can affect the structure and/or function of one or several structures of 
the eye, such as the cornea, anterior segment, lens or retina.  
 
A large number of inherited eye disorders have been identified; these include 
conditions limited to the eye, as well as complex disorders such as chromosomal 
abnormalities or genetic syndromes with ocular manifestations that are associated 
with other systemic anomalies such as hearing impairment, learning disability or 
neurological deficits. The eye is an organ that is easily accessible for examination, and 
can provide a diagnostic window for wider systemic diseases; examples include the 
cherry red spot seen in Tay-Sachs and Sandhoff disease, angioid streaks in 
pseudoxanthoma elasticum, the iridescent “Christmas tree” cataract in myotonic 
dystrophy, lens subluxation in Marfan syndrome and homocystinuria, or the whorl-like 
corneal opacities or corneal verticillata seen in Fabry disease. Whilst inherited eye 
diseases are rare individually, together they contribute significantly to the burden of 
visual impairment and blindness. 
 
Visual impairment is a major public health problem worldwide, with the World Health 
Organisation (WHO) estimating that in 2010, there were 285 million people globally of 
all ages who were visually impaired, of whom 39 million were blind (70) [according to 
the International Classification of Diseases Update and Revision 2006, visual 
impairment is classified as a visual acuity of less than 6/18, whilst a visual acuity of 
less than 3/60 would be classified as blindness (Snellen values) (71)]. In response to 
this global need, the WHO, in collaboration with the International Agency for the 
Prevention of Blindness (IAPB), launched the VISION 2020: The Right to Sight global 
initiative, aiming to eliminate avoidable blindness in the world by the year 2020, with 




Inherited eye diseases contribute significantly to the burden of childhood blindness, 
accounting for approximately 40-50% of all childhood blindness in industrialised 
countries and 20-30% in developing nations (although this likely represents an 
underestimate due to poor clinical facilities and access in some regions) (73). Globally, 
the main inherited eye diseases that cause visual impairment are retinal dystrophies, 
corneal dystrophies, congenital and juvenile cataracts, aniridia and albinism (74). In 
the UK, inherited eye diseases account for a third of all children with severe visual 
impairment or blindness, with retinal dystrophies, microphthalmia/anophthalmia, 
nystagmus and albinism being important hereditary causes (75, 76). Hereditary retinal 
disorders are the most common cause of certifiable visual impairment in working age 
adults (accounting for a fifth of certifications in this age group) (77), and the third most 
common cause of certifiable visual impairment overall in the UK (78). 
 
Blindness is a major disability that impacts on the physical, mental and social health 
of affected individuals, and places a significant emotional and financial burden on 
affected families and the wider community. As individuals with isolated inherited eye 
diseases often develop visual impairment at a young age and have a normal life 
expectancy, these conditions are associated with significant morbidity and socio-
economic impact. Childhood blindness is a particularly significant problem in 
developing countries because many families to not have adequate access to 
healthcare and ophthalmic services due to a lack of infrastructure, resources and 
funding in some regions.  
 
Establishing a precise clinical and molecular diagnosis in individuals with inherited eye 
diseases usually involves a thorough clinical examination to delineate the ocular 
phenotype and establish the presence or absence of any associated systemic 
features, a genetic workup including pedigree construction to show medical histories 
and genetic relationships within a family that might suggest a possible mode of 
inheritance, followed by chromosomal or molecular analysis to try identify the 
underlying genetic aetiology. An accurate disease diagnosis can bring about many 
important benefits for both patients and their families. It improves understanding of the 
disease which aids clinical management decisions and provides useful prognostic 
information for affected families. It can highlight the need for periodic screening to 
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enable early diagnosis or facilitate early treatment to prevent visual morbidity, such as 
prophylactic laser or cryotherapy treatment to prevent retinal detachment in individuals 
with Stickler syndrome (79). An accurate molecular diagnosis enables informed 
genetic counselling about the medical implications for the affected individual and 
members of the wider family, and it may provide advice on recurrence risk crucial for 
couples who wish to have more children. Determination of carrier status may provide 
reassurance that the risk of having affected children is low, or it may highlight a need 
for prenatal diagnostic evaluation and follow-up.  
 
Determining the underlying genetic diagnosis in inherited eye diseases however is 
often challenging due to the phenotypic and genetic heterogeneity of these conditions. 
For instance, pleiotropic disorders such as Bardet-Biedl syndrome (BBS) can create 
diagnostic difficulties due to the multiple, seemingly unrelated phenotypic 
manifestations of the disease (80). Some inherited eye diseases such as inherited 
retinal dystrophies demonstrate remarkable genetic heterogeneity with overlapping 
clinical phenotypes; to date there are over 271 disease-associated genes (RetNet 
https://sph.uth.edu/retnet/, accessed 28.04.2021), spanning the entire spectrum of 
Mendelian (autosomal dominant, autosomal recessive and X-linked) and non-
Mendelian (mitochondrial and digenic) inheritance (Figure 1.6). Recent advances in 
molecular diagnosis have also highlighted numerous inaccuracies in the traditional 
phenotype-based corneal dystrophy classification due to the genetic and phenotypic 
heterogeneity associated with the condition. For instance, mutations in two separate 
genes (KRT3 and KRT12) have both been shown to cause the Meesman dystrophy 
phenotype, whilst several distinct corneal dystrophy phenotypes including Reis-
Buckler, Thiel-Behnke, granular, lattice and Avellino corneal dystrophies have now all 
been shown to be caused by mutations in the same TGFBI gene. This has led to a 
revised classification by the International Committee for Classification of Corneal 
Dystrophies (IC3D) incorporating this new genetic understanding of corneal 
dystrophies, with TGFBI-associated dystrophies now classified into a single grouping 






Figure 1.6 Genes associated with inherited retinal dystrophies 
The coloured circles represent clinical diagnoses; overlapping circles indicate the significant 
clinical and genetic heterogeneity associated with inherited retinal dystrophies. Abbreviations: 
COD, cone dystrophy; CORD, cone-rod dystrophy, CSNB, congenital stationary night 
blindness, LCA, Leber congenital amaurosis; MD, macular dystrophy, RP, retinitis 
pigmentosa; VR, vitreoretinopathy. Modified from Berger et al (83) 
 
Establishing an accurate clinical and molecular diagnosis is a particularly significant 
problem in developing countries, where there is limited access to ophthalmic 
equipment and expertise needed for performing and interpreting the detailed 
phenotyping studies needed for diagnosis due to regional geographical limitations or 
restricted local clinical resources. This problem is further compounded by a relative 
lack of knowledge regarding the specific nature and causes of inherited ocular 
diseases in developing nations. 
 
Advances in next generation sequencing (NGS) technologies have ushered in a new 
era in molecular diagnostics by facilitating the sequencing of whole exomes or 
genomes of large cohorts of individuals with inherited eye diseases. This has not only 
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led to the identification of numerous new genetic causes responsible for a wide 
spectrum of inherited eye diseases such as corneal dystrophies, retinal dystrophies, 
and ocular developmental defects (84, 85), but may also permit a hypothesis-free 
diagnostic approach in settings where clinical information is limited, a situation 
commonly encountered in developing nations due to geographical isolation and limited 
access to healthcare services (see thesis chapter 5.3). There is a global responsibility 
to support genomic health initiatives in these nations so that the transformative 
potential of genomic medicine can be translated into meaningful health outcomes that 
benefit populations worldwide (59, 86). 
 
1.4.1 Gene therapy in inherited eye diseases 
 
Inherited eye diseases have historically played an important role in defining the basic 
principles of genetics. In 1876, the Swiss ophthalmologist Johann Friedrich Horner 
described the characteristic X-linked recessive pedigree pattern in a family with colour 
blindness, furthering progress in the understanding of sex-linked heredity; Horner’s 
law stated that “colour-blind fathers have colour-normal daughters; and these colour-
normal daughters are the mothers of colour-blind sons” (87). In 1936, Imai and 
Moriwaki first suggested cytoplasmic inheritance (now known as mitochondrial 
inheritance) to account for the maternal inheritance pattern of Leber hereditary optic 
neuropathy (88). The patchy retinal pigmentary pattern seen in heterozygote carriers 
of X-linked ocular albinism was seen to support the Lyon hypothesis, which postulated 
the random inactivation of one of the X chromosomes in somatic cells of females (89). 
Knudson’s observations on retinoblastoma led to the development of the two-hit 
hypothesis in 1971, fundamental to our understanding of tumour suppressor genes 
and familial cancer syndromes (90). And the first convincing report of digenic 
inheritance in human disease was in 1994 for retinitis pigmentosa caused by mutations 
in the PRPH2 and ROM1 genes (91).  
 
Today, advances in molecular genetics have in turn contributed significantly to 
ophthalmic genetics, advancing our understanding of the molecular biology of eye 
development and vision and the pathophysiological basis of eye diseases. For 
instance, mechanistic dissection of photoreceptor degeneration in retinal dystrophies 
identifies genes affecting a wide variety of cellular functions, including ciliary transport, 
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phototransduction and the visual cycle, lipid oxidation, protein degradation, cell 
signalling and cell-cell interactions, intracellular transport, phagocytosis and RNA 
splicing (92). Knowledge of the underlying genetic and molecular causes of disease 
can allow redeployment of existing therapies in targeting the biochemical pathways 
involved in disease pathogenesis, which may slow or halt disease progression, or 
enable restoration of protein or cell function through gene therapy or other 
experimental approaches.  
 
The eye has a number of advantages as a target organ for gene therapy (93, 94). It is 
easily accessible by surgical approaches, and ocular tissues can be imaged and 
quantified in vivo with non-invasive imaging techniques such as electroretinography. 
Due to its small anatomical size and subdivision into smaller compartments, only small 
volumes of gene delivery vectors need to be administered to ensure delivery to target 
tissues. The relatively tight blood-retina barrier allows concentration of vectors within 
the target area and limits potential complications from systemic exposure, whilst at the 
same time altering the trafficking of immune cells from the systemic circulation to the 
eye and providing an “immune-privileged” state that limits the immune reaction to a 
given gene vector. The duplicity of the eye as an organ, and the bilateral nature of 
many inherited eye diseases, allows the option of treating just one eye, and 
considering the untreated eye as an ideal within-subject experimental control for 
comparisons on the safety and efficacy of treatment.  
 
Gene therapy approaches have mainly focused on adeno-associated virus (AAV) or 
lentivirus vector-based gene replacement strategies in inherited retinal dystrophies, 
conditions for which management options were previously limited to visual 
rehabilitation, educational and social support. The recent approval of Luxturna® 
(voretigene neparvovec) for the treatment of RPE65-mediated inherited retinal 
dystrophy in Europe and the United States (95, 96), together with early promising 
results from clinical trials currently underway for a further range of retinal dystrophies 
associated with CHM, PDE6B, RPGR, MERTK, MYO7A, ABCA4, RS1, CNGA3 and 
CNGB3 mutations (94), marks a new era in the treatment of these previously incurable 
and sight depriving conditions. Non-viral systems for gene delivery such as 
electroporation, nanoparticles and liposomes are also being studied, and although 
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these will be cheaper and easier to produce, they currently do not seem to show the 
same therapeutic promise (94). 
 
Antisense oligonucleotides are another promising therapeutic strategy that can be 
used to target disease mutations, with several different approaches currently 
undergoing clinical trials in inherited retinal dystrophies. One approach uses the 
antisense molecule to block the activation of cryptic splice sites and restore normal 
splicing mechanisms, and is useful for diseases resulting from aberrant splicing; this 
approach is currently under investigation for the treatment of Leber congenital 
amaurosis due to a splice site mutation in the CEP290 gene (97). Another approach 
based on splice modulation is being studied for the treatment of syndromic and non-
syndromic retinitis pigmentosa caused by mutations in the USH2A gene; a common 
site of disease mutations is within exon 13 of this gene, and the antisense molecule is 
designed to cause skipping of this exon from the USH2A mRNA, resulting in an in-
frame transcript that is translated into a shorter but still functional usherin protein (98). 
A further approach can be used for diseases caused by dominant negative mutations, 
where the antisense molecule targets and degrades the mutant mRNA; this approach 
is currently being trialled for the treatment of autosomal dominant retinitis pigmentosa 
caused by RHO gene mutation (99). 
 
Another gene-based therapeutic strategy under investigation is the use of small 
molecule translational read-through inducing drugs or TRIDs such as PTC124 
(Ataluren) or aminoglycoside antibiotics such as gentamicin (G418). These act by 
interfering with the proof-reading abilities of translationally active ribosomes, allowing 
“read-through” of premature termination codons (PTCs) and translation of a full-length 
protein from the mutant mRNA. This approach may be useful for recessive diseases 
where nonsense mutations are a significant cause of disease, and where a small 
amount of functional protein may be sufficient to rescue the disease phenotype, and 
has been studied for a number of inherited ocular conditions including choroideraemia, 
retinitis pigmentosa, Usher syndrome and aniridia (100). TRIDs have several 
advantages compared to gene replacement strategies; the size of the gene is not 
crucial (compared to the limited packaging capacity of commonly used viral vectors), 
and the targeted genes remain under endogenous control, maintaining tissue-specific 
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timing and duration of gene expression and splicing. Concerns remain however over 
long-term toxicity and the need for repeated dosing. 
 
Recently, the first in-human trial of genome editing using the clustered regularly 
interspersed palindromic repeat (CRISPR)/Cas9 system has been performed to target 
and delete a cryptic splice site and restore normal splicing in individuals with Leber 
congenital amaurosis (101), with plans for a similar trial targeted to Usher syndrome 
(102, 103). 
 
Although progress is not as advanced as for inherited retinal dystrophies, gene therapy 
approaches are also being investigated as a therapeutic option for other inherited eye 
diseases including Leber hereditary optic neuropathy (104), mucopolysaccharidoses 
(105), Fuchs corneal endothelial dystrophy associated with expansion of a non-coding 
trinucleotide repeat in TCF4 (106), and MYOC-associated glaucoma (107). 
 
Challenges remain in the development of molecular therapies for inherited eye 
diseases, both in terms of technical hurdles, and the social responsibility to provide 
equitable access to these transformative therapies given the significant human cost of 
sight loss for affected individuals (108). Despite this, advances in molecular 
technologies have greatly expanded the diagnostic capabilities and therapeutic 
landscape for inherited eye diseases, providing an optimistic outlook for individuals 
with these previously untreatable conditions. 
 
1.5 Disease gene and variant identification strategies 
 
Identification of disease genes enables an accurate molecular diagnosis in affected 
individuals, resulting in improved clinical care. It is also crucial to understanding the 
underlying genetic and molecular pathways of disease, which may in turn highlight 
potential therapeutic targets. The rapid evolution and widespread introduction of next 
generation sequencing (NGS) technologies such as whole exome and whole genome 
sequencing in research as well as clinical diagnostic settings has allowed rapid 
progress in the identification of genes and variants associated with inherited eye 
diseases. The combined approach of NGS in parallel with autozygosity mapping, a 
powerful tool in the study of autosomal recessive diseases in endogamous 
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communities, has been successful in uncovering novel causes of inherited eye 
diseases in community settings (38, 60), and was the primary approach adopted in 
many studies outlined in this thesis. Further background information on autozygosity 
mapping and advances in NGS technologies is contained in Appendix A 
 
1.6 Project aims 
 
The overarching objective of this PhD project involves the delineation and 
characterisation of the phenotypic, genetic and molecular spectrum of inherited eye 
diseases in community settings including the Amish, Pakistani and Palestinian 
communities. This will increase scientific understanding of the genetic causes and 
molecular pathways underlying ocular diseases, and drive advances that will benefit 
patients worldwide with the same condition. In order to achieve this, the specific aims 
of the study include: 
 
1. screening of established disease genes in affected families with isolated and 
syndromic inherited eye diseases including: anophthalmia, infantile nystagmus 
and oculocutaneous albinism (OCA), anterior segment dysgenesis and 
congenital cataracts, as well as inherited retinal dystrophies to identify 
previously reported and novel pathogenic gene variants. Alongside this, 
comprehensive literature reviews will be undertaken to determine the clinical 
and molecular spectrum of inherited eye diseases in communities, facilitating 
the development of targeted genetic testing strategies that will enable improved 
and efficient disease diagnosis and early intervention, 
 
2. investigation of the pathogenicity of two common TYR gene variants through 
co-segregation studies in Amish OCA families, together with analysis of 
extensive UK and international OCA patient cohorts and functional assays. This 
will provide novel insights into OCA molecular pathogenesis, and help resolve 






3. perform detailed clinical phenotyping in combination with comprehensive 
genomic studies in molecularly undiagnosed individuals with inherited eye 
diseases. This will enable the identification, consolidation and characterisation 










General laboratory consumables were purchased from Rainin, STARLAB and Alpha 
Laboratories. Reagents used are reported in Table 2.1. 
 
Table 2.1 Reagents used in the study 
Reagents Manufacturer 
Agarose (molecular grade) Fisher Scientific 
Boric acid Fisher Scientific 
dNTP set Solis BioDyne 
DMSO Sigma-Aldrich 
DreamTaqTM DNA polymerase Thermo Fisher Scientific 
DreamTaqTM green buffer (10x) Thermo Fisher Scientific 
Ethanol Fisher Scientific 
Ethidium bromide Fisher Scientific 
Exonuclease I (Exo I) New England Biolabs 
GeneRulerTM 1kb Plus DNA ladder Thermo Fisher Scientific 
Lithium acetate dihydrate Alfa Aesar 
Shrimp alkaline shosphatase (rSAP) New England Biolabs 
 
2.2 Clinical methods 
 
2.2.1 Ethical approval for study 
 
Ethical approval was granted from the ethical approval committees of: 
• University of Exeter Medical School, Exeter, UK 
• South Central – Hampshire A Research Ethics Committee, Southampton, UK 
• Akron Children’s Hospital, Ohio, USA 
• Baylor College of Medicine, Texas, USA 
• University of Arizona, Arizona, USA 
• International Islamic University, Islamabad, Pakistan 
• Kohat University of Science and Technology, KPK, Pakistan 
• University of Health Sciences, Lahore, Pakistan 
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• Shah Abdul Latif University, Sindh, Pakistan 
• Arab American University, Jenin, Palestine  
The study protocol adhered to the tenets of the Declaration of Helsinski. Written 
informed consent was obtained from all participants prior to their inclusion in this study 
with parental written consent provided on behalf of children involved in the study. 
 
2.2.2 Patient ascertainment and phenotyping 
 
Recruitment of families from the North American Amish communities, as well as 
communities in Pakistan and Palestine, was performed by collaborating researchers. 
All study participants were phenotypically assessed and overseen by local clinicians. 
A medical history was obtained, including a documentation of visual symptoms. Facial 
photographs and videos were used to document skin and hair tone and nystagmus. 
Visual acuity testing was performed using Snellen charts, and colour vision testing 
using Ishihara charts. The anterior and posterior segment of the eye was examined by 
slit lamp biomicroscopy or direct fundoscopy. Additional investigations were performed 
in selected affected individuals where possible; these include retinal imaging studies 
such as colour fundus photography and ocular coherence tomography (OCT), as well 
as electrophysiological testing including electroretinography. Subsequent to molecular 
genetic studies, additional targeted clinical investigations were occasionally 
undertaken to clarify the clinical significance of any candidate variants identified.  
 
Considerable diagnostic difficulties were encountered by clinicians in some 
communities, where affected families resided in rural regions with a lack of medical 
infrastructure, limiting access to specialised equipment required for detailed and 
accurate ocular phenotyping. Local clinicians and scientists were supported by myself 
(clinical ophthalmologist) in the collection and review of the highest quality clinical 





2.3 Molecular genetic methods 
 
2.3.1 Sample acquisition and data management 
 
The research study was carried out in compliance with the Human Tissue Authority 
(HTA) Codes of Practice and Standards (Code E: Research). All blood and buccal 
samples and subsequent DNA extractions used in this project were stored in HTA-
licensed premises with research carried out in accordance with the Human Tissue Act 
2004. Each participating individual was assigned a unique study identification number. 
A master list of study participants linking the identification number to the study 
individual was recorded in a password protected database and stored on university 
servers. All data management was GDPR compliant. 
 
Participating individuals had either peripheral venous blood samples taken in EDTA-
containing vacutainer tubes, or buccal cell collection using the ORAcollect® for 
paediatrics kit (DNA Genotek). Blood and buccal sample tubes were labelled with their 
study identification number on arrival; blood samples were stored at -20°C, whilst 
buccal samples were stored at room temperature, prior to DNA extraction. 
 
2.3.2 DNA extraction and quantification 
 
DNA extraction from whole blood 
 
Genomic DNA extraction for venous blood samples was performed using the 
ReliaPrepTM Blood gDNA Miniprep System (Promega). Blood samples were 
thoroughly mixed by hand for at least 2 mins. 200 μl of blood was added to 20 μl of 
proteinase K solution in a 1.5 ml microcentrifuge tube and mixed briefly. 200 μl of cell 
lysis buffer was then added to the tube, which was capped and mixed by vortexing 
(Topmix FB15024 Vortex Mixer, Fisher Scientific) for at least 10 sec, followed by an 
incubation for 10 mins at 56°C on a heating block (Mixer HC Thermoblock, STARLAB). 
After this incubation period, the tube was removed from the heating block, and 250 μl 
of binding buffer was added to the tube, which was then capped and mixed for 10 sec 
using a vortex mixer. At this stage, the lysate was visually checked to ensure a dark 




The contents of the tube were then added to a ReliaPrepTM binding column placed in 
an empty collection tube, which was capped and centrifuged for 1 min in a 
microcentrifuge (Biofuge Pico Microcentrifuge, Heraeus) at maximum speed (13,000 
rpm, 16,060 g-force). The binding column was checked to make sure that the lysate 
had completely passed through the membrane, and if there was lysate still visible on 
top of the membrane, the column was centrifuged for a further 1 min. The collection 
tube containing the flow-through was then removed, and the liquid discarded as 
hazardous waste. The binding column was placed in a fresh collection tube, and 500 
μl of column wash solution was added to the column, this was then centrifuged for 3 
mins at maximum speed, and the flow-through discarded. This last step was repeated 
twice more for a total of three washes.  
 
The column was then placed in a clean 1.5ml microcentrifuge tube, and 200 μl of 
nuclease free water was added to the column. This was centrifuged for 1 min at 
maximum speed to elute the DNA. 
 
DNA extraction from buccal cells 
 
Genomic DNA extraction for buccal samples was performed using the Xtreme DNA kit 
(Isohelix). The sample tubes containing the stabilised swab heads were first incubated 
in a water bath at 50°C for 1 hour. 20 μl of proteinase K solution was then added to 
the sample tube, which was immediately mixed by vortexing (Topmix FB15024 Vortex 
Mixer, Fisher Scientific), and then further incubated in a water bath (Unstirred Digital 
Water Bath, Clifton) at 60°C for 1 hour. 750 μl of column binding buffer was added to 
the tube, which was mixed by vortexing for 30 sec. 1.25ml of ethanol was then added 
to the tube, and this was mixed by vortexing.  
 
700 μl of the sample was added to an Xtreme DNA column placed in a collection tube, 
and this was centrifuged for 1 min in a microcentrifuge (Biofuge Pico Microcentrifuge, 
Heraeus) at maximum speed (13,000 rpm, 16,060 g), with the flow-through then 
discarded. This step was repeated until all the sample had been loaded onto the 
column. 750 μl of wash buffer solution was then added to the column, and this was 
centrifuged at maximum speed, with the flow-through discarded. This step was 
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repeated once for a total of 2 washes. The column was then placed in a clean 
collection tube and centrifuged at maximum speed for 3 mins to remove all traces of 
ethanol.  
 
Following this, the column was placed in a clean 1.5 ml microcentrifuge tube and 100 
μl of elution buffer (preheated to 70°C) was added to the centre of the membrane. The 
column was allowed to stand for 3 mins, following this it was then centrifuged at 
maximum speed for 1 min to elute the DNA. 
 
DNA quantification and storage 
 
Extracted DNA was quantified using a spectrophotometer (NanoDropTM 2000, Thermo 
Fisher Scientific) to measure the absorption of UV light at 260 nm (peak absorbance 
wavelength of nucleic acids) in a 1 μl sample aliquot. The NanoDropTM software 
automatically calculates the nucleic acid concentration (in ng/μl) using a modified 
Beer-Lambert equation, which correlates the calculated absorbance with 
concentration.  
 
The quality of the extracted DNA was also assessed simultaneously by measuring the 
absorption of UV light at 280 nm (strong absorbance wavelength of proteins and 
phenolic compounds) and 230 nm (strong absorbance wavelength of organic 
compounds). The absorbance at 260 nm, 280 nm and 230 nm normalised to a 10 mm 
pathlength is denoted by A260, A280 and A230 respectively, and the A260/A280 and 
A260/A230 ratios were used to assess DNA purity. A A260/A280 ratio of ~1.8 
generally indicates “pure” DNA; an appreciably lower ratio indicates the possible 
presence of protein or other contaminants that absorb strongly at or near 280 nm. The 
A260/A230 ratio is a secondary measure of nucleic acid purity, with values for “pure” 
nucleic acid often higher than the respective A260/A280 values and commonly in the 
range of 1.8 - 2.2; an appreciably lower ratio may indicate the presence of co-purified 









Oligonucleotide primer pairs for dideoxy sequencing were designed using reference 
genomic sequences accessed from the UCSC Genome Browser 
(https://genome.ucsc.edu/) and the open-source software Primer3Plus 
(http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi) for primer design. 
Occasionally, it was necessary to design some primers by eye where the regions 
flanking the target sequence were highly repetitive or GC rich and hence not conducive 
to automatic primer design. Primers were selected based on the following principles: 
 
• Primer size between 20-26 nucleotides in length 
• Similar predicted melting temperatures for the primer pair  
• Primers that specifically anneal only to the region of interest with no alternative 
binding sites in the genome identified [checked using the human BLAT search 
tool at UCSC Genome Browser (https://genome.ucsc.edu/cgi-bin/hgPcr)] 
• Primers that did not contain any common single nucleotide polymorphisms 
(SNPs) (≥1% minor allele frequency or MAF in dbSNP build 151) or repetitive 
elements (including low-complexity sequences and interspersed repeats) 
identified using the RepeatMasker software tool [checked using the human 
BLAT search tool at UCSC Genome Browser (https://genome.ucsc.edu/cgi-
bin/hgPcr)] 
• A PCR product size of between 200 to 1000 bp in length (where possible) 
• An PCR product GC content of less than 60% (where possible) 
 
Oligonucleotide primers were ordered and manufactured by Integrated DNA 
Technologies IDT™ and were received in lyophilised form. Primers were re-
suspended in double-distilled water (ddH2O) as per manufacturer’s instructions to 
achieve a 100 μM stock solution and stored at -20°C. A subsequent 5 μM working 
dilution of 200 μl was made for PCR amplification and sequencing, and was stored at 







PCR reactions for each primer pair were first optimised using a temperature gradient 
protocol to determine the optimal primer annealing temperature for achieving a high 
yield of PCR product with minimal non-specific amplification (Figure 2.1). The 
temperature gradient would typically be run across 12 reactions, with each reaction 
having a different annealing temperature ranging from 52-64°C, each differing by 
approximately 1°C.  
 
 
Figure 2.1 Temperature gradient optimisation example 
Agarose gel electrophoresis image of PCR reaction using primers designed to amplify the 
OCA2 p.(Ala787Val) variant. 58°C was the optimal annealing temperature chosen as it was 
the lowest temperature with a bright and clear band. 
 
PCR was performed using a 10 μl reaction mixture (Table 2.2). The DreamTaqTM 
Green Buffer contains MgCl2 (at a concentration of 20 mM) and is optimised for PCR 
reaction with the DreamTaqTM DNA Polymerase, the standard Taq polymerase used 
in the lab. The buffer also contains a density reagent and two tracking dyes, allowing 
direct loading and visualisation of PCR products onto the agarose gel, as well as 
facilitating the monitoring of the electrophoresis progress. The dNTP Mix solution was 






Table 2.2 Standard PCR reaction mixture 
Component (concentration) Volume 
Primer forward (5 μM) 0.4 μl 
Primer reverse (5 μM) 0.4 μl 
DreamTaqTM green buffer (10x) 1.0 μl 
DreamTaqTM DNA polymerase (5 units/μl) 0.1 μl 
dNTP mix solution (10 mM) 0.4 μl 
DNA (10-30 ng/μl) 0.8 μl 
ddH2O 6.9 μl 
Total 10 μl 
 
Modifications to the standard PCR reaction mixture were occasionally required. For 
instance, where the PCR products had an unavoidably high GC content (typically 
>60%) and where there was non-specific priming or poor PCR product yield, the PCR 
reaction was supplemented with the addition of 10% DMSO. In DNA templates with a 
high GC content, there is increased difficulty in denaturing the template due to the 
increased hydrogen bond strength, causing intermolecular secondary structures to 
form more readily, which can compete with primer annealing (109). DMSO is thought 
to resolve secondary structure formation by binding to the major and minor grooves of 
the template DNA, hence destabilising the double helix structure and promoting 
denaturation (109). 
 
PCR was performed in a thermal cycler (Mastercycler® ep gradient S, Eppendorf) 
following a touchdown PCR protocol (Table 2.3). This method aims to increase 
specificity of the PCR reaction by reducing off-target priming, and uses an initial 
annealing temperature (Ta) that is greater than the projected melting temperature of 
the primers, followed by a gradual decrease in annealing temperature over 
subsequent cycles until the desired annealing temperature (as identified through 





Table 2.3 Touchdown PCR protocol 
Step  Temperature Time 
1 Initial denaturation 95°C 5 mins 
2 Denature 95°C 30 sec 
3 Anneal Ta + 4°C 30 sec 
4 Extension 72°C 30-60s 
Repeat steps 2-4 for a total of 2 cycles 
5 Denature 95°C 30 sec 
6 Anneal Ta + 2°C 30 sec 
7 Extension 72°C 30-60 sec 
Repeat steps 5-7 for a total of 2 cycles 
8 Denature 95°C 30 sec 
9 Anneal Ta 30 sec 
10 Extension 72°C 30-60 sec 
Repeat steps 8-10 for a total of 35 cycles 
11 Final extension 72°C 5 mins 
Abbreviation: Ta, annealing temperature. 
 
The duration of the extension step was modified depending on the size of the PCR 
product; for product sizes of less than 500 bp in length, an extension time of 30 sec 
was used, for PCR product sizes between 500 to 750 bp long, an extension time of 45 
sec was used, and where the PCR product was over 750 bp in length, an extension 
time of 60 sec was used. Specific PCR conditions for each primer pair are contained 
within Appendix D. 
 
Agarose gel electrophoresis 
 
In agarose gel electrophoresis, the agarose gel forms a highly cross-linked matrix 
through which the negatively charged DNA molecule is forced to migrate in response 
to an electric current towards the positive anode. This technique can be used to 
separate DNA fragments by size, as shorter DNA molecules will migrate more rapidly 
through the matrix compared to longer molecules, and will travel a greater distance 
across the agarose gel in a given period of time. In this study, agarose gel 
electrophoresis was mainly used to determine the adequacy of the DNA amplification 




1% agarose gels were made by heating 1.0 g molecular grade agarose powder with 
100 ml 1X lithium acetate borate (LAB) buffer (consisting of 10 mM lithium acetate and 
10 mM boric acid, made by dissolving 51 g of lithium acetate dehydrate and 31 g boric 
acid in 1 litre of distilled water to make a 1 litre 50X stock solution, before being diluted 
to 1X) in a 700 W microwave till the agarose has completely dissolved. The agarose 
solution was left to cool to approximately 50-60°C before 5 μl of 1% ethidium bromide 
(a DNA-binding fluorophore) was added, this was then poured into a gel tray with a 
well comb in place, and left to sit at room temperature for approximately 30 to 60 mins 
until the gel was completely solidified.  
 
The agarose gel was then placed in an electrophoresis tank containing 1X LAB buffer, 
and 3 μl of PCR product was loaded directly into the wells (no loading buffer was 
required due to the use of DreamTaqTM Green Buffer for the PCR reaction), together 
with an appropriate molecular weight marker, most typically the GeneRulerTM 1kb Plus 
DNA Ladder, to allow sizing of the PCR product.  
 
The gel was run at 150 V constant voltage for approximately 30 mins, and then imaged 
using an ultraviolet transilluminator, causing fluorescence of the ethidium bromide and 
allowing visualisation of the DNA banding pattern. The image was photographed using 
a gel imaging and analysis system (InGenius gel documentation system and 
GeneSnap image acquisition software, Syngene). 
 
PCR clean-up and dideoxy sequencing 
 
Prior to sequencing, unincorporated primers and nucleotides were removed using a 
combination of the hydrolytic enzymes exonuclease I (Exo I) (which degrades single 
stranded DNA including residual primers and superfluous PCR products) and shrimp 
alkaline phosphatase (rSAP) (which dephosphorylates and hence deactivates the 
remaining nucleotides) (111).  
 
An ExoSAP enzyme mix was first prepared, consisting of 2.5 μl of Exo I (20,000 U/ml) 
and 25 μl rSAP (1000 U/ml), made up to 1 ml with ddH2O. 2 μl of this ExoSAP enzyme 
mix was then added to 5 μl of PCR product, and this mixture was incubated at 37°C 
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for 30 mins (for digestion of excess primers and dephosphorylation of nucleotides), 
followed by a second incubation at 95°C for 5 mins for enzyme inactivation. 
 
The ExoSAP treated PCR products were sequenced by Source BioScience 
(https://www.sourcebioscience.com/), with the generated chromatogram data file 
visualised using a chromatogram viewer (FinchTV, Geospiza). 
 
2.3.4 Single nucleotide polymorphism (SNP) genotyping 
 
Within community settings, affected individuals for autosomal recessive diseases are 
typically homozygous for founder mutations that occur at an increased frequency 
within such populations, and reside within identical-by-descent haplotypes (60, 112). 
Homozygosity mapping techniques, which highlight shared regions of homozygosity 
between affected individuals, therefore facilitate an efficient means of identifying 
candidate disease genes within these regions. In this study, this was performed using 
genome-wide SNP genotyping (by Dr Barry Chioza and Joe Leslie, University of 
Exeter) using the Illumina CytoSNP-12v2.1 array and following the Infinium® HD 
Assay Ultra manual protocol. This protocol is performed over 3 days with 200 ng of 
DNA at a concentration of 50 ng/μl per sample. 
 
Day 1: DNA samples were denatured using a buffer containing 0.1 N sodium 
hydroxide, and then neutralised. Samples were amplified during an overnight 
incubation at 37°C. 
 
Day 2: Amplified DNA samples were enzymatically fragmented using the Illumina 
fragmentation solution (FMS), using endpoint fragmentation to avoid 
overfragmentation. The DNA was then precipitated using 100% 2-propanol and the 
Illumina precipitation solution (PM1), and collected via a 20 min centrifugation 
performed at 4°C. The DNA was then resuspended using the Illumina resuspension, 
hybridisation and wash solution (RA1), and then denatured at 95°C for 20 mins. The 
denatured samples were cooled at room temperature for 30 mins before being loaded 
onto the BeadChips (with each chip holding 12 samples). This was then incubated in 




Day 3: Beadchips were prepared for the staining process by washing with the Illumina 
Prepare BeadChip Buffer 1 (PB1) solution in order to remove unhybridised and 
nonspecifically hybridised DNA samples from the BeadChips. Labelled nucleotides 
were dispensed onto the BeadChip through the flow-through chambers to perform 
single-base extension of primers hybridised to the DNA samples. The BeadChips were 
then stained using the Illumina XStain HD BeadChip process and imaged on an 
Illumina iScan System. The iScan system uses a laser to excite the fluorophores of 
the single-base extension product on the beads of the BeadChip. Light emissions from 
the fluorophores were recorded by the reader, allowing high resolution images of the 
BeadChip to be taken. The data from these images was analysed using the Illumina 
GenomeStudio Integrated Informatics Platform, allowing the genotype to be 
determined. 
 
Further analysis was undertaken using the Illumina KaryoStudio v1.4 software for 
identification of cytogenetic or chromosomal structural aberrations. The generated 
data was also exported into Microsoft Excel 2013, and analysed visually, as well as 
using an Excel macro written by Dr Barry Chioza, to highlight notable genomic regions 
(>1 Mb) with a shared haplotype. 
 
2.3.5 Next generation sequencing (NGS) 
 
TruSightTM One Sequencing Panel 
 
The Illumina TruSightTM One clinical exome sequencing panel was performed by Luke 
O’Gorman and Chelsea Norman, University of Southampton. This panel provides 
targeted sequencing for 4813 genes associated with clinical phenotypes, including a 
number of known causative genes for inherited ocular disease. Next generation 
sequencing was performed using the Illumina TruSightTM capture kit and the NextSeq 
500 platform (Illumina), with an approximate read depth and coverage of 20X minimum 





Whole exome sequencing (WES) 
 
WES was predominantly performed by either BGI Tech Solutions (BGI Genomics, 
Hong Kong) using a BGISEQ-500 platform or by the Exeter Sequencing Service 
(University of Exeter, UK) using a Illumina NextSeq 500 platform, with an approximate 





Alignment of NGS data to the reference human genome sequence 
Raw sequence data in FASTQ format was aligned to the Genome Reference 
Consortium human genome build 37 (GRCh37) using the BWA-MEM (v0.7.12) (113) 
alignment algorithm, generating output files in Sequence Alignment/Map (SAM) 
format, which were then converted into Binary Alignment/Map (BAM) format using 
SamFormatConverter (Picard Tools v2.15.0) for further analysis. FixMateInformation 
(Picard Tools v2.15.0) was used to verify read pair information between each read and 
its corresponding mate pair and fix information errors if necessary, sorting the output 
file by read coordinates. Duplicate reads were removed using MarkDuplicates (Picard 
Tools v2.15.0). This identifies the duplicate reads by matching all read pairs with 
identical 5’ coordinates and orientations, avoiding bias in variant calling by presenting 
variants with artificially high read depth support. Indel (insertion and deletion) 
realignment and base quality recalibration was performed using the Genome Analysis 
Toolkit (GATK) v3.70 (114). 
 
Identification of sequence variation 
Variant calling for SNPs and short indels was performed using GATK HaplotypeCaller 
(v3.70) with a variant call format (VCF) file generated for each individual. This was 
filtered for quality control based on read depth (DP), mapping quality (MQ), strand 
bias, and relative position of the variant within the read.  
 
Copy number variants (CNV) (WES data only) were detected using ExomeDepth 
(115), which uses read depth data to call CNVs from exome sequencing experiments, 




Annotation of sequence variation 
Functional annotation of variants in the filtered VCF file was then performed using 
Alamut® Batch (v1.10), facilitating interpretation of variants in a clinical context. Each 
variant was annotated on all available transcripts.  
 
Variant prioritisation 
Variants (SNPs and short indels) were prioritised using the following criteria (Table 
2.4). 
 
Table 2.4 Criteria used for variant prioritisation 
Criteria Description 
Call quality • VCF filter = PASS 
• MQ ≥ 50 
• DP ≥ 5 
Integrative Genome Viewer (IGV) was also used to 
visualise the aligned sequencing data and genomic region 
adjacent to the variant 
Consistent with mode 
of inheritance 
If pedigree suggests: 
• Autosomal recessive inheritance: homozygous and 
compound heterozygous variants 
• Autosomal dominant inheritance: heterozygous 
variants 
• X-linked inheritance: hemizygous variants (in males) 
Frequency in control 
datasets 
MAF <0.01 in: 
• gnomAD (v2.1.1 and v3.1.1) (all populations) 
• Relevant internal control exome dataset of unrelated 
Amish (220) or Pakistani (65) individuals 
Predicted impact on 
protein or splicing 
• Non-synonymous missense variants 
• Presumed loss of function variants 
• Splicing variants, defined as intronic variants within 
5bp of the intron-exon junction 
In silico pathogenicity 
predictions 
Non-synonymous missense variants: 
• SIFT score < 0.05 
• PolyPhen-2 score > 0.15 




• Local splicing effect predictions calculated using the 
Alamut® Batch interpretation algorithm that interprets 
splice site signals recognised by MaxEntScan, 
SpliceSiteFinder-like (SSF) and Splice Site Prediction 
by Neural Network (NNSplice)  
Previously reported 
variants 
• ‘Pathogenic’ and ‘Likely pathogenic’ annotation in 
ClinVar  
• ‘Disease-causing mutation’ and ‘Disease-causing 
mutation?’ annotation in HGMD professional v2020.4  
For glossary of terms see Appendix A. 
 
2.4 Literature review 
 
Literature reviews were performed using Pubmed (https://pubmed.ncbi.nlm.nih.gov/), 
Google Scholar (https://scholar.google.com/) and HGMD® Professional 2020.4 
(https://my.qiagendigitalinsights.com/bbp/view/hgmd/pro/start.php) to retrieve all 
reported disease-associated loci and variants. Additional information collated where 
relevant included the number of families and number of affected individuals within 
each family, their country of origin, and reported phenotype. The variants were then 
searched for within NCBI ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/) to identify any 










OCA refers to a group of genetically and clinically heterogeneous disorders 
characterised by abnormal melanin synthesis, resulting in decreased or absent 
pigmentation of eyes, skin and hair. Six genes involved in the melanin biosynthesis 
pathway are known to cause non-syndromic OCA, with gene variants in TYR, OCA2, 
TYRP1, SLC45A2, SLC24A5 and C10orf11 associated with OCA subtypes 1, 2, 3, 4, 
6 and 7 respectively. OCA5 has been mapped to the chromosome 4q24 locus, 
although the gene responsible has not yet been identified (117). OCA may also be a 
part of a broader systemic phenotype in conditions associated with lysosomal storage 
defects such as Hermansky-Pudlak syndrome (associated with pathogenic variants in 
HPS1, HPS3, HPS4, HPS5, HPS6, AP3B1, DTNBP1, BLOC1S3, BLOC1S6 and 
AP3D1) and Chediak-Higashi syndrome (associated with pathogenic variants in 
LYST). Both syndromic and non-syndromic forms of OCA are inherited as autosomal 
recessive conditions.  
 
Ocular features are present in individuals with OCA, and are characteristic of the 
disease. These include photophobia, nystagmus, foveal hypoplasia, iris 
transillumination and abnormal decussation of nerve fibres at the optic chiasm 
resulting in crossed asymmetry on visual evoked potential testing (118). These ocular 
features may however be variable with no single defining characteristic found to be 
present in every individual with OCA (119). The cutaneous phenotype may also vary, 
ranging from total absence to near normal levels of pigmentation, and can be difficult 
to evaluate, particularly in individuals with a lightly pigmented ethnic background (120, 
121). As such, OCA can be difficult to distinguish clinically from several other ocular 
disorders with overlapping phenotypical features, such as GPR143-associated X-
linked ocular albinism, where the hypopigmentation is limited to the eye (122), 
FRMD7-associated X-linked idiopathic congenital nystagmus (123), SLC38A8-
associated foveal hypoplasia (also known as FHONDA; foveal hypoplasia, optic nerve 
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decussation defects, and anterior segment dysgenesis) (124), and dominant PAX6-
related ocular developmental disorders (125). 
 
OCA1, associated with TYR gene variants, is the most common OCA subtype found 
in Caucasians accounting for ~50% of cases worldwide (126, 127). TYR encodes the 
enzyme tyrosinase, which is the critical and rate limiting enzyme in the biosynthesis of 
melanin in follicular and epidermal melanocytes in hair and skin, as well as in uveal 
melanocytes in the iris, ciliary body and choroid, and RPE cells in the eye (128). 
Disease-associated variants in the TYR gene cause complete or partial OCA1 
depending on their impact on the residual activity of the encoded mutant tyrosinase 
enzyme (129). TYR gene variants that result in a severe reduction or complete 
abolition of enzyme activity are associated with OCA1A, characterised by an almost 
complete absence of hair, skin and eye pigmentation (129, 130). Hypomorphic TYR 
variants in which mutant tyrosinase possess residual catalytic activity are associated 
with OCA1B, where affected individuals present with a milder phenotype with reduced 
levels of pigmentation (129, 130).  
 
This chapter entails clinical and genomic investigations into the cause of OCA in four 
interlinking Amish families, which alongside functional studies and a review of 
previously published OCA genomic studies, highlights the pathogenicity of two 
common hypomorphic TYR variants p.(Ser192Tyr) and p.(Arg402Gln) that were 
previously largely considered non-pathogenic polymorphisms. Additionally, this 
chapter compiles genetic findings regarding the causes of OCA in 36 families from 
several communities in Pakistan. Together with a comprehensive literature review of 
all pathogenic gene variants associated with OCA in the Pakistani population, these 
findings permit a detailed understanding of the molecular spectrum of OCA in 
Pakistan. 
 
Within this chapter, I was responsible for the interpretation and analysis of all collected 
clinical data for all affected individuals, including the development of clinical proformas 
to aid collaborating scientists acquire the best quality and most relevant clinical data 
for the Pakistan OCA families (families 5 - 40) described in chapter 3.3. I performed 
DNA extraction for a proportion of affected families (remaining DNA extraction largely 
completed by Joe Leslie, University of Exeter), primer design for amplification of TYR 
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exons 4 and 5 (primers for amplification of TYR exons 1-3 designed by Dr Gaurav 
Harlalka, University of Exeter) as well as for all variants identified in families 5 – 39, 
and completed all cosegregation studies. I was also responsible for analysing results 
of all exome sequencing and SNP mapping studies performed in this chapter. All 
literature reviews within this chapter were performed by myself, including the statistical 
analysis across different OCA cohorts in chapter 3.2, as well as the compilation of all 






3.2 Evidence that the Ser192Tyr/Arg402Gln in cis Tyrosinase gene 
haplotype is a disease-causing allele in oculocutaneous albinism 




The apparent missing heritability in OCA is well described, with ~25-30% of clinically 
affected individuals lacking two clearly pathogenic sequence alterations within the 
same OCA gene; this proportion is higher in individuals with a partial OCA phenotype 
(129, 131). Several hypotheses have been proposed to explain this missing 
heritability, including variants in promoter or other regulatory elements, as well as 
epistatic or synergistic interactions between known genes (129, 132). Two TYR 
sequence variants [NM_000372.4:c.575C>A; p.(Ser192Tyr) or S192Y and 
c.1205G>A; p.(Arg402Gln) or R402Q], previously described as non-pathogenic 
polymorphisms due to their frequency in the general population (25% and 18% 
respectively), have been found to be enriched in cohorts of OCA patients with only 
one identified TYR mutation (126, 129, 133-141), leading to suggestions that these 
variants may in fact account for some of this missing heritability (117, 126, 127, 133, 
134, 137, 142-145). This has however been disputed by others (136, 138, 146) who 
have hypothesised that these variants may be pathogenic only when present in cis, 
and inherited in biallelic fashion with a second deleterious TYR variant for tyrosinase 
activity to be sufficiently reduced to a level that will cause an OCA phenotype (132, 
145, 147). This hypothesis is supported by increasing numbers of individuals with OCA 
reported to carry one pathogenic variant as well as the p.(Ser192Tyr) and 
p.(Arg402Gln) variants in TYR (132, 141, 148, 149). However, due to the high 
frequency of the p.(Ser192Tyr) and p.(Arg402Gln) variants in the general population, 
and the often small family sizes common to modern European populations, in many 
cases it has not been possible to obtain informative allele segregation to phase gene 
variants and prove inheritance of a cis p.(Ser192Tyr)/p.(Arg402Gln) haplotype in trans 
with the pathogenic TYR alteration in all affected individuals (145, 148). The remaining 
uncertainty in clinical interpretation of this haplotype limits its routine reporting in 
diagnostic gene panels. This has important diagnostic implications; designating the 
TYR p.(Ser192Tyr)/p.(Arg402Gln) haplotype as pathogenic could substantially 
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increase the diagnostic yield by ~25-50% in albinism patient cohorts with missing 
heritability (132). This also further supports the hypothesis that the prevalence of 
OCA1, commonly quoted as ~1 in 40,000 (130), likely represents a substantial 
underestimation particularly amongst Caucasian populations with fair pigmentation 
(149).  
 
This study entails extensive genetic studies stemming from the investigation of a large 
multigenerational extended Amish family, alongside functional studies, and a review 
of genotyped UK based albinism cohorts and of existing literature, to provide strong 
evidence supporting pathogenicity of the TYR p.(Ser192Tyr)/(Arg402Gln) in cis 
haplotype and its contribution to OCA1B in European populations. 
 
3.2.2 Materials and methods 
 
 
Amish patient ascertainment and molecular genetic analysis 
 
Affected individuals and unaffected family members from four Ohio and Wisconsin 
Amish families with a common Ohio ancestry were recruited to this study with informed 
consent (Figure 3.1). A medical history was taken in all recruited family members, as 
well as detailed phenotyping of skin and hair pigmentation, particularly in the context 
of familial pigmentary background. A diagnosis of nystagmus was established in all 
affected individuals (apart from individual X:5), and further ophthalmic investigations 
including electroretinography and OCT were performed in selected individuals. A 
diagnosis of albinism was made following a set of diagnostic criteria proposed by Kruijt 
et al (119). 
 
Blood/buccal samples were obtained with informed consent for DNA extraction 
(section 2.3.2). Exome sequencing (WES for individual IX:9 and Illumina TruSightTM 
One clinical exome sequencing panel for individual IX:22) was performed as described 
in section 2.3.5. Bioinformatic analysis of exome data was performed as per section 
2.3.5, with additional filtering performed using the “Albinism or congenital nystagmus 





Primers were designed as described in section 2.3.3 to cover all coding exons and 
associated intron-exon junctions of TYR (Appendix Table D1). As the 3’ region 
encompassing coding exons 4 and 5 of TYR shares high homology with a pseudogene 
(TYRL) (150), locus-specific amplification primers were designed for TYR exons 4 and 
5 to prevent co-amplification of TYR and TYRL and subsequent misinterpretation of 
results. PCR and dideoxy sequencing was performed as described in section 2.3.3 to 
genotype and confirm appropriate segregation of candidate disease variants in all 
available affected and unaffected individuals.  
 
Establishment of Tyr mutant cell lines, cell culture conditions and enzymatic activity 
assays 
(Performed by Chelsea Norman and Aida Sanchez-Bretaño, University of 
Southampton) 
 
The plasmid vector p3XFLAG-CMV-14 containing TYR cDNA was purchased from 
Addgene (Massachusetts, USA) and was initially deposited by Ruth Halaban (151). 
Upon arrival, sequencing revealed the p.(Ser192Tyr) (c.C575A) common population 
variant to be present. Site-directed mutagenesis was used to create the wild-type 
sequence (c.575C, p.192Ser) as well as the p.(Arg402Gln) variant. Site-directed 
mutagenesis was carried out using the non-strand displacing activity of Pfu DNA 
polymerase to incorporate and extend the mutagenic primers. The reaction mixture 
contained Phusion Pfu Polymerase and its buffer, forward and reverse primers (0.5 
µM), dNTPs (200 µM), and the cDNA template. PCRs were performed in a total volume 
of 50 µl. Touch-down PCR conditions were set at 98°C for 30 sec followed by 30 cycles 
of 98°C for 10 sec, 45-72°C for 10 - 30 sec and 72°C for 15-30 sec, and a final 
extension step of 72°C for 5 - 10 min. The PCR product was treated with DpnI to digest 
the methylated parental DNA.  
 
Purified mutated tyrosinase PCR products were employed to transform NEB® 5-alpha 
Competent E. coli (High Efficiency; New England Biolabs, UK) via heat shock method. 
Briefly, 50 µl of thawed cells were kept on ice and combined with approximately 100 
ng of plasmid DNA and incubated for 30 min. The cell-DNA mixture was heat shocked 
at 42˚C for 30 sec and then placed on ice for 5 min. Cells were given S.O.C medium 
and incubated for an hour in a shaking incubator before being plated on ampicillin 
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selection (100 ug/ml) LB agar plates. After overnight incubation at 37˚C, single 
ampicillin resistant colonies were picked and grown in LB broth for approximately 16 
hours, at which point the cells were pelleted by centrifugation and the DNA extracted. 
When the stocks were diminished, competent cells were produced through treatment 
with CaCl2 and subsequently transformed using the heat shock method described 
above.  
 
Human Embryonic Kidney 293 Freestyle (HEK293F) cells (Invitrogen, California, USA) 
were cultured in Freestyle culture medium (Invitrogen, California, USA) at 37˚C in a 
shaking incubator at 125 rpm with 8% CO2. When cells reached a density of 1 x106 
cells/ml, they were transfected with 30 µg of plasmids containing the p.(Arg402Gln) or 
p.(Ser192Tyr) mutations or co-transfected with both plasmids. The lipid-based 
reagent, 293fectin (60 µl) (ThermoFisher, UK), was diluted in Opti-MEM 
(ThermoFisher, UK) and incubated at room temperature for 5 min. DNA and 293fectin 
were combined, gently mixed and incubated at room temperature for 30 min before 
adding to cells. Then, cells were incubated in 6-well plates for 72 hours at 31°C or 
37°C to reach 90% confluency, and the enzymatic activity assays were performed. 
 
DOPA-oxidase activity was assessed in the different mutants. First, transfected cells 
from the different mutant clones were treated with L-DOPA, and the DOPA-oxidase 
activity was measured as the accumulation of the downstream product, dopachrome, 
following the manufacturer’s protocol. Briefly, cells cultured in 6-well plates were lysed 
in NP40 Cell Lysis Buffer (ThermoFisher, UK) containing 1 mM phenylmethylsulfonyl 
fluoride (PMSF) (in DMSO with a final concentration of 1%) and 1X protease and 
phosphatase inhibitor (Halt™ Phosphatase Inhibitor Cocktail, Thermo Fisher 
Scientific, UK), and protein concentration was measured by BCA assay (Thermo 
Scientific™ Pierce™ BCA Protein Assay Kit). Samples were then diluted into 4 µg/µl, 
and 50 µl or 30 µl sample aliquots were used for the DOPA assays. After adding the 
volume of the samples to 96-well plates, 150 µl of a phosphate buffer with L-DOPA 1 
mM was added to the wells. Enzymatic activity was recorded as the absorbance of 
dopaquinone at 492 nm from the start of L-dopa treatment (0 min) and at 30 min 
intervals thereafter for a total of 180 min at both 31°C and 37°C. Assays were routinely 
performed in triplicate and the results are presented as the means of the independent 




Results of enzymatic activity at 180 min were normalized to wild type, with the values 
for wild type taken to be 100% of the expected enzymatic activity. One-way ANOVA 
was performed followed by a Sidak’s post-hoc test. A probability level of at least 
p<0.05 was considered statistically significant (* p<0.05, ** p<0.01, *** p<0.001, **** 
p<0.0001). 
 
Evaluating the prevalence of TYR p.(Ser192Tyr)/p.(Arg402Gln) haplotype in OCA and 
control cohorts 
 
A clinical cohort of affected individuals with nystagmus and/or albinism was 
retrospectively ascertained through the Southampton (161 individuals) and Salisbury 
(131 individuals) research databases. All individuals had been referred from a regional 
paediatric nystagmus clinic and recruited with informed consent. NGS (Illumina 
TruSightTM One clinical exome sequencing panel), alignment and filtering was 
performed as previously described in section 2.3.5. The genomic data were 
interrogated to ascertain frequency of the TYR p.(Ser192Tyr)/p.(Arg402Gln) haplotype 
in this cohort. A literature review was also performed to evaluate the reported 
prevalence of the TYR p.(Ser192Tyr)/p.(Arg402Gln) haplotype in additional published 
OCA cohorts. This was compared against an in-house exome database of 219 Amish 
individuals unaffected by OCA. Statistical analysis was performed using an 
established software package (R Core Team 2015; R Foundation for Statistical 




Clinical and genetic findings 
 
A large multigenerational extended Amish family residing in Wisconsin (USA) with nine 
affected individuals all exhibiting nystagmus and variable levels of hair and skin 
hypopigmentation was investigated (Figure 3.1A; family 4). On the basis of a detailed 
medical history, assessment of skin and hair pigmentation, and ophthalmic 
investigations in selected affected individuals, a diagnosis of likely mild OCA was 
made in all affected individuals. Two additional Amish families with a total of four 
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affected individuals with a similar clinical phenotype were subsequently recruited 
(Figure 3.1A; families 2 and 3). In addition, a further Amish family with a single affected 
individual with OCA was recruited to the study (Figure 3.1A; family 4). This individual 
displayed clinical features consistent with a complete OCA phenotype, including pale 
skin and white/blonde hair and eyelashes, nystagmus, iris transillumination defects 
and foveal hypoplasia. Affected individuals were not noted to bruise or bleed easily, 
although specific haematological investigations were not performed. Clinical findings 
for all affected individuals are summarised in Table 3.1. 
 
Table 3.1 Summary of clinical features observed in affected individuals in 
families 1 - 4 with OCA 




Other ocular features Other systemic 
features 
1 (X:1) ✓ Blonde Blue Iris transillumination defects, 
depigmented fundus, foveal 
hypoplasia, alternating 
esotropia, optic disc hypoplasia 
- 
2 (X:2) ✓ NA NA Blunted foveal reflex, 
depigmented fundus 
NA 
3 (X:3) ✓ Blonde Blue Iris transillumination defects, 
blunted foveal reflex  
- 
3 (X:4) ✓ Dark 
blonde 
Blue transillumination defects, foveal 
hypoplasia, strabismus  
- 
3 (X:5) NA Strawberry 
blonde 
NA Blunted foveal reflex - 
4 (IX:9) ✓ Blonde Blue Pale fundi, iris transillumination 
defects, foveal hypoplasia, 
myopia, strabismus. 
Nyctalopia, photosensitivity and 
peripheral VF loss with normal 
ERG 
 
4 (IX:10) ✓ Pigmented Blue - Mild learning 
difficulties 
4 (IX:12) ✓ Light brown NA - - 
4 (IX:14) ✓ Dark brown Blue Pale fundi - 
4 (IX:15) ✓ Pigmented Blue - - 
4 (IX:16) ✓ NA NA NA NA 
4 (IX:20) ✓ Blonde Blue - - 
4 (IX:22) ✓ White/ 
blonde 
Blue - - 




Abbreviations: ERG, electroretinogram; NA, information not available; VF, visual field. The (✓) 





All affected individuals were diagnosed with hypomorphic albinism on the basis of a positive 
molecular diagnosis as well as the presence of either one major criterion or two minor criteria 
described by Kruijt et al (119). Major criteria includes foveal hypoplasia ≥ grade 2, crossed 
asymmetry on visual evoked potential testing and ocular hypopigmentation (either iris 
transillumination or fundus hypopigmentation ≥ grade 2), whilst minor criteria includes 
nystagmus, hypopigmentation of skin and hair, and grade 1 fundus hypopigmentation and/or 
foveal hypoplasia. 
 
Exome sequencing was initially performed in two affected individuals in family 4 
(individuals IX:9 and IX:22) for targeted evaluation using the “Albinism or congenital 
nystagmus v1.0” PanelApp virtual gene panel (41 genes). Subsequently, variants 
predicted to have a functional consequence (including CNVs) located genome-wide 
were identified and filtered according to allele frequency (gnomAD MAF of <0.01). This 
identified only a single plausible candidate disease variant in both individuals, a 
heterozygous TYR missense variant (GRCh38) chr11:g.89178708T>G; 
NM_000372.4:c.755T>G; p.(Met252Arg) or M252R. The p.Met252 amino acid residue 
is located in the catalytic domain of the tyrosinase protein, and is conserved across a 
variety of vertebrate species (Figure 3.1B). This variant was absent in gnomAD and 
Genome Project population databases, although it was present in an Amish control 
exome dataset (allele frequency 0.0023) in heterozygous form only. In silico analysis 
of the p.(Met252Arg) variant using SIFT, PolyPhen-2 and PROVEAN predicted the 
variant to be deleterious, possibly damaging and deleterious. This variant has been 
reported in compound heterozygous form [with a previously reported p.(Arg217Trp) 
variant] in a single individual with OCA (141), and is considered to be likely pathogenic. 
Exome sequencing did not identify any additional candidate single nucleotide or 
structural disease variants in any OCA-associated genes.  
 
To explore this apparent missing heritability, targeted dideoxy sequencing of all coding 
regions and intron-exon junctions of the TYR gene was performed in these two 
individuals. This confirmed the presence of the p.(Met252Arg) variant, and also 
identified a further two TYR missense variants (GRCh38) chr11:g.89178528C>A; 
NM_000372.4:c.575C>A; p.(Ser192Tyr) (S192Y) and (GRCh38) 
chr11:g.89284793G>A; NM_000372.4:c.1205G>A; p.(Arg402Gln) (R402Q) in the 
same two individuals, excluded from the exome sequencing analysis based on 
population allele frequencies of 0.25 and 0.18 respectively. Segregation of all three 
TYR variants in all Amish families (families 1-4) is shown in Figure 3.1A, which 
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demonstrates that the p.(Ser192Tyr)/p.(Arg402Gln) variants are linked in cis and 
inherited in a compound heterozygous fashion with p.(Met252Arg) [which itself occurs 
in cis with p.(Arg402Gln)] in all affected individuals except for a single affected 
individual with OCA (family 1; individual X:1), found to be homozygous for 
p.(Met252Arg) through targeted dideoxy sequencing. Individuals compound 
heterozygous for TYR p.(Met252Arg) and p.(Ser192Tyr)/p.(Arg402Gln) alleles 
displayed clinical features suggestive of partial albinism with variable skin and hair 
depigmentation, whilst the individual homozygous for the TYR p.(Met252Arg) variant 
displayed features of classical OCA including nystagmus, iris transillumination defects, 
a depigmented fundus and foveal hypoplasia (Table 3.1). Notably, individuals carrying 
the TYR p.(Met252Arg) variant on one allele and only the p.(Arg402Gln) or the 
p.(Ser192Tyr) variant on the other allele were apparently unaffected with no clinical 
features of OCA (individuals VIII:9, IX:2, IX:21, X:6, X:8, IX:1 and IX:4, Figure 3.1A). 
 
Additive temperature sensitive effects of p.(Ser192Tyr) (S192Y) and p.(Arg402Gln) 
(R402Q) variants on TYR enzymatic activity 
 
The TYR p.(Arg402Gln) variant alone has previously been proposed to contribute to 
OCA when inherited in trans with a pathogenic TYR variant (127, 133-135, 141-144, 
153). Pedigree analysis however appears to dispute this, with five individuals 
compound heterozygous for the pathogenic TYR p.(Met252Arg) variant as well as the 
p.(Arg402Gln) variant and yet showing no clinical features of OCA (individuals VIII:9, 
IX:2, IX:21, X:6 and X:8; Figure 3.1A). At the same time, 13 individuals who were 
compound heterozygous for TYR p.(Met252Arg) and p.(Ser192Tyr)/p.(Arg402Gln) 
alleles all displayed clinical features of partial albinism, suggesting an additive impact 
of the p.(Ser192Tyr) and p.(Arg402Gln) variants on tyrosinase function. To investigate 
this further, functional experiments were designed to study and quantify the effects of 
the p.(Ser192Tyr) and p.(Arg402Gln) variants both independently and in combination, 
compared to wild-type tyrosinase enzyme.  
 
Figure 3.1C shows the DOPA-oxidase activity for all tyrosinase mutants analysed from 
0 mins to 180 mins at 31°C and 37°C. At 37°C, a slight decrease in DOPA-oxidase 
activity of the p.(Ser192Tyr) mutants, and an almost total loss of DOPA-oxidase 
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activity in the p.(Arg402Gln) mutants and p.(Ser192Tyr)/p.(Arg402Gln) double 
mutants was observed. Tyrosinase activity recorded at 31°C was more variable across 
the different mutant groups, with significant decrease in activity in all TYR-mutant cell 
lines compared to wild type. For all the TYR-mutant cell lines, the 
p.(Ser192Tyr)/p.(Arg402Gln) double mutants showed the most reduced tyrosinase 
activity, followed by p.(Arg402Gln) mutant, with the p.(Ser192Tyr) mutant least 
affected. There was a statistically significant difference between all three mutant 
groups, indicative of a cumulative effect of both p.(Ser192Tyr) and p.(Arg402Gln) 





Figure 3.1 Pedigree diagrams, TYR genotype and functional data 
(A) Pedigree diagram of families 1 - 4 showing segregation of the TYR p.(Ser192Tyr), 
p.(Met252Arg), and p.(Arg402Gln) variants. The two disease-causing haplotypes are shaded; 
the p.(Met252Arg) haplotype in blue, and the p.(Ser192Tyr)/p.(Arg402Gln) in cis haplotype in 
yellow, with the relevant amino acid change highlighted in red. All affected individuals inherited 
both the p.(Met252Arg) and p.(Ser192Tyr)/p.(Arg402Gln) in cis haplotypes in compound 
heterozygous fashion, apart from individual X:1, who displayed a more severe albinism 
phenotype and was found to be homozygous for the p.(Met252Arg) variant. No unaffected 
individuals inherited both disease-associated haplotypes, confirming segregation with disease 
in the family. 
(B)(i) Sequence chromatograms showing the TYR c.575C>A; p.(Ser192Tyr), c.755T>G; 
p.(Met252Arg) and c.1205G>A; p.(Arg402Gln) variants in heterozygous form (ii) Schematic 
localisation of TYR p.(Ser192Tyr), p.(Met252Arg) and p.(Arg402Gln) variants within the 
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catalytic tyrosinase domain of the TYR polypeptide. The p.(Ser192Tyr) and p.(Arg402Gln) 
variants are located at or near the copper-containing catalytic binding sites (the red diamonds 
denote the histidine residues that bind to copper atoms and hence structurally coordinate the 
positions of the metal binding sites) (iii) Conservation of the TYR p.(Ser192Tyr), p.(Met252Arg) 
and p.(Arg402Gln) variants across species. 
(C) Tyrosinase activity in wild-type, p.Ser192Tyr (S192Y) mutant, p.Arg402Gln (R402Q) 
mutant and double mutant HEK293 cells. Absorbance of dopaquinone, a product synthesised 
by the transformation of L-DOPA by tyrosinase was quantified as a measure of tyrosinase 
activity in wild-type and TYR-mutant cell lines. Cumulative production of dopaquinone (i, ii)) 
was quantified from the start of the L-DOPA treatment (0 min) to 180 min. Statistical 
differences between cell lines were analysed at 180 min (iii, iv). Data is shown as mean ± SEM 
and statistically significant differences between groups are indicated by asterisks (* p<0.05, ** 
p<0.01, *** p<0.001, **** p<0.0001); ns = not significant 
 
Enrichment of the TYR p.(Ser192Tyr)/p.(Arg402Gln) haplotype in OCA and control 
cohorts 
 
Interrogation of a clinical cohort of 161 affected individuals with nystagmus and/or 
albinism (Southampton cohort) [including individuals previously reported by Norman 
et al and O’Gorman et al (132, 145)] identified 71 individuals with two pathogenic or 
likely pathogenic variants (molecularly diagnosed including TYR, OCA2, GPR143 and 
PAX6 genes), 51 individuals carrying only a single likely disease-associated TYR 
variant with no candidate pathogenic variants identified in other OCA genes (missing 
heritability), and 39 individuals with no disease-associated TYR variants. All patients 
were sequenced using either using the “Albinism or congenital nystagmus v1.0” 
PanelApp gene panel (41 genes) (https://panelapp.genomicsengland.co.uk/panels/) 
or a broader research panel as previously described (132, 145). CNV analysis was not 
performed. Of these, 2 of the 71 individuals in the molecularly diagnosed group and 
49 of the 51 individuals in the missing heritability group were found to have a genotype 
consistent with the presence of the TYR p.(Ser192Tyr)/p.(Arg402Gln) haplotype (i.e. 
individuals who were homozygous or heterozygous for both these variants) (Table 
3.2); this information was unavailable for the 39 molecularly undiagnosed individuals 
in this clinical cohort.  
 
A review of seven published OCA cohorts with missing heritability (i.e. individuals in 
whom only a single pathogenic TYR variant has been identified), together with our 
study cohort, found that approximately half of all affected individuals (50.7%) had a 
genotype consistent with the TYR p.(Ser192Tyr)/p.(Arg402Gln) haplotype (Table 3.2). 
This is markedly enriched compared to molecularly diagnosed TYR OCA cohorts 
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(2.0%), as well a control cohort of 219 Amish individuals with no OCA diagnoses 
(31/219 or 16.9%; Pearson’s Chi-squared test, p < 2.2 x 10-16 ). These findings strongly 
suggest that the TYR p.(Ser192Tyr)/p.(Arg402Gln) haplotype contributes to the OCA 
phenotype. 
 
Additionally, 49 affected individuals in the Southampton and Salisbury missing 
heritability study cohorts identified as carrying only a single pathogenic or likely 
pathogenic TYR variant were also found to harbour homozygous or heterozygous TYR 
p.(Ser192Tyr) and p.(Arg402Gln) variants; of these, familial segregation was 
performed in 41 individuals and their parents to assess the phase. In 23 individuals, 
this confirmed that the TYR p.(Ser192Tyr) and p.(Arg402Gln) variants were inherited 
in cis, and this haplotype was in trans to the previously identified pathogenic or likely 
pathogenic TYR variant (Table 3.3). For the remaining 18 cases, definitive segregation 
was not possible. Notably, no case was identified in which segregation showed that 
p.(Ser192Tyr) and p.(Arg402Gln) were not in trans with the pathogenic or likely 
pathogenic variant.  
 
In five of the seven published OCA cohorts with missing heritability reviewed, it was 
possible to determine the cis/trans phase of the TYR p.(Ser192Tyr) and p.(Arg402Gln) 
variants in a proportion of individuals reported (136, 139, 141, 148, 149) (Table 3.3); 
in the remaining individuals this was not possible due to familial samples being 
unavailable for segregation analysis, or uninformative segregation results (owing to 
the high allele frequency of the p.(Ser192Tyr) and p.(Arg402Gln) TYR variants in the 
general population). For the remaining two studies of OCA cohorts with missing 
heritability, the cis/trans phase of the TYR p.(Ser192Tyr) and p.(Arg402Gln) variants 
could not be determined from the reported genotypes (126, 134). There were 41 OCA 
individuals with missing heritability from these five studies in whom the 
p.(Ser192Tyr)/p.(Arg402Gln) haplotype was possible, and where the cis/trans phase 
of the TYR p.(Ser192Tyr) and p.(Arg402Gln) variants could also be determined. In 
accordance with the findings from our local research cohorts, together with this 
additional informative cohort derived from five published studies, the TYR 
p.(Ser192Tyr)/p.(Arg402Gln) haplotype segregated in trans with the pathogenic TYR 
variant in all cases (amounting to 25.5% of total missing heritability cases; Table 3.3). 
Taken together with the findings in Table 3.2, this suggests that the 
78 
 
p.(Ser192Tyr)/p.(Arg402Gln) haplotype completes the molecular diagnosis in ~25-
50% of OCA individuals with missing heritability.
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Table 3.2 Prevalence of TYR p.(Ser192Tyr)/S192Y and p.(Arg402Gln)/R402Q variants in OCA cohorts  
 OCA cohorts with missing heritability  
(individuals with only 1 TYR pathogenic or likely pathogenic variant identified) 
Molecularly diagnosed OCA1 cohorts  
(individuals with 2 TYR pathogenic or likely pathogenic variant 
identified)  
This study* Hutton & 
Spritz 2008a 









Gronskov 2019 Campbell 2019 Hutton & Spritz 
2008b 














AROA or OA) 
Nystagmus and at 
least one other 
ocular feature of 
albinism, no skin 
hypopigmentation 
OCA OCA1 OCA1 Albinism (OCA, 
AROA or OA) 
Country 
(ethnicity) 





NA (Iranian) France Scandinavia 
(Scandinavian) 





NA (Iranian) Scandinavia 
(Scandinavian) 
No of individuals 
in cohort 
51 20 13 3 6 158 29 4 71 9 19 2 
No of individuals 
hom or het for 
both TYR S192Y 
& R402Q 




































*This cohort includes individuals previously reported in Norman et al and O’Gorman et al 
Abbreviations: AROA, autosomal recessive ocular albinism; het, heterozygous; hom, homozygous; OCA, oculocutaneous albinism; OA, ocular 
albinism; no, number  
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Table 3.3 Potential contribution of TYR p.(Ser192Tyr)/p.(Arg402Gln) haplotype to molecular diagnoses in OCA cohorts with 
missing heritability 
This includes individuals with only 1 TYR pathogenic or likely pathogenic variant identified 
 
Study This study* Oetting 2009 Ghodsinejad 
Kalahroudi 2014 




OCA1 OCA1 Nystagmus and/or 
absence of fovea 
Albinism (OCA, 
AROA or OA) 
Nystagmus and at 
least one other 
ocular feature of 
albinism, no skin 
hypopigmentation 
Country (ethnicity) England NA (Iranian) France Scandinavia 
(Scandinavian) 
England 
Number of individuals in cohort 51 3 6 158 29 4 
Number of individuals hom or het for both TYR S192Y 
and R402Q, where S192Y/R402Q haplotype is possible 
49 2 0 64 21 4 
Number of individuals in whom it was possible to 
determine the phase of TYR S192Y, R402Q and 
pathogenic or likely pathogenic variants (“informative 
cohort”) 
23 2 6 31 6 2 
Number of individuals in whom TYR S192Y and R402Q 
were in cis, and in trans to pathogenic or likely 
pathogenic TYR variant in the informative cohort 
23 2 0 31 6 2 
Proportion of “informative cohort” where S192Y/R402Q 
haplotype is possible and molecular diagnoses due to 
TYR S192Y/R402Q haplotype in trans to pathogenic or 







possible in any 







Combined proportion of “informative cohort” where 
molecular diagnoses is due to TYR S192Y/R402Q 




Proportion of total cohort where molecular diagnoses 
due to TYR S192Y/R402Q haplotype in trans to 













Combined proportion of total cohort where molecular 
diagnoses is due to TYR S192Y/R402Q haplotype in 





*This cohort includes individuals previously reported in Norman et al and O’Gorman et al 








The pathogenicity of TYR p.(Ser192Tyr) and p.(Arg402Gln) variants and their 
contribution to the OCA phenotype, either in isolation or when linked in cis, has 
been heavily debated in many studies (117, 126, 127, 133, 134, 136-138, 142-
146). As such, these TYR variants are variably reported by clinical testing 
laboratories and potentially excluded, even when shown to be in cis. Here 
genomic and functional data, initiated by a search for the cause of OCA in a 
number of Amish families, provide irrefutably strong evidence that the TYR 
p.(Ser192Tyr) and p.(Arg402Gln) variants are pathogenic when in cis. The 
increased frequency of the TYR p.(Met252Arg) variant in the Amish community, 
likely due to founder effects and endogamy together with the large family sizes 
typical within the community, permitted empowered co-segregation studies able 
to determine the haplotype, phasing and inheritance of the common 
p.(Ser192Tyr) and p.(Arg402Gln) TYR variants together with the p.(Met252Arg) 
variant in a large number of related individuals for the first time.  
 
A number of previous studies have shown that the TYR p.(Arg402Gln) variant 
is present at increased frequency in OCA patients in whom only a single clearly 
deleterious sequence alteration in TYR has been detected (126, 129, 133-141, 
149), and is proposed to contribute to OCA when inherited in trans with a 
pathogenic TYR variant (127, 133-135, 141-144, 153). This has been disputed 
by Oetting et al, who describe 10 unaffected parents of OCA individuals who 
carried a combination of both a TYR pathogenic variant as well as the 
p.(Arg402Gln) variant in trans, and yet showed no clinical features of OCA 
(136). Recently, however, molecular and phenotypic analysis of a large cohort 
of 268 French OCA1 individuals suggests that compound heterozygosity for a 
known pathogenic TYR variant and the hypomorphic p.(Arg402Gln) variant may 
be associated with a variable but generally mild form of albinism that may 
remain clinically undiagnosed, with the authors supporting consideration of 
p.(Arg402Gln) as a mildly pathogenic, but definitely pathogenic, TYR variant 
when associated in trans with another pathogenic variant (154). It should be 
noted that the TYR p.(Arg402Gln) variant is not generally thought to be 
sufficiently deleterious to cause OCA in homozygous form, with a homozygous 
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prevalence of 7.47% in population databases (non-Finnish European 
population, gnomAD v2.1.1), as well as several studies that have reported on 
individuals homozygous for the p.(Arg402Gln) with no clinical features of 
albinism (136, 138, 155).  
 
It has been proposed that a second TYR variant, p.(Ser192Tyr), acting in cis 
with the p.(Arg402Gln) variant, may have an additive effect producing a greater 
reduction in enzyme activity compared to each variant individually (145, 147), 
although this too has been disputed (154). Our study demonstrates that 
inheritance of either variant individually in compound heterozygous form with 
the deleterious p.(Met252Arg) variant is insufficient to result in a clinically 
significant OCA phenotype (individuals VIII:9, IX:1, IX:2, IX:4, X:6 and X:8; 
Figure 3.1A), although we acknowledge that subtle asymptomatic clinical 
findings such as mild iris transillumination or foveal hypoplasia were not 
specifically excluded. The p.(Ser192Tyr) and p.(Arg402Gln) variants are 
believed to have arisen independently on different ancestral haplotypes (156), 
and although these variants individually in Caucasian populations are common 
with allele frequencies of 36% and 27% respectively (gnomAD v2.1.1), their 
combined presence in cis on a recombinant haplotype is relatively rare, 
predicted to be between 1.1% to 1.9% in European populations (145, 147, 149). 
This study, alongside other previous studies (126, 132, 136, 141, 145, 148, 
149), provides strong support to show that the TYR 
p.(Ser192Tyr)/p.(Arg402Gln) haplotype is enriched in Caucasian OCA cohorts 
with missing heritability (Table 3.2), and contributes to an OCA1B diagnosis 
when inherited in trans with a second deleterious TYR variant (Table 3.3), 
particularly in individuals with lower pigmentary backgrounds, who may be more 
susceptible to the damaging effects of hypomorphic variants (135, 157).  
 
Given the number of apparently unaffected individuals homozygous for the 
p.(Ser192Tyr)/p.(Arg402Gln) haplotype reported in the literature (147-149), the 
penetrance of the p.(Ser192Tyr)/p.(Arg402Gln) haplotype might appear to be 
incomplete, confounding the argument that it is a pathogenic allele. The 
phenotype of OCA2 can be modified by variants in MC1R (158) or TYRP1 
(159), and the phenotype of OCA3 by haploinsufficiency of OCA2 (160); 
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additionally, possible digenic inheritance in OCA involving combinations of 
TYR, OCA2 and SLC45A2 variants has been proposed (161, 162). Similarly, 
the apparent reduced penetrance of the p.(Ser192Tyr)/p.(Arg402Gln) 
haplotype may relate to the modifying effects of sequence variants in genes 
encoding other melanosomal proteins, although other genetic and molecular 
studies would be required to confirm this. However, we propose that individuals 
homozygous for the hypomorphic p.(Ser192Tyr)/p.(Arg402Gln) allele have 
instead a consistent but mild phenotype which is easily missed by incomplete 
phenotyping. In support of this, our studies identified five individuals with a 
clinical diagnosis of ‘possible hypomorphic’ OCA who were homozygous for 
TYR p.(Ser192Tyr)/p.(Arg402Gln), with no other known or likely TYR or other 
OCA gene-associated variants identified (Table 3.4). All were noted to have 
foveal hypoplasia on OCT investigation, but most had very mild, if any, other 
OCA features. Additionally, an apparently unaffected relative in our study was 
also identified as homozygous for TYR p.(Ser192Tyr)/p.(Arg402Gln). Despite 
the absence of nystagmus or any other pigmentary phenotype in this unaffected 
individual and visual acuities of 0.1 and 0.08 LogMAR (right and left eye 
respectively), further detailed clinical investigation identified very mild iris 
transillumination and significant foveal hypoplasia (Table 3.4 and Figure 3.2). A 
review of all affected and apparently unaffected individuals homozygous for 
both TYR p.(Ser192Tyr) and p.(Arg402Gln) variants in the literature and our 
study cohorts identified 13 affected individuals in three studies, and foveal 
hypoplasia as well as iris transillumination was documented in all these 
individuals (148, 149) (Table 3.4). It therefore seems likely that individuals 
homozygous for both common variants and thus the hypomorphic 
p.(Ser192Tyr)/p.(Arg402Gln) allele, have such a mild phenotype that they can 
easily go unidentified and unreported due to minimal effects on visual function 





Figure 3.2 Foveal hypoplasia in individual homozygous for TYR 
p.(Ser192Tyr)/p.(Arg402Gln) haplotype 
SD-OCT (Spectral domain optical coherence tomography; Spectralis‐OCT, Heidelberg 
Engineering, Heidelberg, Germany)  image of right (A) and left (B) eyes showing grade 
3 foveal hypoplasia in an apparently unaffected individual homozygous for both TYR 
p.(Ser192Tyr) and p.(Arg402Gln) variants [foveal hypoplasia graded following 
structural grading system based on OCT data proposed by Thomas et al (163)] 
 
The TYR p.(Arg402Gln) variant is located near the copper-containing catalytic 
binding site CuB, and functional studies have shown that this amino acid 
alteration results in an enzyme with decreased thermal stability, disrupted 
copper binding and reduced catalytic activity, thought to be mediated by 
decreased protein stability resulting in increased retention of the mutant 
tyrosinase protein as an unprocessed and misfolded glycoform in the 
endoplasmic reticulum (ER) (147, 155, 164-169). The TYR p.(Ser192Tyr) 
variant is located within the copper-containing catalytic binding site CuA, and 
has been shown to reduce tyrosinase enzymatic activity and melanocyte 
pigment production independent of the p.(Arg402Gln) variant (147, 170, 171). 
Genome-wide association studies have identified associations with skin, hair 
and eye pigmentation for both p.(Ser192Tyr) and p.(Arg402Gln) variants (172-
176), suggesting these variants have a role in normal pigmentary variation, and 
that the double-variant p.(Ser192Tyr)/p.(Arg402Gln) haplotype appears to 
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show an additive effect on these pigmentary phenotypes compared to each 
variant individually (147). It is difficult however from literature review alone to 
quantify the functional effects of the p.(Ser192Tyr) and p.(Arg402Gln) variants, 
both independently and in combination, compared to wild-type tyrosinase 
enzyme. This issue arises from the historical use of the human TYR expression 
construct pcTYR containing the p.(Ser192Tyr) variant to study the effects of 
“wild-type” tyrosinase activity (155, 177). Computational approaches to TYR 
functional activity, based on protein flexibility and dynamic properties, suggest 
that the p.(Ser192Tyr) and p.(Arg402Gln) variants both result in a TYR protein 
that is less stable and has reduced enzyme activity compared to a wild-type 
molecule; the combined effect of having both changes together in a single TYR 
molecule however has not been previously investigated (178). This study now 
shows for the first time a thermosensitive additive decrease in enzymatic 
function of the double-variant p.(Ser192Tyr)/p.(Arg402Gln) TYR protein 
compared to each variant acting individually (Figure 3.1C), lending further 
support to pathogenicity of the p.(Ser192Tyr)/p.(Arg402Gln) haplotype. 
Homology modelling of tyrosinase protein structure does not appear to show a 
direct interaction between the 192 and 402 amino acid residues (149), and 
therefore this additional reduction in enzyme function in the double-mutant 
protein may instead be mediated by a combination of increased ER retention of 
the misfolded mutant protein [caused by p.(Arg402Gln) reducing protein 
stability] and reduced enzyme activity of any released mutant protein [possibly 
resulting from steric hindrance effects of p.(Ser192Tyr) affecting the CuA 
binding site] (170), as proposed by Gronskov et al (149).  
 
Subcellular localisation studies have determined that disease-associated TYR 
variants commonly result in near absolute and irreversible ER retention of the 
mutant protein. The p.(Arg402Gln) variant however results in a thermosensitive 
tyrosinase protein that is retained in the ER at higher temperatures, but is able 
to partially exit the ER at lower, more permissive temperatures (164, 167, 169). 
Homozygosity for the p.(Ser192Tyr)/p.(Arg402Gln) haplotype may therefore 
still permit sufficient quantities of mutant tyrosinase to reach the inner surface 
of the melanosomal membrane, where the mutant protein is still able to 
participate in protein-protein interactions with other melanosomal proteins 
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involved in melanogenesis, such as TYRP1 and TYRP2 (179, 180), resulting in 
a less severe functional impact and a milder pigmentary phenotype that may 
not always be clinically significant. This thermosensitivity of the double variant 
mutant TYR protein also provides a compelling explanation for our novel 
discovery of a consistent foveal hypoplasia phenotype in individuals who are 
homozygous for both p.(Ser192Tyr)/p.(Arg402Gln) TYR variants, as higher 
temperatures within the developing eye may result in a larger impact of these 
variants on tyrosinase function (133), whilst lower temperatures at the skin and 
extremities instead results in greater preservation of mutant protein function 
and a milder and more variable pigmentary phenotype. 
 
Together, our studies define the genotype, biochemical and phenotype 
correlation of the p.(Met252Arg) and p.(Ser192Tyr)/p.(Arg402Gln) TYR 
variants and collectively demonstrate that the in cis 
p.(Ser192Tyr)/p.(Arg402Gln) allele is pathogenic. As such, the TYR 
p.(Ser192Tyr)/p.(Arg402Gln) haplotype should be included as a pathogenic 
allele in future and retrospective genetic diagnoses of OCA, supporting the idea 
for a review of all previously undiagnosed OCA cases where these variants 
have been excluded. Reporting of the p.(Ser192Tyr)/p.(Arg402Gln) genotype 
in individuals in whom only a single deleterious TYR variant has been identified 
could permit a 25-50% uplift in confirmatory molecular diagnoses (when phase 
has been determined) in this diagnostically challenging patient group (Tables 
3.2 and 3.3). Additionally, for patients with an albinism phenotype but no 
apparent variants in albinism genes, consideration of these variants when 
identified in cis as a pathogenic allele in its own right may also help provide 
clinical direction. For example, in individuals heterozygous for this allele, 
alternative diagnoses such as syndromic albinism might be considered less 
likely, as they would be considered ‘at least a carrier of a pathogenic OCA1B 
allele’, and genomic data may be re-examined in a targeted fashion to search 
for further non-coding splice or structural variants in the TYR gene. Additionally, 
in individuals with a very mild albinism phenotype or isolated foveal hypoplasia, 
identification of this pathogenic allele in homozygous form may provide the 




Achieving an accurate molecular diagnosis will bring about important benefits 
in affected individuals and their families. It allows accurate prognostic 
information and family counselling to be provided, avoids the need for further 
invasive investigations to confirm the clinical diagnosis or rule out syndromic 
forms of the disease or masquerading conditions, and has important 
therapeutic implications, given the emerging therapies currently under 





Table 3.4 Review of individuals homozygous for both TYR p.(Ser192Tyr) 
and p.(Arg402Gln) 
Individuals with an alternative molecular diagnosis responsible for the albinism 
phenotype were excluded from this review 
 











93 individuals with a clinical 
diagnosis of albinism; 
diagnostic criteria included 
nystagmus, reduced visual 
acuity, iris translucency, 
fundus hypopigmentation, 
and foveal hypoplasia 
6 individuals 
• 5 with clinical 
diagnosis of 
AROA 
• 1 with clinical 
diagnosis of 
OCA 
• All 6 individuals were first 
investigated by sequential Sanger 
sequencing of 6 genes only (TYR, 
OCA2, TYRP1, SLC45A2, 
LRMDA, GPR143) 
• 3 of the 6 individuals were further 
investigated by whole genome 
sequencing and data analysis of 





12 individuals with 
nystagmus, at least one 
other ocular feature of 
albinism, and no apparent 
skin hypopigmentation in 
the context of their family 
2 individuals  
(Proband 7 and 8; 
not related) 
Proband 7 
• Genomic data analysis limited to 
nystagmus and foveal hypoplasia 
gene panel (26 genes evaluated) 
• Clinical information: iris 
transillumination, foveal 
hypoplasia, fundal 
hypopigmentation, probable VEP 
crossed asymmetry 
Proband 8 
• Genomic data analysis limited to 
ocular/oculocutaneous albinism 
gene panel (18 genes evaluated) 
• Rare, likely pathogenic TYRP1 
variant [c.208 G>A, p.(Ala70Thr)] 
also identified in this individual 
• Affected brother with nystagmus, 
who was homozygous for both 
TYR p.(Ser192Tyr) and 
p.(Arg402Gln) but WT for the 
TYRP1 variant 
• Clinical information: iris 
transillumination, foveal 
hypoplasia, fundal 





130 individuals with a 
clinical diagnosis of 
nystagmus and/or albinism 
 
All were investigated with 
Illumina TruSightTM One 
5 individuals W1703356 
• Foveal hypoplasia noted on OCT 
• No other TYR or albinism-
associated variant identified 
W1919237 




clinical exome sequencing 
followed by additional 
filtering using virtual gene 
panel analysis using the 
“Albinism or congenital 
nystagmus v1.0” Panelpp 
gene panel  
• No other TYR or albinism-
associated variant identified 
• Biallelic ABCA4 variants also 
identified and further investigation 
with ERG planned; however foveal 
hypoplasia is not a known feature 
of ABCA4-associated retinal 
dystrophy 
W2002293 
• Possibly afoveate (poor quality 
OCT scans) 
• No other TYR variant or albinism-
associated variant identified 
• Maternal uncle apparently affected 
with nystagmus 
W1905299 
• Afoveate, pale skin and hair, good 
albinism phenotype 
• No other TYR variant or albinism-
associated variant identified 
W1817121 
• Afoveate; sister also afoveate but 
with no nystagmus 
• No other TYR variant or albinism-
associated variant identified 




2 genetic epidemiological 
longitudinal studies: 
Brisbane Twin Nevus 
Study (1155 nuclear 
families) and Queensland 
Familial Melanoma Project 
(1211 melanoma cases) 
2 individuals Both individuals fair skinned with 
fair/blond hair and blue eye colour, no 
clinical diagnosis of OCA (but ocular 




100,000 genomes pilot 
dataset of 4046 individuals 
with no clinical features 
suggestive of albinism 
2 individuals  No detailed ocular phenotyping 
available 
This study Southampton cohort:  
161 probands with 




This apparently unaffected individual 
was father to two affected siblings who 
were both clinically diagnosed with 
nystagmus and/or OCA (see below). 
Both affected siblings were 
heterozygous for a known pathogenic 
TYR variant, and also homozygous for 
both TYR p.(Ser192Tyr) and 
p.(Arg402Gln). This unaffected parent 
was asymptomatic but was noted to 
have with mild iris transillumination and 
foveal hypoplasia on OCT (see Figure 
3.2) in the absence of nystagmus or a 
pigmentary phenotype, and had normal 
visual acuities of 0.1 and 0.08 LogMAR 
(right and left eye respectively).  
This study Amish Exome Database: 
Control exome database of 
219 Amish individuals 
unaffected by OCA 




Individuals with albinism likely due to heterozygous deleterious TYR variant in combination 
with homozygosity for p.(Ser192Tyr)/p.(Arg402Gln) 
This study Southampton cohort:  
161 probands with 
nystagmus and/or albinism 
and relatives 
2 individuals Affected siblings, both also 
heterozygous for a known pathogenic 
TYR variant  
This study Salisbury cohort: 
130 individuals with a 
clinical diagnosis of 
nystagmus and/or albinism 
1 individual W1809902 
Also heterozygous for a TYR 




990 index patients with at 
least one of the main 
characteristic ocular 
features of albinism - either 
nystagmus or an absence 
of the fovea 
1 individual TYR/R402Q-P13 
Also heterozygous for a known 
pathogenic TYR c.1118C>A; 
p.(Thr373Lys) variant (166) 
 
Abbreviations: AROA, autosomal recessive ocular albinism; ERG, electroretinogram; 
OCA, oculocutaneous albinism; OCT, optical coherence tomography; VEP, visual 









In Pakistan, geographical constraints and marriage patterns within communities 
may give rise to genetic isolates in which an increased frequency of certain 
disease-associated founder mutations may occur (183). Knowledge of the 
specific spectrum and frequency of such genetic variants within different 
regions is fundamental to the development of effective and more tailored 
diagnostic genetic testing strategies, targeting variants relevant to a particular 
population. This will permit rapid and cost-efficient screening and diagnostic 
assays that will allow accurate disease diagnosis, improved carrier detection 
and appropriate counselling for affected families.  
 
As part of an ongoing international collaboration, genomic studies were 
undertaken in a number of OCA families from several communities in Pakistan 
to define the specific molecular causes of disease. In parallel with this, an 
extensive literature review of previous reported genetic causes of OCA in 
individuals from Pakistan was undertaken. This knowledge advances the 
understanding of the relative contribution of pathogenic OCA variants in 
Pakistan. 
 
3.3.2 Materials and methods 
 
This study entails the genetic and clinical investigations in 36 Pakistani families, 
from different ethnic groups and provinces in Pakistan (Table 3.5). Medical 
histories were taken from all families, and a diagnosis of OCA was established 
in all affected individuals. Following results from genetic analyses and the 
identification of pathogenic variants in OCA-associated disease genes, affected 
members in all families were revisited, and a detailed medical history was 
ascertained. Facial photographs and videos were taken with consent to 
document phenotypic features and confirm disease status. Ophthalmic 
examinations were completed using the best locally available resources with 
support from visiting ophthalmologists from local collaborating hospitals. This 
included visual acuity testing using Snellen charts and LVRC (low vision 
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resource centre) numbers – LVRC distance LogMAR Visual Acuity Chart, 
colour vision testing using Ishihara charts and funduscopic examination by 
direct ophthalmoscopy where possible in the affected individuals examined. 
 
Blood samples were taken with informed consent for DNA extraction (see 
section 2.3.2). As the TYR gene is a small gene comprising only five coding 
exons, all families were first investigated by targeted dideoxy sequencing for 
variants in one affected individual in each family, using primers designed as 
described in section 2.3.2 (Appendix Table D2). This defined the likely disease-
causing variant(s) in 21 families (families 5 - 25). 
 
In all remaining families (families 26 - 40), next generation sequencing was 
performed on a single affected individual in each family using the Illumina 
TruSightTM One clinical exome sequencing panel as described in section 2.3.5. 
TruSightTM One clinical exome sequencing was also subsequently performed 
in a single affected individual (IV:7) in family 23, and in a molecularly 
undiagnosed affected individual (VI:5) in family 33. Bioinformatic analysis of 
exome data was performed as per section 2.3.5. Primer design (Appendix 
Table D2), PCR and dideoxy sequencing was performed as described in 
section 2.3.3. to genotype and confirm appropriate segregation of the candidate 
disease variant in all available affected and unaffected individuals. SNP 
genotyping was performed in two affected individuals in family 40 (IV:2 and 
IV:3) as described in section 2.3.4. 
 
A literature review was performed as described in section 2.4 to retrieve all 
variants and loci associated with OCA in Pakistan. Findings are summarised in 
Appendix C. 
 
3.3.3 Results: clinical and genetic findings 
 
Study subjects from 36 families with OCA were enrolled from the Punjab, KPK 
and Balochistan provinces in Pakistan. The apparent mode of inheritance in all 
families was consistent with an autosomal recessive disorder. All affected 
individuals displayed the cardinal clinical features of OCA with white-to-golden 
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blonde hair, pale-to-reddish white skin, decreased visual acuity, nystagmus and 
photophobia. Clinical examination in all affected individuals examined 
demonstrated the classical ophthalmic features of albinism, namely: 
nystagmus, foveal hypoplasia and a hypopigmented albinotic fundus. 
 
Targeted dideoxy sequencing of the TYR gene identified a number of novel and 
previously reported variants in families 5 - 25 (findings summarised in Table 
3.5). All identified variants appeared to segregate appropriately for autosomal 
recessive disease in all families investigated (Figure 3.4), apart from family 23, 
where a well reported TYR NM_000372.4:c.1037-7T>A splice variant (153, 
184-190) was initially identified through targeted TYR gene sequencing in 
individual IV:5 in homozygous form. This variant segregated appropriately in 
affected and unaffected individuals in family 23 apart from affected individual 
IV:7, in whom the TYR c.1037-7T>A variant was only detected in heterozygous 
form. TruSightTM One clinical exome sequencing was subsequently performed 
in this individual, which led to the identification of a further heterozygous TYR 
variant, c.1255G>A; p.(Gly419Arg) that has been reported in numerous 
Pakistani families residing in several regions of Pakistan including Punjab, KPK, 
Sindh, and Azad Jammu and Kashmir (131, 186, 188, 191-194) (Table 3.5). 
This variant was subsequently confirmed by dideoxy sequencing in individual 
IV:7, but was not present in affected individuals IV:3 and IV:5. 
 
TruSightTM One clinical exome sequencing identified a number of novel and 
known variants in OCA2 in families 26 - 39, with findings summarised in Table 
3.5. All identified variants segregated appropriately for an autosomal recessive 
disease in all families investigated (Figure 3.4), apart from family 33, where the 
previously reported OCA2 NM_000275.3:c.1045-15T>G splice variant (186, 
193) was identified in homozygous form in affected individuals IV:1, IV:5, V:3, 
V:8, VI:2 and VI:3, but only in heterozygous form in affected individual VI:5. 
TruSightTM One clinical exome sequencing was subsequently performed in this 
individual, but this did not identify any further candidate disease variants in 




The novel TYR c.132T>A; p.(Ser44Arg) and c.1002delA; p.(Ala335Leufs*20) 
variants were present in the gnomAD population database in heterozygous 
form in 5 individuals from the Latino/admixed American population (gnomAD 
v2.1.1; MAF 0.00001989) and 1 individual from the South Asian population 
(gnomAD v3.1.1; MAF of 0.000006571), with no homozygous individuals 
identified. The novel OCA2 c.1762C>T; p.(Arg588Trp) variant was present in 
homozygous form in 5 South Asian individuals in gnomAD (v2.1.1), with a MAF 
of 0.0009973 (MAF of 0.005131 in the South Asian population). The remaining 
novel variants identified in this study, TYR c.240G>C; p.(Trp80Cys), TYR 
c.667C>T; p.(Gln223*) and OCA2 c.2458T>C; p.(Ser820Pro) were all absent 
in gnomAD (Table 3.6). In silico analysis of the novel variants identified was 
undertaken using the variant prediction tools SIFT, PolyPhen-2, PROVEAN and 
MutationTaster2. These were largely in agreement and predicted a deleterious 
effect for all novel variants assessed, apart from OCA2 c.1762C>T; 
p.(Arg588Trp), where pathogenicity predictions were conflicting (Table 3.6). 
Localisation of the novel TYR and OCA2 missense variants within the 
respective polypeptide is shown in Figure 3.3 alongside conservation analysis 
of the affected amino acid residue across a range of vertebrate species. 
 
In family 40, TruSightTM One clinical exome sequencing in a single affected 
individual initially failed to identify any candidate disease variants likely 
responsible for the OCA phenotype. Whole genome SNP mapping was 
subsequently performed in both affected individuals, and identified a 7.42 Mb 
region of homozygosity in chromosome 15q13.1 (GRCh38 chr15:g.22180552; 
rs4462663 to chr15:g.29601735; rs1459361) common to both affected family 
members and encompassing the OCA2 gene (Figure 3.5B). Array analysis 
identified an intragenic homozygous deletion of ~63.4 kb within the OCA2 gene 
in both affected individuals, resulting in a deletion of exon 19, and predicted to 
result in a frameshift (Figure 3.5B). Exome data, analysed visually using IGV, 
indicated no reads over exon 19, with a good depth of sequencing reads 
covering the adjacent exons 18 and 20, again supporting a homozygous 




A literature and genomic database review of known causes of OCA in families 
from Pakistan was undertaken. Together with the current study, this identified 
reports of 838 individuals from 197 Pakistani families with 93 candidate mapped 
loci or causative genetic variants in 13 genes or loci (Appendix C), with variable 

















TYR  c.132T>A p.(Ser44Arg) Novel 0.00001989/  Not present 5 Balochistan Khatak 
NM_000372.5    0 (0)  6 KPK 
(Peshawar) 
Pashton 
 c.240G>C p.(Trp80Cys) Novel Not present Not present 7 KPK Pathan 
      8 KPK Pathan 







 c.308G>A p.(Cys103Tyr) Lasseaux et al (141) Not present Not present 10 Punjab 
(Sahiwal) 
Khokar 
 c.346C>T p.(Arg116*) Oettinga et al (196); Wei 
et al (162); Gula et al 
(192); Thomas et al 
(144); Lin et al (197); 








 c.649C>T p.(Arg217Trp) Tripathi et al (198); 






12 Punjab Rajput 
 c.667C>T p.(Gln223*) Novel Not present Not present 13 KPK (Bunar) Pashton 
 c.715C>T p.(Arg239Trp) Nakamura et al (199); 
Renugadevi et al (200); 
Zhong et al (189) 
0.00002790/ 
0.00006551 (0) 
Not present 14 Punjab 
(RYK) 
Turk 
 c.832C>T p.(Arg278*) Tripathi et al (194); 
Takizawa et al (201); 
Weia et al (162); Weib et 
al (171); Wang et al 
(202); Shahzad et al 
(186); Lionel et al (203); 
Rego et al (204); Lin et 
al (197); Zhong et al 





15 Punjab Punjabi 
     16 Punjab 
(Lahore) 
Gujjar 





 c.1255G>A p.(Gly419Arg) King et al (206);  
Chaki et al (207);  
Gula et al (192); 
Shahzad et al (186); 








    19 Punjab 
(Gujranwala) 
Arain 
     20 Punjab Virk 
     21 Punjab 
(Lahore) 
Malik Awan 
     22 NA NA 
 c.1037-7T>A Affects splicing Spritza et al (184); 
Ribero et al (185); 
Shahzad et al (186); 
Marti et al (153); 
Ceyhan-Birsoy et al 
(187); Gulb et al (188); 
Zhong et al (189); Hou 









 c.1255G>A p.(Gly419Arg) See above entry for 
families 18-22 
See above entry 
for families 18-22 
See above entry 
for families 18-22 
   
 c.832C>T p.(Arg278*) See above entry for 
families 15-17 
See above entry 
for families 15-17 
See above entry 




 c.1002delA p.(Ala335Leu 
fs*20) 
Novel Not present Not present    
 c.832C>T p.(Arg278*) See above entry for 
families 15-17 
See above entry 
for families 15-17 
See above entry 




 c.1255G>A p.(Gly419Arg) See above entry for 
families 18-22 
See above entry 
for families 18-22 
See above entry 
for families 18-22 
   
OCA2 
NM_000275.3  
c.1456G>T p.(Asp486Tyr) Jaworek et al (193); 








    27 Punjab 
(Borewala) 
Dogar 
    28 NA NA 
 c.2207C>T p.(Ser736Leu) Spritzb et al (208); Marti 







29 NA NA 
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 c.2360C>T p.(Ala787Val) Oettingb et al (210); 
Zhang et al (211) 
0.00002475/ 







 c.2458T>C p.(Ser820Pro) Novel Not present Not present 31 Punjab Niaz 
 c.1045-15T>G Affects splicing Jaworek et al (193); 
Shahzad et al (186) 
0.00002394/ Likely pathogenic 
(VCV000617802) 
32 Punjab Niaz 
   0.0001960 (0) 33 KPK Afridi 
    34 KPK 
(Peshawar) 
Pashton 
    35 KPK 
(Peshawar) 
Pashton 





Novel Not present Not present 37 KPK 
(Peshawar) 
Pashton 
 c.1327G>A p.(Val443Ile) Lee et al (212); Norman 
et al (213); Marti et al 
(153); Rego et al (204); 
Campbell et al (214); 





38 Punjab Saraiki 





   
 c.2020C>G p.(Leu674Val) Mondal et al (215); 





39 KPK Yousafzai 
 c.408_409delAA p.(Arg137Ilefs*
83) 
See above entry for 
family 37 
See above entry 
for family 37 
See above entry 
for family 37 
   
 Exon 19 deletion Frameshift - - - 40 NA NA 
 
Abbreviations: gnomAD, genome aggregation database; hom, homozygous; KPK, Khyber Pakhtunkhwa; MAF, minor allele frequency; RYK, 




Table 3.6 Novel TYR and OCA2 variants identified in this study 
Gene Variant gnomAD v2.1.1 In silico 





0.00001989 0 0 Deleterious Possibly 
damaging 
Deleterious Disease causing 
 c.240G>C; 
p.(Trp80Cys) 
Not present Not present Not present Deleterious Probably 
damaging 
Deleterious Disease causing 
 c.667C>T; 
p.(Gln223*) 
Not present Not present Not present - - - Disease causing 
 c.1002delA; 
p.(Ala335Leufs*20) 





Not present Not present Not present Deleterious Possibly 
damaging 
Deleterious Disease causing 
 c.1762C>T; 
p.(Arg588Trp) 
0.0009973 0.005131 5 Deleterious Benign Deleterious Polymorphism 
 c.408_409delAA; 
p.(Arg137Ilefs*83)  
Not present Not present Not present - - - Disease causing 
 
Abbreviations: gnomAD, genome aggregation database; Hom, homozygous; MAF, minor allele frequency, SAS, South Asian. SIFT, Polyphen-2 





Figure 3.3 Novel missense TYR and OCA2 variants identified in this study 
Schematic showing domain architecture of A(i) TYR and B(i) OCA2 [adapted from UniProt (216)] and the location of novel missense variants 
identified. Abbreviations; SP, signal peptide; TM (in light blue), transmembrane domain. For the TYR polypeptide, the red diamonds denote the 
histidine residues that bind to copper atoms and hence structurally coordinate the positions of the copper-containing catalytic binding sites. For 
the OCA2 polypeptide, the citrate transporter domain is outlined in red. Conservation analysis: multiple species alignments of amino acid 













Figure 3.4 Pedigrees and genotype data for families 5 - 39 
Pedigree diagrams of families 5 - 39 investigated with OCA, showing segregation of (A) TYR 
and (B) OCA2 variants identified. Genotypes are shown beneath each family member 





Figure 3.5 Family 40 pedigree and OCA2 genotype data 
(A) Pedigree of family 40 showing segregation of OCA2 structural variant identified. 
Genotypes are shown beneath each family member investigated (+, variant; -, wild type). 
(B) Screenshot from KaryoStudio software showing ideogram of chromosome 15 and the loss-
of-heterozygosity region encompassing OCA2, shared between both affected individuals IV:2 
and IV:3, as well as a homozygous deletion within this region in the OCA2 gene  
(C) Integrative Genome Viewer (IGV) screenshot showing absence of sequence reads over 




This study describes the findings from genetic analyses of 36 families of Pakistani 
descent, identifying a total of 22 likely disease-associated variants in TYR and OCA2 
responsible for OCA in Pakistani communities. These studies have identified four 
novel TYR variants and three novel OCA2 variants (Table 3.6), expanding the 
molecular spectrum of disease-causing OCA variants globally.  
 
Four of the OCA-associated variants identified in this study, TYR c.1037-7T>A (family 
23), and OCA2 p.(Leu674Val) (family 39), p.(Val443Ile) and p.(Arg588Trp) (both 
family 38), are present in gnomAD in homozygous form in one, one, four and five 
individuals respectively. The individual homozygous for TYR c.1037-7T>A is of 
Ashkenazi Jewish origin, whilst the individuals in gnomAD homozygous for the above 
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OCA2 variants are all of South Asian ancestry. These variants all segregated with 
disease in compound heterozygous form in their respective families. Hypomorphic 
TYR variants are well defined in the aetiology of the OCA1B subtype, where reduced 
tyrosinase activity results in a milder phenotype with reduced levels of pigmentation in 
affected individuals. These variants may therefore represent hypomorphic variants 
that cause only a partial loss of TYR or OCA2 gene function, with homozygotes 
exhibiting a mild phenotype, accounting for the homozygous individuals present in the 
gnomAD database. 
 
The OCA2 p.(Leu674Val) variant has previously been described in association with 
OCA in two Indian individuals in both homozygous and compound heterozygous form 
(215). Both individuals exhibited an incomplete albinism phenotype, with the individual 
heterozygous for the p.(Leu674Val) as well as a c.775dupG variant showing clinical 
features of nystagmus, hazel irides, light golden-brown hair and pinkish skin. The 
individual homozygous for the p.(Leu674Val) variant showed clinical features of brown 
irides with iris transillumination, silky-brown hair and very fair pinkish skin with no 
apparent nystagmus (215). This study detected the same p.(Leu674Val) variant in 
compound heterozygous form in family 39, together with a novel frameshift OCA2 
variant, with affected individuals again displaying an incomplete OCA phenotype with 
nystagmus, blue irides, light brown hair and pink skin. The p.(Leu674Val) variant may 
therefore represent a milder OCA2 mutation contributing to an incomplete OCA 
phenotype when occurring in conjunction in compound heterozygous form with a more 
deleterious OCA2 variant. 
 
Although individuals homozygous for the TYR c.1037-7T>A and OCA2 p.(Val443Ile) 
variants have been identified in gnomAD, these variants have also previously been 
described in multiple OCA individuals in European and Chinese populations (153, 184, 
189, 211, 212, 217), supporting pathogenicity. Some affected individuals compound 
heterozygous for the OCA2 p.(Val443Ile) variant have been described as having a 
partial albinism phenotype (213, 214), suggesting that these may be pathogenic, albeit 
hypomorphic, variants. The OCA2 p.(Arg588Trp) variant affects a moderately 
conserved amino acid residue, although multiple in silico prediction tools are 
conflicting in their predictions of pathogenicity (Table 3.6). For affected individual II:1 
in family 38 who was compound heterozygous for OCA2 p.(Arg588Trp) and 
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p.(Val443Ile) variants, re-analysis of the exome data could not identify any other 
candidate variants in any of the known OCA associated genes. Ultimately, functional 
characterisation of the variant would be helpful to determine the nature of the mutation 
and the extent of its biological impairment (218). 
 
In family 23, two different TYR variants [c.1037-7T>A and p.(Gly419Arg)] were 
identified segregating with OCA within the same extended consanguineous family. 
The presence of >1 disease-associated variant in a family may give rise to atypical 
inheritance patterns or phenotypical outcomes, complicating interpretation of linkage 
analysis and co-segregation results, clinical interpretation, patient counselling and 
management. This intra-familial locus heterogeneity is particularly relevant within 
community isolates including those within Pakistan, and has been demonstrated to 
occur in up to 15% of a cohort of Pakistani families with presumed autosomal 
recessive hearing loss (219). In consanguineous families with likely monogenic 
diseases, where pedigree analysis suggests an autosomal recessive inheritance, but 
where there is failure to identify a single rare segregating candidate disease variant in 
all affected individuals, the possibility of a second disease variant or even a second 
disease gene should be considered. 
 
In family 33, the previously described disease-associated OCA2 c.1045-15T>G splice 
variant was detected in six out of seven affected individuals, but only in heterozygous 
form in the seventh affected individual (individual VI:5, highlighted by an (*) in Figure 
3.4), with no other candidate variants in any of the known OCA associated genes 
detected in this individual. Interestingly, this heterozygous OCA2 c.1045-15T>G 
individual displayed a somewhat different phenotype compared to affected individuals 
who were homozygous for the variant, with a darker hair colour (golden brown instead 
of blonde). Unlike in family 23 described above, further genetic studies failed to identify 
a second variant in the same OCA disease gene responsible for disease in this 
individual. There is a high level of missing heritability in OCA, with 25% of patients 
investigated only having detectable mutations in a single OCA allele (129). This may 
be due to variants in the gene promoter or other regulatory regions that may not be 
detected or recognised by current sequencing technologies. It is known that the 
phenotype of OCA2 can be modified by MC1R or TYRP1 mutations, demonstrating a 
synergistic interaction between genes throughout this pigment pathway (220, 221). 
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Possible digenic inheritance involving genetic interactions between heterozygous TYR 
and OCA2 variants has also recently been described in three Pakistani OCA families 
(191). Consequently, the missing heritability in this individual may reflect an 
undetected mutation in an OCA disease gene or other pigment pathway gene that 
interacts with OCA2. Interestingly, our research group has recently provided strong 
supporting evidence for pathogenicity of a TYR haplotype consisting of a combination 
of two common hypomorphic TYR variants in cis, which when inherited in trans to a 
known TYR deleterious mutation, is likely to account for a proportion of OCA1B cases 
with apparent missing heritability (see chapter 3.2). A similar situation may explain the 
OCA2 missing heritability in family 33. 
 
Gross deletions in the OCA2 gene are increasingly being recognised as a molecular 
mechanism of disease in OCA2, with 42 such mutations reported to date (HGMD; 
accessed 15.04.2021), including the 2.7 kb intragenic deletion spanning exon 7 that 
is the most common cause of OCA2 in individuals of sub-Saharan African heritage 
(222). Intragenic OCA2 deletions are also increasingly recognised in Pakistani 
communities (140, 186, 188). Shahzad et al reported five gross deletions in OCA2, 
including one family of Malick ethnicity with an exon 19 deletion (186). More recently, 
a further OCA2 exon 19 deletion was reported in two further Pakistani families of 
Pashtun origin recruited from Tank city, KPK, with different deletion coordinates to the 
family reported by Shahzad et al (188). One limitation of this study is the inability to 
accurately map breakpoints with the genomic strategies employed, and therefore it is 
not possible to determine if the OCA2 exon 19 deletion in family 40 is the same as 
either of those previously reported in Pakistani families. Prior studies do however 
support OCA2 exon 19 deletion as a mechanism of disease, with the exon skipping 
predicted to result in a frameshift and loss of function via nonsense-mediated decay. 
The significant contribution of OCA2 gross deletions to OCA in Pakistani families also 






Figure 3.6 Contribution of OCA genes to OCA within Pakistan and Europe  
European figures are derived from (141, 153) 
 
The genetic studies described here, together with a comprehensive literature review 
encompassing a combined cohort of 838 individuals from 197 Pakistani families 
(Appendix C), highlight TYR and OCA2 as the major genes contributing to OCA in 
Pakistan comparable to the prevalence in European populations (141, 153), 
accounting for 50.1% and 35.4% of molecularly diagnosed cases respectively (Figure 
3.6).  
 
While most of the TYR and OCA2 variants described in this study are present in only 
one or a few families, some appear to be commonly associated with OCA in Pakistan. 
These include TYR variants p.(Arg278*) (identified in families 15 - 17, 24, and 25) and 
p.(Gly419Arg) (identified in families 18-22, 23, 25), as well as OCA2 variants c.1045-
15T>G (identified in families 32 - 36) and p.(Asp486Tyr) (identified in families 26 - 28), 
which each account for ~20% of all TYR or OCA2 alleles in Pakistani OCA families 
(Appendix C). While it is not possible to conclusively determine whether common 
variants represent recurrent (‘hot spot’) gene variants or regional founder variants 
without more detailed genetic analyses, there is evidence in the literature to support 
both mechanisms. For example, the OCA2 c.1045-15T>G and p.(Asp486Tyr) variants 
have not been reported outside Pakistan, and most likely stem from a single gene 
mutation event that occurred in a founder ancestor individual and which was 
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transmitted to subsequent generations, accumulating at an increased frequency in the 
community. Conversely, whilst the TYR p.(Arg278*) variant appears to occur at an 
increased frequency in the Pakistani population, this variant has also been identified 
in numerous OCA families from various ethnicities and geographical locations, 
including India (131, 215, 223-225), Guyana (194), Japan (201, 226, 227), China (162, 
171, 189, 197, 202, 228-230), Korea (231), Europe (131), Mexico (131) and Israel 
(232), and likely represents a recurrent gene mutation.  
 
Founder mutations often represent important causes of disease in a particular region, 
and knowledge of their presence, frequency and clinical outcomes is of enormous 
value for local healthcare resource planning and for designing community-specific 
diagnostic testing and counselling protocols. As with ancestral founder mutations, 
knowledge of recurrent gene mutations is of great utility in the development of cost-




3.4 Conclusions and future work 
 
This chapter details the significant scientific and clinical insights gained from studies 
of OCA in families from Amish and Pakistani communities. The unique genomic 
architecture of the Amish community, together with the relatively high frequency of 
OCA type 1B in the population, enabled empowered genetic studies able to determine 
the haplotype, phasing and inheritance of the hypomorphic p.(Ser192Tyr) and 
p.(Arg402Gln) TYR variants in a large number of related individuals for the first time. 
The pathogenicity of these two common TYR variants has been heavily debated for 
some time, and this study now provides irrefutably strong evidence that the TYR 
p.(Ser192Tyr) and p.(Arg402Gln) variants are pathogenic when inherited in cis. This 
finding has important diagnostic implications, as considering and reporting this in-cis 
haplotype as a pathogenic allele could increase the molecular diagnoses in the 
diagnostically challenging albinism patient cohorts with missing heritability and/or 
partial or mild albinism phenotypes. It will be crucially important to accurately 
determine the phase of these common variants, and due to the high frequencies of 
these variants alone in the population which can limit informative phase studies in 
relatives, consideration should perhaps be given to the use of amplicon-based long-
read sequencing technologies that allow haplotype phasing in the genomic workup of 
such patients (233). 
 
Studies of families with OCA in Pakistan have identified novel TYR and OCA2 disease 
variants, and expand current knowledge of the molecular spectrum and specific 
genetic causes of OCA within Pakistani communities, highlighting a number of 
regional founder variants. The approach adopted in this study, starting with targeted 
dideoxy sequencing of TYR, followed by exome sequencing in combination with whole 
genome SNP mapping studies in selected individuals, permits a rapid and cost-
effective means of achieving a molecular diagnosis in Pakistani OCA families. In 
combination with existing datasets, these studies enable accurate genetic testing and 
provide valuable information to aid the diagnosis and counselling of affected 








Cilia are evolutionary conserved microscopic, hair-like structures or organelles that 
protrude from the cell surface. They have important and diverse biological roles in 
cellular motility and the cell cycle, as well as performing extracellular sensory functions 
(234). Cilia are broadly divided into two types; motile cilia, and immotile or primary 
cilia. A single, non-motile (primary) cilium is present in almost every vertebrate cell, 
whilst cells with motile cilia are present only in specific organs such as the reproductive 
system or respiratory tract (235). The beating of motile cilia (or flagella) serves to 
generate fluid movement across cell surfaces, and is responsible for the movement of 
mucus up the respiratory tract, propulsion of sperm, and establishment of left-right 
asymmetry in the embryonic node (234). Primary cilia on the other hand transduce 
extracellular information to the intracellular environment, and have roles in 
photoreception in photoreceptor cells, olfaction in olfactory neurons, and 
mechanosensation of fluid flow in kidney epithelial cells (234). Primary cilia also play 
an important role in several signal transduction pathways, including the noncanonical 
Wnt/planar cell polarity pathway, and the Hedgehog signalling pathway (234).  
 
The term “ciliopathy” was first used in 1984 to describe the atypical bronchial cilia 
noted in a subset of children with recurrent respiratory tract infections (236). Today, 
ciliopathies generally refer to a group of inherited disorders resulting from pathogenic 
variants in the highly conserved genes involved in the correct assembly and 
maintenance of cellular cilia or their anchoring structures, the basal bodies, resulting 
in defective proteins that compromise ciliary structure or function (237, 238). To date, 
pathogenic variants in approaching 200 genes have been associated with 35 
ciliopathy disorders, typically segregating in an autosomal recessive form (239). 
Ciliopathies arise due to dysfunction of: 
 
• Proteins that primarily localise to - and function within - the ciliary compartment 
and/or basal body (239). For example, mutations in genes encoding 
components of the BBsome, an octomeric protein complex functioning as a 
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cargo adapter and utilising intraflagellar transport machinery for the trafficking 
of ciliary membrane proteins, result in BBS (240). 
• Proteins that are not localised within the cilia, but are required for ciliary 
formation or function (239). For example, mutations in genes encoding the 
cytoplasmic proteins required for pre-assembly of the multi-subunit axonemal 
dynein arms in the cytoplasm prior to their transport into the cilia and flagella, 
result in primary ciliary dyskinesia (PCD) (241). 
 
Genetic defects associated with ciliopathies can affect both motile and non-motile 
primary cilia, either separately or in combination (239). Additionally, some ciliary 
proteins have recognised extraciliary sites and functions (242). These factors likely 
contribute to the extensive phenotypic heterogeneity associated with ciliopathies 
(Figure 4.1). 
 
Ciliopathies associated primarily with impairment of motile cilia are characterised by 
dysfunction of specific tissues and organs that contain motile cilia machinery. The 
most common motile ciliopathy is PCD, where severe impairment of mucociliary 
clearance in the respiratory epithelium leads to chronic airway disease. Additionally, 
defects in ependymal cilia can result in hydrocephalus, defects in sperm flagella or in 
the cilia in fallopian tubes can lead to subfertility, and cilia defects in the left-right 
organiser during early embryonic development may result in laterality defects such as 
situs inversus and heterotaxy (243, 244). 
 
Defects in the sensory and/or signalling functions of primary cilia are often associated 
with wide phenotypic variability compared to motile ciliopathies. These sensory 
ciliopathies range from single organ disorders such as RP1 and RP1L1-associated 
non-syndromic retinal dystrophy, to complex multisystem disorders such as BBS, 
Joubert syndrome (JBTS) and MORM syndrome (comprising Mental retardation, 
truncal Obesity, Retinal dystrophy and Micropenis) (239). This likely reflects the varied 
and widespread cellular and tissue distribution of primary cilia within the human body 
(245), as well as their key role in many intracellular signal transduction cascades (243). 
In fact, many of the developmental anomalies associated with syndromic sensory 
ciliopathies are thought to result from compromised cellular signalling, such as 
polydactyly (defective Hedgehog signalling) and retinal degeneration (defective G-
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protein coupled receptor signalling) seen in BBS and JBTS (246). Retinal 
degeneration is frequently observed in diverse ciliopathy syndromes (Figure 4.1), 
caused by dysfunction of the retinal photoreceptor, a highly specialised neuronal cell 
type whose outer segment compartment is a ciliary organelle of modified structure and 




Figure 4.1 Ciliopathy abacus 
Schematic representation of common clinical manifestations associated with ciliopathies and 
their occurrence in each ciliopathy syndrome. The adding of various affected target organs 
(as an abacus) contributes to the specific ciliopathy syndrome.  
 
Abbreviations: BBS, Bardet-Biedl syndrome; CNS, central nervous system; JBTS, Joubert 
syndrome; LCA, Leber congenital amaurosis; NPHP, nephronophthisis. Image modified from 
(235, 248) and created with BioRender  
 
This chapter entails a description of clinical and genomic investigations and findings 
undertaken in Amish and Pakistani families with phenotypic features that are highly 
suggestive of a ciliopathy disorder. While distinguishing clinical features may be 
present, these (and other) phenotypically overlapping ciliopathy conditions can be 
extremely difficult to differentiate clinically. This is particularly the case in developing 
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nations given the limited resources available for detailed phenotyping, and 
geographical constraints restricting access to clinical services for affected families. 
This work was undertaken to broaden the understanding of the molecular basis, nature 
and spectrum of ciliopathy disorders in communities, and to translate that knowledge 
into improved regional clinical diagnostic services for these disorders. 
 
Within this chapter, I was responsible for the interpretation and analysis of all collected 
clinical data for all affected individuals in families 41 – 44. I performed DNA extraction 
for recruited individuals in family 43 (remaining DNA extraction largely completed by 
Joe Leslie, University of Exeter). I was also responsible for the analysis of all exome 
sequencing results, as well as primer design and subsequent cosegregation studies 
for all variants identified in families within chapters 4.2 and 4.3. I performed the 
literature review and analysis of all published SCAPER patients described in chapter 





4.2 Consolidating the phenotypic features of MORM syndrome, and 
a review of INPP5E-related disorders  
 
4.2.1 MORM syndrome 
 
MORM syndrome is an ultra-rare ciliopathy disorder, first described in 2009 in nine 
affected individuals from a single extended family in Northern Pakistan, caused by 
homozygosity for a specific nonsense mutation in the INPP5E gene (249). In the same 
year, homozygous missense INPP5E variants were identified in seven 
consanguineous families genetically linked to the first Joubert syndrome locus 
(JBTS1) on 9q34 (250). JBTS is characterised by a distinctive cerebellar and 
brainstem malformation (known as the “molar tooth” sign), hypotonia in infancy with 
later development of ataxia, and developmental delay, and commonly associated with 
ocular involvement (including progressive retinopathy and/or coloboma) (251-253). 
The cardinal clinical features of MORM syndrome include intellectual disability (mental 
retardation), truncal obesity, non-progressive retinal dystrophy and micropenis (251). 
Both JBTS and MORM syndrome show clinical overlap with ciliopathy syndromes, 
consolidating INPP5E as a ciliopathy disease gene. 
 
Here, clinical and genomic investigations were undertaken in an extended Pakistani 
family with multiple affected individuals displaying variable phenotypic features 
suggestive of a ciliopathy disorder. Molecular data and comprehensive clinical 
assessments, together with a review of all previously published patients, highlight the 
wide phenotypic spectrum of INPP5E-related disorders, and provide an insight into 
their molecular basis. 
 
4.2.2 Materials and methods 
 
Affected individuals underwent clinical examination at local government hospitals. 
Blood samples were taken with informed consent for DNA extraction (see section 
2.3.2). WES was undertaken using DNA from a single affected individual in family 41 
(individual VI:3) at BGI Hong Kong, as described in section 2.3.5. Bioinformatic 
analysis of exome data was performed as per section 2.3.5, with additional virtual 
gene panel analysis subsequently undertaken using the “rare multisystem ciliopathy 
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disorders v1.84” PanelApp Panel (https://panelapp.genomicsengland.co.uk/). 
Additional filtering was performed to retain heterozygous variants compatible with 
triallelism (254). Primer design (Appendix Table D2), PCR and dideoxy sequencing 
was performed as described in section 2.3.3 to genotype and confirm appropriate 
segregation of the candidate disease variant in all available affected and unaffected 
individuals. 
 
A literature review was performed as described in section 2.4 to retrieve all reported 
INPP5E disease-associated variants. Findings are summarised in Table 4.2. 
 
4.2.3 Results: clinical and genetic findings 
 
A large multigenerational extended family (family 41) with nine affected individuals 
(V:1, VI:2, VI:3, VI:6, VI:7, VI:9 - 12) residing in a remote rural village in Punjab, 
Pakistan, was investigated. Clinical features in affected individuals included hypotonia, 
intellectual disability (mild/moderate and non-progressive), obesity, visual impairment, 
aggressive and hyperactive behaviour, delayed language acquisition, speech 
impairment and micropenis in males (Table 4.1). 
 
Table 4.1 Summary of clinical features observed in affected individuals in family 
41 with MORM syndrome and homozygous for the INPP5E p.(Gln627*) variant 
 
 
Abbreviations: F, female; M, male; ND, no data available; yrs, years; (S), severe/profound; 
(M), mild/moderate. The (✓) and (✗) symbols indicate the presence of absence of a feature in 




After filtering WES data in a single affected individual (VI:3), only a single plausible 
candidate disease variant of potential relevance to the phenotype was identified, 
entailing a homozygous INPP5E nonsense variant (GRCh38) chr9:g.136429731G>A; 
NM_019892.6:c.1879C>T; p.(Gln627*). This variant was absent in gnomAD (v2.1.1 
and v3.1.1) and from a control exome dataset of 100 ethnically matched controls 
undertaken in the Human Molecular Genetics laboratory in Pakistan. This variant is 
reported as pathogenic in ClinVar (accession VCV000000396), and has previously 
been reported in homozygous form in a single family with MORM syndrome from the 
same province in Pakistan (249, 251). This variant segregated appropriately for an 
autosomal recessive condition in the family (Figure 4.2). 
 
Additional analysis of exome data undertaken using the “rare multisystem ciliopathy 
disorders v1.84” PanelApp virtual gene panel did not identify any homozygous or 
compound heterozygous candidate variants compatible with the phenotype. No 




INPP5E, located on chromosome 9q34.3, encodes inositol-polyphosphate 5-
phosphatase E, a 72-kDa protein with an N-terminal proline rich domain, a central 5-
phosphatase catalytic domain, and a C-terminal CaaX motif. The encoded protein 
hydrolyses the 5-position phosphate from the inositol ring of the membrane‐associated 
phosphatidylinositols phosphatidylinositol 4,5-bisphosphate [PtdIns(4,5)P2] and 
phosphatidylinositol 3,4,5-trisphosphate [PtdIns(3,4,5)P3] (255). INPP5E is widely 
expressed, with enrichment in the testis and brain (255). In dividing cells, INPP5E 
localises to the cytosolic face of the Golgi, possibly mediated by its N-terminal proline-
rich domain (255). In ciliated cells, the C‐terminal CaaX motif is proposed to facilitate 






Figure 4.2 Family 41 pedigree showing INPP5E c.1879C>T genotype data  
(A) Pedigree diagram of family 41 showing segregation of the INPP5E c.1879C>T; p.(Gln627*) 
variant, co-segregating appropriately for an autosomal recessive condition. Genotypes are 
shown beneath generations IV to VI (+, c.1879C>T; -, wild type). 
(B) Sequence chromatogram of INPP5E c.1879C>T in a homozygous affected individual.  
(C) Schematic showing domain architecture of INPP5E [adapted from Bielas et al (250)] and 
location of the c.1879C>T; p.(Gln627*) variant. IPPc; Inositol Polyphosphate Phosphatase 
catalytic domain. 
(D) Conservation analysis: multiple species alignments of the partial amino acid sequences of 
INPP5E in a variety of vertebrate species. The p.(Gln627*) variant is predicted to result in a 
truncated protein with deletion of the 18 C-terminal amino acids, including the highly 






Inpp5e knockout mice exhibit embryonic or perinatal lethality, and exhibit features of 
ciliopathy syndromes, including anophthalmia, polydactyly, polycystic kidneys, 
skeletal defects and cerebral developmental defects such as anencephaly and 
exencephaly (251). Post-natal Inpp5e knockout in 4-week-old mice results in further 
ciliopathy features including obesity, retinal degeneration and cystic kidneys (251). 
Additionally, ciliogenesis defects and abnormal cilia morphology have been noted in 
Inpp5e knockout mice embryos (251) as well as in inpp5e knockdown or knockout 
zebrafish embryos (256), supporting the importance of INPP5E in ciliogenesis and 
cilia maintenance, and linking dysfunctional ciliary phosphoinositol metabolism to the 
development of ciliopathy.  
 
 
Figure 4.3 Localisation of INPP5E disease-associated variants 
Schematic showing domain architecture of INPP5E protein [adapted from Bielas et al (250)] 
with localisation of all reported disease-associated variants to date.  
 
Autosomal recessive pathogenic variants in INPP5E have been associated with two 
different ciliopathy disorders, JBTS and MORM syndrome (Table 4.2). Pathogenic 
variants in INPP5E are most commonly associated with JBTS, and these largely 
missense variants are clustered adjacent to or within the 5-phosphatase catalytic 
domain (Figure 4.3).  
 
To date, there has only been a single variant associated with MORM syndrome, 
[INPP5E c.1879C>T; p.(Gln627*)], reported in only a single extended Pakistani family 
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with 14 affected individuals (251) (Table 4.2). This same variant was also identified in 
family 41 investigated in this study, who originate from the same province as the 
original reported family, and thus likely represents a regional founder variant in the 
Punjab region in Pakistan. Disease-associated INPP5E variants have also been 
reported in diverse populations of different ethnicities and geographical locations 
globally (Figure 4.4) (Table 4.2). In particular, two recurrent (‘hot spot’) gene variants 
have been described; the INPP5E p.(Arg435Gln) variant has been reported in six 
families from Turkey, Saudi Arabia, USA and Japan (250, 253, 257-259), whilst the 
p.(Arg621Gln) variant has been reported in six families from Algeria, Brazil, USA, 
Japan and Israel (253, 258, 260-263). Of interest, other variants disrupting the same 
amino acid residue as these recurrent INPP5E variants have also been described in 
affected individuals with INPP5E-associated disorders (264-266), suggesting the 




Figure 4.4 Geographical distribution of INPP5E disease-associated variants 
Size of circles relates to the number of individuals identified with the same variant in the same 
country. The INPP5E p.(Gln627*) MORM syndrome-associated variant is indicated by the 
green circle. Of note are the recurrent INPP5E p.(Arg435Gln) and p.(Arg621Gln) variants, 
highlighted by the red and orange circles respectively. 
 
The affected individuals in the original MORM syndrome family reported by Hampshire 
et al and Jacoby et al (249, 251) were described to have a constellation of clinical 
features that were suggestive of a ciliopathy disorder, but the phenotype was thought 
to be unique, and named MORM syndrome. Although patients said to have MORM 
122 
 
syndrome show significant clinical overlap with other ciliopathies, the authors 
distinguished MORM syndrome from JBTS and BBS on the basis of absence of 
polydactyly and the nature of visual impairment in MORM syndrome patients 
compared to patients with these other ciliopathy syndromes. In MORM syndrome, 
visual impairment due to retinal dystrophy presents early, but is non-progressive, 
whereas BBS tends to be associated with later onset retinal dystrophy and progressive 
visual impairment (249). Other distinguishing features of MORM syndrome include an 
absence of characteristic BBS facial features, and the presence of a small penis 
without testicular anomalies (249). The clinical features observed on examination of 
the nine affected individuals in this study were consistent with those in the previously 
reported family, consolidating intellectual disability (mild to moderate and non-
progressive), obesity, visual impairment, aggressive and hyperactive behaviour, 
hypotonia and micropenis in males as core phenotypical features of MORM syndrome 
(Table 4.1).  
 
The MORM syndrome-associated INPP5E nonsense variant is located within the last 
exon of the INPP5E gene, and is therefore predicted to escape nonsense-mediated 
decay, generating a prematurely truncated INPP5E protein lacking the terminal 18 
amino acids with loss of the C-terminal CaaX domain (251). The CaaX motif (where C 
is a cysteine reside, aa are two small generally aliphatic residues, and X is any amino 
acid residue, contributing to its specificity) (267) acts as a signal for post-translational 
modification by farnesylation, leading to membrane targeting and attachment of the 
protein (268). Functional studies have demonstrated diminished capacity of the 
MORM syndrome-associated mutant truncated protein to stabilise the primary cilium, 
most likely due to a defect in ciliary localisation and protein interaction (251). Of 
particular note, this mutant protein still retains its catalytic domain with no impairment 
of enzymatic activity (251), in contrast to JBTS-associated missense mutations, where 
the mutant protein appears to localise correctly to the cilia, but is associated with 
reduced enzymatic activity (250, 269). It is tempting to postulate that this represents 
the molecular basis for the genotype-phenotype correlation associated with JBTS- and 
MORM-associated INPP5E mutations. Interestingly, apart from individuals with 
MORM syndrome, there has only been one other affected individual identified with 
biallelic truncating variants in INPP5E [homozygous for INPP5E c.1629C>G; 
p.(Tyr543*)] (253). This nonsense mutation was predicted to result in the production 
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of a truncated protein lacking the final part of the catalytic domain as well as the CaaX 
motif (although functional studies were not performed), similar to the MORM 
syndrome-associated variant, yet the affected individual had a clinical diagnosis of 
JBTS with the classic “molar tooth” sign on neuroimaging pathognomic of JBTS. In 
addition, De Goede et al reported an extended Pakistani family with 6 affected 
individuals all homozygous for an INPP5E p.(Tyr588Cys) missense variant displaying 
considerable phenotypic variability, with one individual demonstrating the classic 
“molar tooth” sign on neuroimaging, suggestive of a JBTS diagnosis, whilst another 
individual in the same family had a micropenis and clinical other features more 
consistent with MORM syndrome (269). It is important to note that it has not been 
practical to undertake neuroimaging in this study family, nor was it undertaken in the 
original family reported by Hampshire et al and Jacoby et al (249, 251), and so it 
remains unclear whether the cerebellum and brainstem are normal in the affected 
individuals with MORM syndrome, and hence the true extent to which MORM 
syndrome can be distinguished from JBTS.  
 
Biallelic INPP5E variants have also been associated with isolated retinal dystrophies, 
including Leber congenital amaurosis, retinitis pigmentosa, macular and cone-rod 
dystrophy (260, 261, 266, 270-272) (Table 4.2). Interestingly, in at least four affected 
individuals, systemic features were specifically excluded, suggesting that some 
individuals with disease-causing INPP5E variants never develop the extraocular 
manifestations typically associated with JBTS or MORM syndrome (260, 266, 270, 
271, 273). None of the individuals with INPP5E-associated isolated retinal dystrophy 
carry a combination of two loss-of-function variants, suggesting that complete loss of 
INPP5E function will always result in a systemic phenotype (Table 4.2). Apart from 
this observation, there does not seem to be a consistent correlation between an 
isolated retinal dystrophy or syndromic ciliopathy phenotype, and the nature of the 
variation (missense, nonsense or frameshift variants) (Figure 4.3). In fact, certain 
INPP5E variants p.(Arg515Trp), p.(Arg621Gln) and p.(Tyr543*) have been associated 
with both JBTS as well as isolated retinal dystrophy (250, 253, 258, 260-263, 270, 
274) (Table 4.2). 
 
Overall, these reports suggest that INPP5E variants may be associated with a wide 
range of ciliopathy phenotypes. Due to the phenotypic variability associated with 
124 
 
ciliopathies, it is often difficult to make diagnostic distinctions on the basis of clinical 
assessment alone, particularly in developing nations due to often-limited resources 
and social constraints. Identification of this INPP5E likely founder mutation will now 
enable targeted genetic testing for this variant in individuals in Northern Pakistan with 
an overlapping clinical presentation, permitting a rapid and cost-effective means of 
achieving a molecular diagnosis. 
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Table 4.2 Summary of all reported disease-associated INPP5E variants 
Type of 
variant 










Missense c.844G>A p.(Gly282Arg) Macular 
dystrophy 
1 (1) Germany Birtel et al (270) VUS 
(VCV000967675) 
 c.848C>T p.(Ala283Val) LCA 1 (1) China Wang et al (266) Not present 
 c.856G>A p.(Gly286Arg) JBTS 1 (1) Afghanistan Travaglini et al (253) Not present 
 c.874C>G p.(Arg292Gly) RP 1 (1) USA Stone et al (261) Likely pathogenic 
(VCV000857108) 
 c.907G>A p.(Val303Met) JBTS 3 (3) Italy (2); 
Uncertain (1) 
Travaglini et al (253); 
Toma et al (275); 
Bachmann-Gagescu 
et al (276) 
Pathogenic/ VUS 
(VCV000217653) 
 c.944C>T p.(Pro315Leu) JBTS 2 (2) USA (1); 
Uncertain (1) 
Stone et al (261); 
Bachmann-Gagescu 
et al (276) 
Pathogenic/ VUS 
(VCV000217662) 
 c.1021G>A p.(Gly341Ser) JBTS 2 (3) Uncertain Bachmann-Gagescu 
et al (276) 
Pathogenic 
(VCV000217661) 
 c.1024T>C p.(Cys342Arg) JBTS 1 (1) China Chen et al (277) Not present 
 c.1035G>C p.(Arg345Ser) JBTS 1 (1) Israel Travaglini et al (253) Not present 
 c.1064C>T p.(Thr355Met) JBTS 2 (2) Uncertain Bachmann-Gagescu 
et al (276) 
Pathogenic 
(VCV000217655) 
 c.1073C>T p.(Pro358Leu) RP 1 (1) China Xu et al (271) Not present 
 c.1132C>T p.(Arg378Cys) JBTS 2 (3) Italy Bielas et al (250) Pathogenic/ likely 
pathogenic 
(VCV000000400) 
 c.1133G>A p.(Arg378His) LCA 1 (1) Brazil Porto et al (260) Likely pathogenic 
(VCV000866268) 
 c.1154G>A p.(Cys385Tyr) JBTS 1 (1) Uncertain Bachmann-Gagescu 





 c.1162G>T p.(Val388Leu) JBTS 1 (2) Uncertain Bachmann-Gagescu 
et al (276) 
Pathogenic 
(VCV000217663) 
 c.1249T>C p.(Ser417Pro) JBTS 1 (1) Uncertain Bachmann-Gagescu 
et al (276) 
Pathogenic 
(VCV000217664) 
 c.1277C>A p.(Thr426Asn) JBTS 1 (3) Switzerland Poretti et al (278) Not present 
 c.1303C>G p.(Arg435Gly) JBTS 1 (1) Turkey Sönmez et al (264) Not present 
 c.1303C>T p.(Arg435Trp) JBTS 1 (1) India Shetty et al (265) Likely pathogenic 
(VCV000375472) 
 c.1304G>A p.(Arg435Gln) JBTS 6 (7) Turkey (2); Saudi 
Arabia (1); USA 
(1), Japan (1); 
Uncertain (1) 
Bielas et al (250); 
Travaglini et al (253); 
Alfares (257); Fleming 
et al (258); Suzuki et 
al (259); Bachmann-
Gagescu et al (276); 
Pathogenic 
(VCV000000399) 
 c.1388C>T p.(Ala463Val) JBTS 1 (1) Saudi Arabia Alfares (257) Likely pathogenic 
(VCV000800892) 
 c.1426G>A p.(Gly476Arg) JBTS 1 (1) Japan Suzuki et al (259) Not present 
 c.1468G>T p.(Asp490Tyr) JBTS 1 (1) Uncertain Bachmann-Gagescu 
et al (276) 
Pathogenic 
(VCV000217665) 
 c.1534C>T p.(Arg512Trp) JBTS 2 (6) Oman Bielas et al (250) Not present 
 c.1535G>A p.(Arg512Gln) JBTS 1 (1) Yemen Ben-Salem et al (274) VUS 
(VCV000847803) 
 c.1543C>T p.(Arg515Trp) Cone-rod 
dystrophy 
1 (1) USA Stone et al (261) Pathogenic 
(VCV000000397) 
   JBTS 3 (7) Oman Bielas et al (250); 
Ben-Salem et al (274) 
 
 c.1565G>C p.(Gly522Ala) JBTS 3 (6) USA Hardee et al (252); 
Fleming et al (258); 
Summers et al (279) 
Likely pathogenic 
(VCV000530891) 
 c.1577C>T p.(Pro526Leu) JBTS 1 (1) Uncertain Bachmann-Gagescu 
et al (276) 
Pathogenic/ VUS 
(VCV000217660) 
 c.1600T>G p.(Tyr534Asp) JBTS 1 (2) Algeria Travaglini et al (253) Not present 
 c.1668C>G p.(Asp556Glu) LCA 1 (1) China Wang et al (266) Not present 
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 c.1669C>T p.(Arg557Cys) RP 1 (1) China Xu et al (271) Likely pathogenic 
(VCV000426905) 
 c.1684A>G p.(Ser562Gly) JBTS 1 (2) Uncertain Bachmann-Gagescu 
et al (276) 
Pathogenic 
(VCV000217654) 
 c.1688G>A p.(Arg563His) JBTS 2 (5) Turkey (1); UAE 
(1) 
Travaglini et al (253); 
Bielas et al (250) 
Pathogenic 
(VCV000000398) 
 c.1738A>G p.(Lys580Glu) JBTS 1 (3) Egypt Bielas et al (250) Not present 
 c.1753C>T p.(Arg585Cys) RP 1 (1) USA Stone et al (261) Not present 
   JBTS 2 (3) Italy Travaglini et al (253); 
Toma et al (275) 
Not present 
 c.1754G>A p.(Arg585His) JBTS 1 (1) UAE Bachmann-Gagescu 
et al (276) 
Pathogenic 
(VCV000217657) 
 c.1763A>G p.(Tyr588Cys) JBTS 1 (6) Pakistan de Goede et al (269) VUS 
(VCV000635031) 
 c.1774C>G p.(Arg592Gly) JBTS 1 (1) USA Stone et al (261) Not present 
 c.1861C>T p.(Arg621Trp) LCA 1 (1) Uncertain Wang et al (273) Likely 
pathogenic/ VUS 
(VCV000426904) 
 c.1862G>A p.(Arg621Gln) LCA 2 (2) Brazil (1); Israel 
(1) 
Porto et al (260); 
Sharon et al (263) 
Likely pathogenic 
(VCV000812336) 
   Cone-rod 
dystrophy 
1 (1) USA Stone et al (261)  
   JBTS 3 (4) Algeria (1); Japan 
(1); USA (1) 
Travaglini et al (253); 
Tsurusaki et al (262); 
Fleming et al (258) 
 
 c.1921T>C p.(Cys641Arg) JBTS 2 (4) Egypt Travaglini et al (253) Not present 
Nonsense c.1629C>A p.(Tyr543*) Macular 
dystrophy 
1 (1) Germany Birtel et al (270) Not present 
 c.1629C>G p.(Tyr543*) JBTS 1 (1) Italy Travaglini et al (253) Not present 
 c.1879C>T p.(Gln627*) MORM 
syndrome 
2 (23) Pakistan Jacoby et al (251); 






Frameshift c.473delG p.(Gly158Valfs*40) JBTS 1 (1) USA Fleming et al (258) Likely pathogenic 
(VCV000451128) 
 c.1760delT p.(Val587Glyfs*7) JBTS 1 (2) Uncertain Bachmann-Gagescu 
et al (276) 
Pathogenic 
(VCV000217656) 
 c.1784_1787delTGAG p.(Val595Glyfs*21) JBTS 1 (1) USA Fleming et al (258) Not present 
 c.1897_1898delCA p.(Gln633Glufs*64) JBTS 1 (1) Uncertain Bachmann-Gagescu 
et al (276) 
Pathogenic 
(VCV000217658) 
 c.700dupC p.(Leu234Profs*56) JBTS 1 (1) Japan Tsurusaki et al (262) Not present 
 
Abbreviations: JBTS, Joubert syndrome; LCA, Leber congenital amaurosis; RP, retinitis pigmentosa; UAE; United Arab Emirates; USA, United 




4.2.5 A novel BBS5 variant associated with BBS in a Pakistani family 
 
An additional multigenerational Pakistani family (family 42) residing in a remote village 
in the KPK province of Pakistan was also investigated. The two affected individuals in 
this family were also described as having clinical features suggestive of a ciliopathy 
disorder including moderate developmental delay/intellectual disability, visual 
impairment, truncal obesity, postaxial polydactyly, renal anomalies and 
hypogonadism, although this was phenotypically distinct from that of family 41 
described above. WES identified the likely cause of disease as a novel homozygous 
frameshift mutation (NM_152384.2: c.196delA; p.(Arg66Glufs*12)) in BBS5. To date, 
there have only been two BBS5 variants associated with BBS in Pakistani families, 
and this finding significantly expands on the contribution of BBS5 mutations to BBS in 
Pakistan. A full description of the clinical and genomic investigations performed, as 
well as a comprehensive literature review of all published genetic causes of BBS in 








4.3 Phenotypic heterogeneity in an extended Amish family with BBS 





BBS is a rare, genetically heterogeneous, pleiotropic disorder, first described in the 
early 1920s by French paediatrician Georges Louis Bardet and Hungarian pathologist 
Arthur Biedl (235). BBS has an estimated prevalence of 1:125,000 - 160,000 in 
Northern Europe (280, 281), but is significantly more common in certain isolated 
communities such as the mixed Arab populations of Kuwait (1:36,000) (282) and in 
the Newfoundland population (1:18,000) (283). Primary features of BBS include retinal 
dystrophy, intellectual disability, postaxial polydactyly, obesity, renal dysfunction and 
hypogonadism (284). Retinal degeneration is the most highly penetrant feature of this 
condition (280, 285); in fact, after Usher syndrome, BBS is the second most common 
form of syndromic retinal degeneration (261). Other variable features of BBS include 
dental anomalies, cardiovascular defects, hearing loss, speech impairment, diabetes 
mellitus and other limb defects (284). To date, pathogenic variants in 21 genes have 
been associated with BBS in autosomal recessive or triallelic forms (286); some BBS 
genes have also been implicated in other related clinical presentations including 
syndromic ciliopathies as well as non-syndromic retinal dystrophies (Table 4.3). 
 
Functionally, the majority of these genes either code for components of the core 
BBSome complex (BBS1, BBS2, BBS4, BBS5, BBS7, TTC8, BBS9, BBIP1), an 
octomeric protein complex involved in vesicular trafficking to the ciliary membrane 
(287), or for components of the chaperonin complex (MKKS, BBS10, BBS12), which 
plays an essential role in the assembly, stabilisation and regulation of the BBSome 
complex (288). Other BBS-associated genes code for proteins responsible for 
BBSome trafficking and localisation (ARL6, CEP290 and LZTFL1) (289-291). The 
functions of some BBS genes, such as C8orf37, and their role in ciliary function, have 





Table 4.3 Summary of genes associated with BBS 
BBS type BBS gene Allelic disorders Functions 
BBS1 BBS1 - Component of BBSome 
complex 
BBS2 BBS2 Retinitis pigmentosa Component of BBSome 
complex 
BBS3 ARL6 Retinitis pigmentosa GTPase; facilitates vesicular 
and interciliary trafficking 
BBS4 BBS4 - Component of BBSome 
complex 
BBS5 BBS5 - Component of BBSome 
complex 
BBS6 MKKS McKusick-Kaufman syndrome Component of chaperonin 
complex 
BBS7 BBS7 - Component of BBSome 
complex 
BBS8 TTC8 Retinitis pigmentosa Component of BBSome 
complex 
BBS9 BBS9 - Component of BBSome 
complex 
BBS10 BBS10 - Component of chaperonin 
complex 
BBS11 TRIM32 Limb-girdle muscular dystrophy E3 Ubiquitin ligase activity 
BBS12 BBS12 - Component of chaperonin 
complex 
BBS13 MKS1 Joubert syndrome; 
Meckel syndrome 
Centriole migration 
BBS14 CEP290 Joubert syndrome; 
Meckel syndrome; 
Senior-Loken syndrome; 
Leber congenital amaurosis 
Interacts with RPGR 
BBS15 WDPCP Congenital heart defects, 
hamartomas of tongue, and 
polysyndactyly syndrome 
Localisation of septins and 
ciliogenesis 
BBS16 SDCCAG8 Senior-Loken syndrome Regulates cell polarity, 
interacts with OFD1 
BBS17 LZTFL1 - Negatively regulates BBSome 
trafficking 
BBS18 BBIP1 - Component of BBSome 
complex 
BBS19 IFT27 - Intraflagellar transport 
BBS20 IFT74 - Ciliogenesis and length 
control 
BBS21 C8orf37 Retinitis pigmentosa; 
Cone-rod dystrophy 
Unknown 





To date, pathogenic alleles associated with overlapping ciliopathy phenotypes have 
been identified in only two genes in the Amish community; the BBS1 (GRCh38) 
chr11:g.66526181T>G; NM_024649.4:c.1169T>G; p.(Met390Arg) variant, 
responsible for the widespread occurrence of BBS in the South-eastern Pennsylvania 
Amish community (294), and the MKKS variants chr20:g.10413265G>A; 
NM_170784.2:c.250C>T; p.(His84Tyr) and chr20:g.10412791C>A; c.724G>T; 
p.(Ala242Ser), which segregate in cis on a haplotype that is common in the Old Order 
Amish community, associated with the phenotypically distinct McKusick-Kaufman 
syndrome (295). 
The present study entails clinical and genomic investigations in a large Amish family 
with multiple affected individuals displaying variable phenotypic features highly of 
BBS, in order to aid diagnosis and clinical management.  
 
 
4.3.2 Materials and methods 
 
Affected individuals and unaffected family members from an extended Amish family 
(family 43) were recruited to this study with informed consent. Blood and buccal 
sample collection and DNA extraction was performed as previously described (see 
section 2.3.2). WES was undertaken using DNA from a single affected individual in 
the family (Individual II:1) at BGI Hong Kong, as described in section 2.3.5. 
Bioinformatic analysis with additional virtual gene panel analysis and filtering to retain 
heterozygous variants compatible with triallelism was performed as described in 
section 4.2.2. Primer design, PCR and dideoxy sequencing (Appendix Table D2) was 
also performed as previously described in section 2.3.3 to genotype and confirm 
appropriate segregation of the candidate disease variant in all available affected and 
unaffected individuals. 
 
4.3.3 Results: clinical and genetic findings 
 
A large extended Amish family (family 43) with four affected individuals (II:1, II:2, II:5 
and II:10) residing in Wisconsin (USA) was investigated. Clinical features in affected 




To identify the causative mutation, targeted dideoxy genotyping was first performed in 
a single affected individual (II:1) for the pathogenic BBS1 and MKKS variants 
previously identified in the Amish community [sequencing was only performed for the 
MKKS p.(His84Tyr) variant as a proxy for the p.(His84Tyr)/(Ala242Ser) double-variant 
haplotype known to be present in the Amish population] (294, 295). Genotyping results 
indicated that the affected individual II:1 was homozygous for the BBS1 p.(Met390Arg) 
variant and wild type for the MKKS p.(His84Tyr) variant. The BBS1 p.(Met390Arg) 
variant is present in gnomAD (v2.1.1 and v3.1.1), with a MAF of 0.00157 and 0.00205 
respectively, higher in the non-Finnish European population (MAF 0.002773 - 
0.002895) and in the Amish population (MAF 0.0307), and also present in a single 
individual in heterozygous form in a control exome dataset of 219 unrelated Amish 
individuals, although there are no homozygous individuals identified in either 
population database. The BBS1 p.(Met390Arg) variant alters a highly conserved 
amino acid residue, and is predicted by multiple in silico tools (SIFT, Polyphen-2 and 
PROVEAN) to have a deleterious effect on protein function. This variant is reported 
as pathogenic or likely pathogenic in ClinVar (accession VCV000012143), and has 
been reported in homozygous and compound heterozygous form in multiple 
individuals with BBS (296, 297). Segregation analysis within the family confirmed that 
all affected individuals were homozygous for the BBS1 p.(Met390Arg) variant; 
however, homozygosity for the BBS1 p.(Met390Arg) variant was also identified in a 
single apparently unaffected individual (II:7) (Figure 4.5).  
WES was subsequently performed in a single affected individual (II:1) in family 43 to 
identify additional variants that could be contributing to phenotypic penetrance under 
the digenic triallelic inheritance model of inheritance using the “rare multisystem 
ciliopathy disorders v1.84” PanelApp virtual gene panel. This confirmed homozygosity 
for the BBS1 p.(Met390Arg) variant, but did not identify any further homozygous or 
compound heterozygous candidate gene variants compatible with the phenotype. Two 
additional candidate heterozygous variants of potential relevance were identified, a 
BBS9 missense variant (GRCh38) chr7:g.33344585C>T; NM_198428.2:c.1280C>T; 
p.(Ala427Val) and a CEP290 missense variant (GRCh38) chr12:g.88090784G>T; 
NM_025114.3:c.3517C>A; p.(Gln1173Lys), although due to time and Covid-19 





Figure 4.5 Family 43 pedigree showing BBS1 p.(Met390Arg) genotype data 
(A) Pedigree diagram of family 43 showing segregation of the BBS1 c.1169C>T; 
p.(Met390Arg) variant, co-segregating appropriately for an autosomal recessive condition 
(apart from the apparently unaffected individual II:7). Genotypes are shown beneath 
generations I and II (+, c.1169C>T; -, wild type).  
(B)(i) Sequence chromatogram of BBS1 c.1169C>T in a homozygous affected individual (ii) 
Schematic showing domain architecture of BBS1 [adapted from Chou et al (298)] and location 
of the c.1169T>G; p.(Met390Arg) variant. This variant is predicted to lie within the 7-bladed β-
propeller domain, depicted in blue. The BBS1 protein is also predicted to contain a single α-
helix as well as a 4α-helix bundle, depicted in red, and a γ-adaptin ear (GAE) domain, depicted 
in green. 
(C) Conservation analysis: multiple species alignments of partial amino acid sequences of 
BBS1 showing conservation of the Met390 amino acid residue across species. 
 
The BBS9 p.(Ala427Val) variant is present in homozygous form in 6 individuals in 
gnomAD (v2.1.1 and v3.1.1), with a MAF of 0.005462 - 0.005745, whilst the CEP290 
p.(Gln1173Lys) variant is absent in homozygous form in both gnomAD v2.1.1 and 
v3.1.1, but present in 19 and 13 individuals in heterozygous form respectively, with a 
MAF of 0.00008544 - 0.00009162. Neither variant has been associated with BBS in 
either autosomal recessive or triallelic forms. In silico predictions for both variants are 
inconsistent with regards to variant pathogenicity. ClinVar interpretations lean towards 
benign interpretation for BBS9 p.(Ala427Val) variant (accession VCV000194138), 
whilst the CEP290 p.(Gln1173Lys) variant is absent in ClinVar. Overall, the clinical 






BBS has traditionally been considered an autosomal recessive condition, established 
by segregation analysis of large pedigrees and consanguineous families. In some 
families however, more complex inheritance patterns have been proposed, which 
possibly account for some of the inter- and intra-familial phenotypic variability typically 
associated with BBS (299-301). 
 
In the early 2000s, it was observed that a number of affected individuals who carried 
biallelic pathogenic variants in one of the BBS genes also carried an additional 
heterozygous variant in another BBS gene, and a “triallelic inheritance” model was 
proposed, suggesting that in some instances a third allele was either necessary for 
the disease to manifest (254, 302, 303), or instead exerted an epistatic effect on the 
BBS phenotype by modifying the age of onset and/or disease severity (304, 305). A 
number of BBS-associated genes have been reported to contribute to this complex 
digenic triallelic inheritance pattern, including BBS1, BBS2, ARL6, BBS4, MKKS, 
BBS7, BBS10, BBS12 and MKS1 (254, 303, 306-311). Additionally, variants in other 
ciliary genes, including CCDC28B (312), ALMS1 (306), NPHP4 (313), TMEM67 (308), 
RPGRIP1L (314), TTC21B (315) and NPHP1 (316) may also exert epistatic effects on 
BBS gene mutations and modify severity of the BBS phenotype. Evidence from a 
homozygous hypomorphic Cep290 mutant mouse model, where the additional loss of 
Bbs4 alleles results in increased obesity and accelerated retinal degeneration 
compared with mice without Bbs4 mutations, supports an interaction between 
BBSome components and ciliary proteins in modifying BBS phenotypic severity (317). 
An increased mutational load leading to dysfunction of more than one component in 
this ciliary protein trafficking pathway could result in an additive impairment of ciliary 
function, providing a plausible mechanistic basis for the variable penetrance or 
phenotypic severity seen in cases of BBS with triallelic inheritance (318). 
  
To date, however, the triallelic inheritance hypothesis in BBS remains controversial. 
There are a few reports of non-penetrant individuals who carry clearly deleterious 
biallelic variants in a single BBS gene, and yet are apparently unaffected (254, 303, 
319, 320). Most of these reports involve the same BBS1 p.(Met390Arg) variant 
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identified in this study, and the presence of a single apparently unaffected 
homozygous individual in this study (individual II:7) is therefore not unprecedented. 
The BBS1 p.(Met390Arg) variant is one of the most common pathogenic variants in 
the BBS1 gene, and has been reported in homozygous and compound heterozygous 
state in multiple affected BBS individuals (296, 297), accounting for up to 80% of BBS1 
cases in European populations (297). A Bbs1 p.(Met390Arg) knock-in mouse model 
recapitulates features of the human BBS phenotype, including retinal degeneration, 
male infertility and obesity (321), clearly defining this as a pathogenic BBS variant 
(ClinVar accession VCV000012143.26). These findings have been used to support 
the triallelic hypothesis, suggesting that at least in some cases a third pathogenic allele 
is required for the disease to manifest. Indeed, Badano and coworkers initially reported 
two BBS families where both the affected individual as well as the unaffected father 
were found to be homozygous for the BBS1 p.(Met390Arg) variant (303). In one of 
these families, the differential penetrance was subsequently explained by the epistatic 
contribution of a heterozygous CCDC28B NM_024296.5:c.330C>T variant identified 
in the affected individual but not in the unaffected father (312). CCDC28B codes for a 
pericentriolar protein that interacts and co-localises with BBS proteins including BBS1, 
BBS2, BBS4, BBS5, BBS6, BBS7, BBS8 (312). The CCDC28B c.330C>T variant is a 
synonymous variant p.(Phe100Phe) that enhances the use of a cryptic splice acceptor 
site, thus introducing a premature termination codon and reducing CCDC28B mRNA 
levels (312). This variant however was not identified in this study. 
 
Functional studies in zebrafish indicate the BBS1 p.(Met390Arg) variant may be a 
hypomorphic variant, as evidenced by partial phenotypic rescue following introduction 
of the variant into zebrafish embryos lacking BBS1 expression (322). This could 
explain the milder disease phenotype associated with homozygosity for the BBS1 
p.(Met390Arg) variant, with a later age of disease onset (306, 310, 323) and a clinical 
presentation that may be limited to retinal degeneration with minor (polydactyly or 
obesity only) or even none of the systemic features commonly associated with BBS 
(319, 323-326). In fact, there have been reports of BBS1 p.(Met390Arg) homozygous 
individuals in their fourth decade of life who were asymptomatic at the time of 
presentation, with genetic investigations only prompted by a routine eye examination 
or a relative with a retinal disease diagnosis (323). An alternative explanation for the 
apparent non-penetrance of the BBS1 p.(Met390Arg) variant in individual II:7 in this 
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study (aged 12 at the time of examination) is that she may actually harbour a very mild 
subclinical phenotype; a further detailed ophthalmic examination would be useful to 
clarify this, although this was unfortunately not possible. It is still difficult to definitely 
ascertain if there are truly non-penetrant individuals with biallelic pathogenic BBS 
variants, particularly with regards to the hypomorphic BBS1 p.(Met390Arg) variant. 
 
There are also numerous studies that do not support a triallelic inheritance pattern 
modifying either penetrance or expressivity (296, 297, 327-331). Although BBS is a 
rare disorder in non-endogamous populations, the large number of BBS-associated 
genes suggests that the cumulative carrier frequency for at least one BBS mutation 
could be as high as 1 in 50 (331), and additional rare heterozygous BBS variants in 
affected individuals are possibly being detected by chance alone. Additionally, the 
third alleles reported in the literature are commonly missense variants, for which 
pathogenicity can sometimes be difficult to evaluate. 
 
Adding further to the genetic complexity in BBS, there is experimental evidence that 
some heterozygous modifier BBS variants may influence disease phenotype via a 
dominant-negative effect, and this may even be the primary mechanism by which 
modifier alleles exacerbate disease phenotype (322). This predicts that carriers of 
dominant negative alleles may manifest subclinical BBS phenotypes. Consistent with 
this hypothesis, BBS carriers have been reported to be at increased risk of retinal 
dysfunction, obesity, hypertension, diabetes and renal disease (332-335), although 
this finding has also been refuted by others (336). 
 
Given the biological and mechanistic overlap of many BBS genes in ciliary function, it 
is quite plausible that the phenotypic variability often observed in BBS could in part be 
due to the modifying effects of sequence variants in genes encoding other ciliary 
proteins, and in reality is likely to reflect a complex interaction between multiple genetic 
factors and environmental influences. It may well be that with continued improvements 
in the identification and functional validation of deep intronic, regulatory region and 
copy number variants, combined with detailed phenotypic characterisations, the 
impact of additional modifier gene variants in BBS can be further clarified (337, 338). 
This will ultimately allow more informative counselling of affected families with regards 
to prognosis and recurrence risk.   
138 
 
4.4 Delineating the expanding phenotype associated with SCAPER 
gene mutation  
 
4.4.1 SCAPER syndrome 
 
SCAPER (S phase cyclin A–associated protein residing in the ER), encoded by the 
SCAPER gene on chromosome 15q24.3, is a cyclin A/Cdk2 regulatory protein that 
interacts with the cyclin A/Cdk2 complex at multiple phases of the cell cycle, and is 
involved in cell cycle progression (339). A potential role for SCAPER in human disease 
was first suggested by Najmabadi et al, who identified a candidate homozygous 
frameshift SCAPER variant as the cause of non-syndromic intellectual disability in a 
small Iranian family (340). Since then, biallelic SCAPER variants have been identified 
in 24 individuals presenting with a novel syndromic disorder characterised by 
intellectual disability and retinitis pigmentosa in association with variable multisystem 
phenotypical presentations. 
 
Here, clinical and genetic findings, including seven novel SCAPER variants, are 
described in six individuals in five families (families 44-48) of Amish, Caucasian and 
South Asian descent. Together with molecular data and comprehensive phenotypic 
assessments, this enabled a more detailed clinical comparison to be drawn between 
the patient cohort described [including previously published individual G001284; 
Patient 3 (family 45) in this study (85)] with the 24 individuals in whom SCAPER 
variants were recently defined (340-345), permitting a more precise definition of the 
clinical phenotype arising from pathogenic SCAPER variation. 
 
4.4.2 Materials and methods 
 
Samples were taken with informed consent for DNA extraction (see section 2.3.2). 
SNP genotyping was performed (Patients 1 and 2; family 44) as described in section 
2.3.4. WES was undertaken as per section 2.3.5, with bioinformatics analysis, primer 
design, PCR and dideoxy sequencing (Appendix Table D2) performed as described 
in section 2.3.3 to genotype and confirm appropriate segregation of the candidate 
disease variant in all available affected and unaffected individuals. Patient 6 (family 
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48) underwent WES at GeneDx and was identified via GeneMatcher (346) as part of 
the Matchmaker Exchange Repositories (347).  
 
A literature review was performed as described in section 2.4 to retrieve all reported 
SCAPER disease-associated variants. Findings are summarised in Tables 4.4 and 
4.5. 
 
4.4.3 Results: clinical and genetic findings 
 
Tables 4.4 and 4.5 summarise the core phenotypical features of individuals in this 
study, aged between 18 months and 31 years (Patients 1 - 6; families 44 - 48), and 
compares these to the clinical features of all SCAPER syndrome patients described 
to date. Intellectual disability and developmental delay was present in all six affected 
individuals, and four patients also exhibited hyperactivity and attention deficit 
hyperactivity disorder (ADHD). Autism and dyspraxia were each noted in one 
individual. Neuroimaging performed in patients 1, 3, 5 and 6 revealed no 
abnormalities. Additional dysmorphic features noted in both Amish siblings (patients 1 
and 2) included inverted nipples, brachydactyly, camptodactyly, proximally placed 
thumbs (Figure 4.6) and a characteristic facial appearance with frontal bossing and 
almond-shaped eyes; growth parameters were all normal. Patients 1, 3 - 6 all 
presented between the ages of 10 - 23 with a reduction in night vision and visual field 
deficits; Patient 2 described no visual symptoms at the time of presentation. Fundus 
examination in patients 3 - 6 revealed findings typical of retinitis pigmentosa including 
optic disc pallor, attenuated retinal vessels and intraretinal mid-peripheral bone-
spicule pigmentation and loss of photoreceptor outer segments with retained central 
macular structure on OCT imaging (Figure 4.6; Table 4.5). Additional variable ocular 
features described in some patients with SCAPER syndrome include cataracts (in two 
individuals) and myopia and keratoconus in one individual each (Table 4.5). 
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Table 4.4 Comparison of clinical findings of all affected individuals with biallelic pathogenic SCAPER variants 




























Arab F 24 NA NA NA NA Normal NA Mild 
(IQ 64) 





Arab F 23 NA NA NA NA Normal NA Mild 
(IQ 56) 







Spanish F 34 NA NA NA NA 24 mo NA Mod None 
reported 







Spanish M 15 NA NA NA NA Delayed NA ✓ None 
reported 
NA ✓ NA NA 
Jauregui c.2023-2A>G/ 
c.2023-2A>G 

































































































































NA ✓ Mod ADHD MRI: 
abnormal‡ 





















✓ NA Prominent nose, 






UL & LL, single 
episode febrile 
seizure 18 mo 
Kahrizi 
(1:III:7) 









19.1 21 mo 2 yrs Mild 
(IQ 67) 





✓ NA Prominent nose, 



















No NP ✓ NA Prominent maxilla 
& micrognathia, 
generalised tonic 


































No NP ✓ NA Prominent 
maxilla, 
generalised tonic 












NA 2.5 yrs 2 yrs Mod 
(IQ 40) 












21.4 18 mo 18 mo Mod 
(IQ 45) 











NA 12 mo 24 mo Mod 
(IQ 40) 













NA 13 mo 24 mo Mod 
(IQ 50) 




































24 mo ✓ Mod Hyper-
activity 
MRI: normal No ✓ Proximally placed 




















22 mo ✓ Mild Hyper-
activity 
NP NA (age) ✓ Proximally placed 














F 28 25th 
cent 
3rd cent NA NA 11 mo ✓ Mod ADHD 
Autism 
Self-harm 






Caucasian F 31 NA NA 57  
(95th 
cent) 



















15-18 ✓ Mild 
(IQ 50-
60) 
ADHD MRI: norm ✓ NA Mod eczema with 
sev skin picking 
behavior 
Summary        8/16 
obese 
 18/23 29/30 9/21  26/27 10/10  
 
Abbreviations: abnorm, abnormal; ADHD, attention-deficit hyperactivity disorder; cent, centile; CT, computerised tomography; F, female; Ht, 
height; ID, intellectual disability; IQ, Intelligence quotient (Wechsler Adult Intelligence Scale); LL, lower limb; M, male; mo, months; Mod, moderate; 
MRI, magnetic resonance imaging; NA, not available; NP, not performed; OFC, occipitofrontal circumference; RP, retinitis pigmentosa; SDS, 
standard deviation scores; Sev, severe; susp, suspected; UL, upper limb; vent, ventricles; Wt, weight; yrs, years. (✓) indicates presence of a 




†Refers to age of examination  
‡Abnormal MRI findings include: mildly enlarged lateral ventricles and several loci of irregular signal in the brain parenchyma above the tentorium, 
in the posterior white matter and along the ependyma.  
 
*Also patient G001284 (Carss et al 2017 and Turro et al 2020 (85, 348)) 
#Also family M8500314 (Hu et al 2018 (344)) 
 
Height, weight, BMI and OFC Z-scores were calculated using a Microsoft Excel add-in to access growth references based on the LMS method 
(349) using a reference European population (350).  





Table 4.5 Ocular findings of all affected individuals with biallelic pathogenic SCAPER variants 
 Presenting 
age (yrs) 















CMO Electrophysiology Other ocular 
findings 
Najmabadi NA NA NA NA NA NA NA NA NA NA NA NA 
Tatour 
(A:II:1) 
12-13 ✓  NA Mod/Sev   NA ✓ ✓ ✓ ✓ ✓ Undetectable rod 





12-13 ✓  NA Mod/Sev  ✓ No ✓ ✓ ✓ No Undetectable rod 




28 ✓  ✓ Mod  NA ✓  
(PSC) 






15 NA ✓  NA NA ✓ ✓ ✓ No Abolished Nil 
Jauregui 9 ✓  NA RE: 0.3 (20/40) 
LE: 0.1 (20/25) 






10 ✓  NA RE: PL 
LE: HM 
✓ ✓  
(PSC) 





15 ✓  NA RE: 0.3 (20/40) 
LE: 0.3 (20/40) 
✓ ✓  
(PSC, nuclear, 
punctate) 





13 ✓  NA RE: 1.0 (20/200) 
LE: 2.0 (20/400) 
✓ ✓  
(PSC) 
✓ ✓ ✓ NA NA Nil 
Wormser 
(P1:V8) 
7 ✓  NA RE: 0.24 (20/33) 
LE: 0.24 (20/33) 
No No NA NA Suspected NA NA Nil 
Wormser 
(P2:III1) 
20 ✓ NA RE: NPL 
LE: NPL 
No ✓  
(mild cortical) 
✓ ✓ ✓ ✓ NA Nil 
Wormser 
(P2:III2) 
28 ✓ NA RE: HM 15cm 
LE: PL 
✓ ✓  
(mild PSC) 
✓ ✓ ✓ ✓ NA Nil 
Wormser 
(P2:III7) 
25 ✓ NA RE: 0.54 (20/70) 
LE: 0.54 (20/70) 
No No No No ✓ NA NA Nil 
Wormser 
(P2:IV1) 
NA Unable to 
assess 
NA Fixes and follows 
objects 
No No ✓ No ✓ NA NA Nil 
Kahrizi 
(1:III:6) 












NA NA NA  No No NA NA ✓ NA NA Nil 
Kahrizi # 
(2:II:2) 
NA NA NA NA ✓ No NA NA ✓ NA NA Nil 
Kahrizi # 
(2:II:4) 
NA NA NA NA No No NA NA ✓ NA NA Nil 
Kahrizi 
(3:IV:1) 
NA ✓ NA NA ✓ No NA NA ✓ NA NA Nil 
Kahrizi 
(3:IV:2) 
NA ✓ NA NA ✓ No NA NA ✓ NA NA Nil 
Kahrizi 
(3:IV:3) 
NA ✓ NA NA ✓ No NA NA ✓ NA NA Nil 
Kahrizi 
(3:IV:5) 
NA ✓ NA NA ✓ No NA NA ✓ NA NA Nil 
Kahrizi 
(4:VI:1) 
NA ✓ NA NA  No NA NA ✓ NA NA Nil 
Family 44 
Patient 1 
13 ✓ No RE: 0.48 (20/60) 
LE: 0.48 (20/60) 





NA NA NA NA NA NA NA NA NA NA NA NA 
Family 45, 
Patient 3* 
14 ✓ ✓ RE: 0.3 (20/40) 
LE: 0.3 (20/40) 






10 ✓ NA RE: 0.2 (20/30) 
LE: 0.3 (20/40) 





NA ✓ ✓ NA NA NA ✓ ✓ ✓ ✓ Severe  Nil 
Family 48, 
Patient 6 
23 Unable to 
definitively 
assess 
✓ RE: 0.2 (20/30) 
LE: 0.3 (20/40) 
✓ ✓  
(nuclear) 
NA ✓ ✓ ✓ Undetectable rod, 
severely  
 cone responses 
Nil 
Summary  20/20 5/6  12/21 9/24 14/16 14/17 26/27 6/11 11/11  
 
Abbreviations: CMO, cystoid macular oedema; HM, detection of hand motion; LE, left eye; Mod, moderate; NA, not available; NPL; no perception 
of light; pERG, pattern ERG; PL, perception of light; PSC, posterior subcapsular cataract; RE, right eye; Sev, severe; VA, visual acuity; , 
reduced. (✓) indicates presence of a feature in an affected subject 
 
*Also patient G001284 (Carss et al 2017 and Turro et al 2020 (85, 348)). 
#Also family M8500314 (Hu et al 2018 (344)). 
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Patients 1 and 2 from family 44 are Ohio Amish siblings. Candidate variants identified 
through WES of DNA from patient 1 were cross-referenced with regions of 
autozygosity common to both affected siblings, identified through whole genome SNP 
genotyping. This identified only a single plausible candidate variant, located within the 
largest (18 Mb) shared region of autozygosity on chromosome 15 [rs1509805 - 
rs4243078; (GRCh38) chr15:g.60281446 - 78374545], a novel homozygous 
duplication variant in exon 18 of the SCAPER gene, predicted to result in a frameshift 
[(GRCh38) chr15:g.76705914dupT, NM_020843.2:c.2236dupA, p.(Ile746Asnfs*6); 
Figure 4.6]. Dideoxy sequencing confirmed the presence and co-segregation of this 
variant in both siblings. This variant was detected in heterozygous form in five 
unrelated individuals in a database of 116 regional Amish controls, corresponding to 
an estimated allele frequency of ~0.04, not uncommon for founder mutations within 
this population.  
 
In patients 3 - 6, NGS identified compound heterozygous SCAPER variants 
summarised in Table 4.4. The SCAPER variants in each of these patients were 
confirmed to be biallelic by familial segregation analysis using dideoxy sequencing. 
SCAPER variants identified in Patients 1, 2, 4 - 6 are novel. The p.(Ile746Asnfs*6) and 
p.(Gln793*) SCAPER variants are present in gnomAD (v3.1.1) a single (non-Finnish) 
European individual, the p.(Arg727*) variant in a single South Asian individual 
(gnomAD v3.1.1), and the p.(Ser1236Tyrfs*28) in a single African/African-American 
individual (gnomAD v2.1.1 and v3.1.1), all in heterozygous form only; remaining 





Figure 4.6 Amish (family 44) pedigree showing SCAPER c.2236dupA, 
p.(Ile746Asnfs*6) genotype data and selected clinical images of affected 
individuals 
(A) Amish (family 44) pedigree (patient 1; VI:1 and patient 2; VI:5) showing segregation of the 
SCAPER c.2236dupA; p.(Ile746Asnfs*6) variant, co-segregating appropriately for an 
autosomal recessive condition. Genotypes are shown beneath generations V and VI (+, 
c.2236dupA; -, wild type).  
(B) Pictorial representation of SNP genotypes across the ~18.1 Mb chromosome 15q21-22 
region identified in the Amish family. 
(C) Sequence chromatogram of SCAPER c.2236dupA in (i) an unaffected wild type individual 
and (ii) a homozygous affected individual. 
(D-K) Clinical features of SCAPER syndrome patients. (D-E) Brachydactyly, camptodactyly 
and proximally placed thumbs in Patient 1. (F-K) Ocular imaging in Patient 3 illustrating 
features of retinitis pigmentosa. Fundus photograph (Optos California) of right (F) and left (G) 
eyes showing optic disc pallor, attenuated retinal vessels and mid-peripheral bone spicule 
pigmentation. Fundus autofluorescence (FAF) imaging of right (H) and left (I) eyes showing 
mid-peripheral hypoautofluorescence with a central ring of hyperautofluorescence 
demarcating the surviving outer retinal structures. Optical coherence tomography (Spectralis-
OCT) of right (J) and left (K) eye central retina demonstrating loss of photoreceptor outer 




Here clinical and genetic studies in six affected individuals (including additional new 
clinical details for Patient 3 (85)) were undertaken, which takes the total number of 
SCAPER syndrome patients described to date to 30. Although the extent for which 
clinical data is available for the previously reported SCAPER patients is variable, the 
detailed clinical phenotyping here allows a more comprehensive clinical comparison 
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to be made with the previously reported cases, confirming the presence of a variable 
pattern of dysmorphic features associated with SCAPER syndrome. It is now clear 
that the cardinal clinical features of the disorder include intellectual disability and 
developmental delay particularly affecting speech and language and motor 
milestones. Intellectual disability in particular appears to be a remarkably penetrant 
feature, and there has only been a single report of a single individual presenting with 
non-syndromic retinitis pigmentosa and no evidence of intellectual disability. This 
individual was found to be homozygous for a c.2023-2A>G SCAPER variant (343), 
with the same variant also reported in homozygous form in two further patients with 
retinitis pigmentosa, ADHD and mild intellectual disability (341). For the SCAPER 
patient with apparent non-syndromic retinitis pigmentosa, collateral history from 
parents and the paediatrician indicated that all developmental milestones had been 
met in time with no signs or symptoms suggestive of intellectual disability, although a 
formal evaluation did not appear to have been performed. There can sometimes be 
difficulties in conclusively defining milder developmental delay where more subtle 
clinical findings may not be identified if not specifically assessed. As such, it is still 
unclear if intellectual disability is invariably present or is instead a common but variably 
penetrant feature of the SCAPER syndrome. 
 
Early adult-onset retinitis pigmentosa is another key clinical finding, and the retinal 
phenotype appears remarkably consistent. In all individuals for whom data are 
available, progressive loss of night vision begins in first or second decade of life. 
Together with studies in mice demonstrating expression of SCAPER in multiple retinal 
layers, particularly in the RPE and photoreceptor inner and outer segments, this 
supports a role for SCAPER in photoreceptor function and/or maintenance (341). 
 
Hyperactivity appears to be a common feature, with some affected individuals 
receiving a formal diagnosis of ADHD. Additionally, variable forms of dysmorphic 
facies are noted in eight individuals in four families, and include a prominent nose, 
prominent maxilla, narrow chin or micrognathia, high forehead or frontal bossing, and 
almond-shaped eyes. 
 
Tapering fingers, brachydactyly and proximally placed thumbs, described in eight 
individuals from two consanguineous Bedouin families belonging to the same tribe in 
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southern Israel, were also identified as a consistent feature in the two Amish siblings, 
confirming the association of this feature with the SCAPER syndrome. Short stature 
and obesity were also a common feature amongst the affected Bedouin patients, and 
this constellation of clinical features including retinitis pigmentosa, obesity, short 
stature, intellectual disability, developmental delay and brachydactyly has 
consequently led to a suggested diagnosis of BBS in these individuals. Preliminary 
functional studies have demonstrated localisation of SCAPER to primary cilia when 
over-expressed in cell culture, as well as SCAPER mutations affecting length of cilia 
in patient fibroblasts, suggestive of a possible role of SCAPER in ciliary dynamics and 
disassembly (342). Although there is some overlap between the clinical features 
characteristic of ciliopathies and those seen in SCAPER syndrome, the Amish siblings 
(who are of normal height and weight for age) demonstrate that the digital, retinal and 
cognitive abnormalities may occur independently of short stature and obesity. The 
other common primary features of BBS, including renal anomalies, post-axial 
polydactyly, hypogonadism (in males) and genital abnormalities (in females) (300), 
have not been reported in association with SCAPER mutation. Whether SCAPER is 
indeed a ciliary protein contributing to a ciliopathy syndrome still remains unclear. 
 
The inverted nipples and pes planus, noted on examination of both Amish siblings, 
have not been previously noted in other individuals with SCAPER variants. These 
features may be unique to this family due to inherited autozygosity or may be 
incompletely expressed in patients with SCAPER variants. There appears to be 
significant variability in the presence and severity of extraocular features associated 
with the SCAPER syndrome (Table 4.4), and detailed assessment of further patients 
with respect to these features may be helpful in clarifying their possible association. 
 
Associated ocular pathology may remain undetected or unrecognised in individuals 
with intellectual disability, as such individuals often have difficulty recognising or 
articulating their visual symptoms. This highlights the importance of visual screening 
and ophthalmological assessment in these patients. Other common ocular features 
include cataracts [in particular posterior subcapsular cataracts, which are commonly 
associated with retinitis pigmentosa (351)], strabismus, and (high) myopia, with 
nystagmus and keratoconus noted in a single patient. The high incidence of cataracts, 
a potentially treatable cause of sight loss, as well as the association with high myopia 
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and its risk of ocular complications, again supports the case for ophthalmological 
screening in early childhood.  
 
The allele frequency (~0.04) of the Ohio Amish SCAPER c.2236dupA; 
p.(Ile746Asnfs*6) founder mutation suggests that despite no previous reports, this 
disorder likely represents an under-recognised cause of retinitis pigmentosa and mild 
intellectual disability within this community. This highlights the importance of careful 
clinical evaluation in children and adults with intellectual disability and enables 
targeted genetic testing for this SCAPER variant for Amish individuals with a similar 
clinical presentation, allowing a more rapid molecular diagnosis and shortening the 
diagnostic odyssey for affected individuals within the community. 
 
Together with the clinical review of all previously published patients, this study 
expands the molecular spectrum of disease-causing SCAPER variants and enables a 
clearer delineation of the core (and variable) phenotypical features of SCAPER 
syndrome to be characterised. These findings also highlight the importance of prompt 
visual screening and ophthalmic assessment in all individuals with SCAPER-
associated disease. Despite the increasing numbers of individuals identified with 
SCAPER syndrome, the precise functions of SCAPER in human growth and 
development are not fully understood. Further studies to elucidate the precise 
molecular and developmental roles of this molecule in human growth and skeletal, 
retinal and brain development and function, will yield important insights into the clinical 
heterogeneity increasingly observed in SCAPER-associated disease.  
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4.5 Conclusions and future work 
 
Four Amish and Pakistani families with overlapping clinical features suggestive of a 
ciliopathy disorder underwent genetic investigations in order to provide an accurate 
molecular diagnosis which could guide the clinical management of affected 
individuals. These studies clearly demonstrate the utility of genomic testing in 
clarifying the precise diagnosis for individuals with ciliopathy disorders. 
 
This study reports on only the second MORM syndrome family described in literature, 
and consolidates the INPP5E c.1879C>T; p.(Gln627*) likely Pakistani founder 
mutation as the cause of this condition. INPP5E variants are more commonly 
associated with the ciliopathy JBTS, and although MORM syndrome appears to be a 
phenotypically distinct disease entity, it is still unclear if MORM syndrome should 
instead be considered within the JBTS clinical spectrum. Neuroimaging studies in 
MORM syndrome patients to confirm the presence or absence of the “molar tooth” 
sign characteristic of JBTS would be important to clarify this. Functional studies have 
described the impact of the MORM variant on INPP5E protein interaction, ciliary 
localisation and catalytic activity (251). The generation of MORM and JBTS mutation-
specific murine and other animal models will be useful to further characterise any 
genotype-phenotype correlation, and provide a useful resource for various cellular and 
molecular studies to investigate the pathomolecular basis of disease. Given that the 
MORM syndrome-associated variant is a nonsense variant, TRIDs may be a valid 
therapeutic approach to explore. These drugs have already been assessed in some 
ciliopathies including Usher syndrome (352) and retinitis pigmentosa (353).  
 
Characterisation of the BBS1 p.(Met390Arg) variant in an extended Amish family 
confirms the phenotypic heterogeneity associated with homozygosity for this recurrent 
variant, although it did not find the evidence to either support or refute the complex 
digenic triallelic inheritance hypothesis in BBS. This hypothesis should be evaluated 
further, in order to provide accurate recurrence-risk estimates to at-risk family 
members, and could aid in the understanding of bio-molecular pathways involved in 
BBS-associated phenotypes, as well as facilitating the understanding of complex 
inheritance in other genetic disorders. Zebrafish and mouse models have been widely 
used in studies of ciliary dysfunction and ciliopathies including BBS (354, 355), with a 
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homozygous hypomorphic Cep290 mutant mouse model shown to demonstrate a 
more severe phenotype associated with the additional loss of Bbs4 alleles (317). 
Similar studies of other BBS loci in the Bbs1 Met390Arg knock-in mouse (321) and  
other BBS animal models may help clarify the role of modifier genes in BBS phenotypic 
expression. Further studies involving the systematic genetic screening of multiple 
ciliopathy genes combined with detailed longitudinal phenotyping in large ciliopathy 
patient cohorts will also be useful to define the interaction and true effects of modifier 
loci, and clarify the molecular basis and disease pathways underlying the clinical 
complexity in BBS and other ciliopathies. Retinal degeneration is a primary feature of 
BBS, associated with a poor visual prognosis, with affected individuals often 
progressing to complete blindness by 15-20 years of age (356). There have been 
some early promising results from retinal gene replacement therapy studies, showing 
trends towards improved retinal electrophysiological function following AAV-mediated 
subretinal gene delivery in Bbs4-null and homozygous Bbs1M390R/M390R mice (357, 
358). This could potentially be combined with an antiapoptotic therapy such as 
systemic Tauroursodeoxycholic acid (TUDCA), which has previously been shown to 
slow retinal degeneration in Bbs1M390R/M390R mice (359). Given that the majority of 
BBS-associated genes code for components of the core BBSome complex or 
chaperonin complex, one major challenge of gene replacement therapy however is 
the need to avoid overexpression of the gene product which could disrupt protein 
complex stoichiometry or lead to cell toxicity (357). 
 
The novel SCAPER c.2236dupA; p.(Ile746Asnfs*6) founder variant identified within 
the Ohio Amish population significantly expands the molecular spectrum of disease-
causing SCAPER variants, and detailed phenotyping studies in our patient cohort 
enabled a clearer delineation of the core (and variable) phenotypical features of 
SCAPER syndrome. Although SCAPER is now considered by some to be a BBS-
associated disease gene (301), it is still unclear whether it is indeed a ciliary protein. 
Preliminary functional studies have demonstrated SCAPER localisation to primary cilia 
when over-expressed in cell culture. It should be noted however that protein over-
expression in cells, particularly with a large tag that may affect protein folding, may 
lead to altered localisation and may not always reflect the true endogenous location of 
the protein (342). Additionally, a review of all published SCAPER syndrome patients 
finds that other common primary features of ciliopathies, including obesity, renal 
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anomalies, post-axial polydactyly, hypogonadism (in males) and genital abnormalities 
(in females) are not always present in affected individuals with SCAPER syndrome. 
Further studies are needed to elucidate possible roles of SCAPER in primary cilia 
function and dynamics. In the adult mouse retina, SCAPER localises to multiple retinal 
layers, with highest expression observed in the RPE and the photoreceptor outer and 
inner segments, which are terminally differentiated postmitotic cells (341). The retinal 
phenotype in SCAPER syndrome does not appear to be congenital in onset, instead 
presenting in the first or second decade of life. SCAPER does not therefore appear to 
play a developmental role in the retina, and may instead be important for 
photoreceptor function and/or maintenance. SCAPER function in the retina does not 
appear to be related to its interaction with cyclin A and its putative role in cell cycle 
control. Further studies to identify possible SCAPER interacting partners in the retina 
may facilitate a better understanding of the underlying molecular disease pathways, 
thereby allowing the development and early deployment of therapies to halt the 







5 IMPROVING KNOWLEDGE OF THE SPECTRUM AND 
CAUSES OF RARE AND ULTRA-RARE GENETIC EYE 




Definitions of rare and ultra-rare disorders vary by country and are not well defined, 
depending on factors such as disease prevalence and severity, heritability and 
treatment availability (360). In Europe, rare disorders are defined as diseases or 
conditions that affect fewer than 1 in 2000 people in the population, whilst ultra-rare 
disorders generally refer to disorders affecting fewer than 1 in 50,000 people (or fewer 
than 20 patients per million) (360, 361). It is currently estimated that there are over 
6000 rare disorders (362), with new conditions continually being identified as research 
advances. Although individually these disorders are uncommon, collectively they can 
affect up to 30 million individuals in Europe (363) and 300 million people worldwide 
(361). 
 
Over 70% of rare diseases have an identified genetic origin (362); in fact, many genetic 
disorders have a relatively low prevalence and incidence and are classified as rare or 
ultra-rare disorders (364). Rare and ultra-rare disorders are often chronic conditions 
associated with significant morbidity, and are also commonly difficult to diagnose and 
treat. In fact, these conditions are often categorised as orphan diseases to highlight 
their severity and the insufficient resources and knowledge available to develop 
diagnostic assays or treatments.  
 
There has been tremendous interest and advances in the field of rare and ultra-rare 
genetic eye diseases in recent times, with increasing characterisation of causal genes 
and underlying disease pathways and delineation of novel inheritance models (365). 
New therapeutic approaches are entering the clinical phase of development, and the 
first ever licensed gene replacement therapy for the treatment of a genetic disease in 
humans, Luxturna® (voretigene neparvovec), was recently approved for the treatment 




Genetic eye diseases are however extremely difficult to study in a global setting due 
to their rarity and associated phenotypic, genetic and allelic heterogeneity. The study 
of inherited eye diseases in genetically isolated populations such as rural Palestinian 
or Pakistani communities provides an important opportunity to learn about the genetic 
causes of inherited eye diseases, whilst also providing desperately required 
healthcare benefits for the families and populations involved. An improved 
understanding of the underlying genetic and molecular causes of disease arising from 
the identification of novel disease genes and variants within communities may then be 
applied to genetically diverse populations such as the UK, and bring about clinical 
benefits for patients worldwide. 
 
In this chapter, clinical and genomic investigations were undertaken in families from 
Pakistani and Palestinian communities with a preliminary clinical diagnosis of various 
forms of genetic eye diseases. These studies identified 18 likely disease-causing 
variants in these families, leading to an accurate molecular diagnosis and subsequent 
refinement of the initial clinical diagnosis, with important treatment and prognostic 
implications for affected individuals and their families.  
 
Within this chapter, I was responsible for the interpretation and analysis of all collected 
clinical data for all affected individuals (families 49 - 66). I performed DNA extraction 
for a proportion of affected families (remaining DNA extraction largely completed by 
Joe Leslie, University of Exeter). I was also responsible for the analysis of all exome 
sequencing results, as well as primer design and subsequent cosegregation studies 
for all variants identified in families within chapters 5.2 and 5.3 (apart from families 50 
– 51, which performed in collaboration with Dr Shamim Saleha, Kohat University of 
Science and Technology, Pakistan). I performed the literature reviews described in 
this chapter (apart from review of all disease-causing ALDH1A3 variants, which was 




5.2 Consolidating biallelic SDHD variants as a cause of 
mitochondrial complex II deficiency 
 
5.2.1 Introduction  
 
The mitochondrial oxidative phosphorylation (OXPHOS) system is composed of five 
multi-subunit transmembrane protein complexes (I-V) encoded by the mitochondrial 
and nuclear genomes, and is the primary mechanism for adenosine triphosphate 
(ATP) production in eukaryotic cells. OXPHOS defects result in mitochondrial disease, 
with an estimated prevalence of 1:4300 (367, 368). 
 
Mitochondrial complex II (succinate dehydrogenase) is composed of two catalytic 
subunits (SDHA/SDHB) anchored to the inner mitochondrial membrane by two smaller 
subunits (SDHC/SDHD) (369, 370). Complex II differs from other mitochondrial 
respiratory chain complexes, in that its four structural subunits and their two assembly 
factors (SDHAF1/SDHAF2) are solely encoded by the nuclear genome. Complex II is 
also unique in being involved in both the mitochondrial respiratory chain and the Krebs 
cycle (368).  
 
Mitochondrial complex II deficiency with multisystem involvement has been reported 
in association with biallelic SDHA (371), SDHB (368), SDHD (372, 373) and SDHAF1 
(369, 374) gene variants, with clinical presentations including Leigh syndrome, 
leukoencephalopathy, optic atrophy and cardiomyopathy with highly variable severity 
and age of onset (371, 375). Complex II deficiency is rare, accounting for only 2-4% 
of OXPHOS defects (372), with variants in SDHA being most common, predominantly 
associated with Leigh syndrome (371). Previously, only two individuals with candidate 
biallelic SDHD variants and isolated complex II deficiency have been reported (372, 
373). This study describes four Palestinian siblings presenting in childhood with 
clinical features indicative of mitochondrial disease and a likely pathogenic 
homozygous SDHD variant, consolidating SDHD gene variants as a likely cause of 





5.2.2 Materials and methods 
 
Blood samples were collected with informed consent for DNA extraction (see section 
2.3.2). SNP genotyping was performed in affected individuals V:2, V:4 and V:6 as 
described in section 2.3.4. WES was undertaken using DNA from a single affected 
individual (V:4) at BGI Hong Kong, as described in section 2.3.5. Primer design, PCR 
and dideoxy sequencing (Appendix Table D2) was performed as described in section 
2.3.3 to genotype and confirm appropriate segregation of the candidate disease 
variant in all available affected and unaffected individuals. 
 
5.2.3 Results: clinical and genetic findings 
 
Four affected Palestinian patients (three male, one female) aged 4 - 20 years, 
comprising of two sibships from an extended interconnecting family (family 49) (Figure 
5.1A), were investigated in this study. All four children presented with developmental 
delay in infancy and variable clinical and laboratory findings suggestive of a 
mitochondrial disorder including elevated serum lactate/urinary Krebs cycle 
metabolites, nystagmus, optic atrophy, progressive microcephaly, generalised 
hypotonia, epileptic seizures, severe/profound intellectual disability/developmental 
impairment, and cardiomyopathy. The affected children were not dysmorphic (Figure 
5.1C), though individuals V:2 and V:4 were noted to have significant hypertrichosis, 
particularly over their back and limbs. MRI neuroimaging was unremarkable for one 
child at 8 months (V:2; Figure 5.1D), however, his sister’s scan revealed delayed 
myelination at age 6 months (V:4). Hirschsprung disease, confirmed by aganglionic 
rectal biopsy, was noted in a single individual (V:2). A full description of the clinical 





Figure 5.1 Family 49 pedigree showing SDHD c.205G>A genotype data, 
neuroimaging and images of affected individuals 
 (A) Pedigree diagram of family 49 showing segregation of the SDHD c.205G>A; p.(Glu69Lys) 
variant, co-segregating appropriately for an autosomal recessive condition. Genotypes are 
shown beneath generations IV and V (+, c.205G>A; -, wild type). DNA was available from all 
but one affected individual (V:5). 
(B) Electropherogram showing the DNA sequence at the position of SDHD c.205G>A in a 
homozygous affected individual. 
(C) T1 and T2-weighted axial views of MRI head of individual V:2 (aged 8 months), showing 
normal myelination and no intracranial abnormalities. 
(D) Image of affected individual V:4, illustrating the absence of any facial dysmorphism. 
(E)(i) Schematic showing domain architecture of SDHD [adapted from UniProt (216)] and the 
location of p.(Glu69Lys), p.(Asp92Gly) and p.(Ter160LeuextTer3) variants within the 
succinate dehydrogenase cytochrome b small subunit (CybS) domain. The orange rectangle 
denotes the transit peptide (TP) domain, the red circle denotes the iron (heme axial ligand) 
binding site shared with SDHC, and the blue circle denotes the ubiquinone binding site shared 
with SDHB (ii) Conservation analyses: multiple species alignments of amino acid sequences 
of SDHD at the locations of the p.(Glu69Lys), p.(Asp92Gly) and p.(Ter160LeuextTer3) 
variants. 
(F) Visual depiction of the two autozygous regions on chromosome 11 (shown in red) common 




Table 5.1 Clinical features of affected individuals with mitochondrial complex II deficiency due to biallelic SDHD variants 















Ethnicity Swiss Irish Palestinian Palestinian Palestinian Palestinian 
Gender F M M F M M 
Age at last evaluation 7 yrs 
(Deceased age 10 yrs) 
Deceased day 1 of 
life from lethal 
cardiomyopathy 
6.4 yrs 4.5 yrs 20 yrs Hx from parents 
Deceased age 10 yrs - 
cardiac arrest 
GROWTH PARAMETERS     
Birth weight kg (SDS) NA 2.62 3.5 (-0.1) 2.8 (-1.4) NA NA 
Birth OFC cm (SDS) NA 34.5 35 (-0.2) 35 (+0.4) NA NA 
OFC cm (SDS) 2° microcephaly from 2 
yrs 
NA 46.5 (-4.4) 49 (-2.0) NA NA 
DEVELOPMENT       
Intellectual disability Severe 
Maximum developmental 
age of 11 mo at 4 yrs 




(from age 3 mo after 
bronchiolitis) 
Several subsequent 
episodes of regression 
after infection/prolonged 
fasting 
NA ✓  
(from age 5 mo 
following surgery)  
Previously was sitting 




(from age 4 mo) 
Previously sitting with 
support, 
 fixing and following, 
mouthing, purposeful 
hand movements 
No clear hx of 
regression 
No clear hx of 
regression 
Gross motor skills NA NA Antigravity movements 
of arms and legs only 
Sits with support. 
Rolls from back to front 
Sits with support Walked with support 




NA NA Vocalisation,  
Makes sucking motions 
if thirsty 
Vocalisation, 
Responds to loud 
noises 
Vocalisation 
Points to indicate 
needs 












NEUROLOGY       
Generalised muscle 
hypotonia 
✓ NA ✓ ✓ ✓ NK 
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NA Generalised seizures 
post surgery 
(6 mo) 
Abnormal movements  
 (4 mo) 
 
Seizures when 
younger now resolved 
 
- 
EEG Normal NA Normal (7 mo) Normal NK NK 
Neuroimaging Normal MRI  
(10 mo and 2 yrs) 





Normal CT brain  
(7 yrs) 
NK 
OCULAR       
Visual impairment ✓ NK ✓ ✓ ✓ NK 
Nystagmus ✓ NK ✓ ✓ ✓ ✓ 
Optic atrophy ✓ NK ✓ ✓ ✓ NK 
Strabismus NA NK NK  ✓ ✓ 
HEARING 
IMPAIRMENT 
 NK     
CARDIAC 
ABNORMALITIES 

















Minimal Lt ventricular 
hypertrophy, with low 
normal Lt ventricular 
function (21yrs) 
✓ 
Echo (5 yrs): Dilated 
cardiomyopathy with 
reduced left ventricular 
ejection fraction, mild 
mitral and tricuspid 
regurgitation  
HYPERTRICHOSIS NK NK ✓ ✓  NK 
METABOLIC 
INVESTIGATIONS 
Raised serum lactate  
(10.2 mmol/L),  
Lactic aciduria and 
ketonuria, urinary Krebs 
cycle intermediates 
Marked defect in 
complex II activity in 
muscle homogenate 
Marked defect in 
complex II activity in 
muscle homogenate 
 
None Raised serum lactate  
(5.58 mmol/L) 










c reductase assay was 
outside the normal 







- - Hirschsprung disease 
diagnosed at 1 mo, 
Frequent LRTI 
- - - 
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Abbreviations: CT, computerised tomography; Echo, echocardiography, F, female; hx, history; M, male; mo, months; MRI, magnetic resonance 
imaging; NA, not available; NK, not known; OFC, occipitofrontal circumference; SDS, standard deviation scores; LRTI, lower respiratory tract 
infection; Lt, left; yr, years; the (✓) and () symbols indicate the presence or absence of a feature in an affected subject respectively 
 
Height, weight, BMI and OFC Z-scores were calculated using a Microsoft Excel add-in to access growth references based on the LMS method 
(349) using a reference European population (350) 
162 
 
Genome-wide SNP genotyping and WES was undertaken assuming that a 
homozygous founder variant was responsible, although also considering other genetic 
mechanisms. SNP genotyping (individuals V:2, V:4 and V:6) identified four notable (>1 
Mb) shared homozygous regions, the two largest identified on chromosome 11; a 
~7.00 Mb region (rs6485795 – rs11246414, chr11:g.47908294 – 54905443 [hg38]), 
and a ~2.42 Mb region (rs120436 – rs12794326, chr11:g.110826521 – 113248134) 
(Figure 5.1F).  
 
WES was performed in affected individual V:4 in family 49 to identify rare functional 
candidate variants. Variants were prioritised as described in section 2.3.5 and cross 
referenced with SNP data, identifying only a single candidate homozygous variant of 
relevance to the phenotype in SDHD [NM_003002.3:c.205G>A; p.(Glu69Lys); 
chr11:g.112088902G>A], located within the second largest shared homozygous 
region. This variant is present in only two heterozygotes in gnomAD (v2.1.1) and is 
predicted to result in a glutamic acid to lysine substitution in an evolutionarily 
conserved Glu69 residue (Figure 5.1E). This variant was previously reported as the 
likely candidate cause of disease in compound heterozygous form in a single individual 
with autosomal recessive encephalomyopathy and isolated mitochondrial complex II 
deficiency (ClinVar accession: VCV000156153.6 and SCV001424558) (372). Dideoxy 
sequencing confirmed co-segregation as appropriate for an autosomal recessive 




A homozygous SDHD c.205G>A; p.(Glu69Lys) missense variant was identified as the 
likely cause of isolated mitochondrial complex II deficiency in three affected children 
from an extended Palestinian family in this study. DNA was unavailable for individual 
V:5, (deceased age 10 years), whose clinical history overlapped that of his sibling 
(individual V:6). Tissues and organs heavily dependent on robust oxidative 
phosphorylation processes tend to be most affected by mitochondrial disease (376), 
explaining why common findings include optic atrophy, leukoencephalopathy, 
myopathy, cardiomyopathy and Leigh syndrome. These clinical features overlap those 
described in the affected individuals in this study, as well as the two individuals with 




Previously, compound heterozygous variants in SDHD (372) including the same 
p.(Glu69Lys) variant identified here and a c.479G>T; p.(Ter160LeuextTer3) alteration 
were identified as the likely candidate cause of disease in a Swiss child presenting 
with developmental regression following a viral infection at three months. Progressive 
ocular (visual impairment, nystagmus, optic disc pallor) and neurological (epileptic 
seizures, ataxia, dystonia and continuous intractable myoclonic movement) 
involvement were described, and the child died aged 10 years. Urinalysis revealed 
lactic aciduria, ketonuria and Krebs cycle intermediates. Complex II activity was 
deficient in skeletal muscle, and complementation studies in patient fibroblasts 
showed restoration of complex II assembly and function with expression of wild-type, 
but not mutant, SDHD cDNA (372). Subsequently an Irish male infant was described 
(373) homozygous for a novel SDHD c.275A>G; p.(Asp92Gly) substitution, presenting 
with cardiomyopathy in utero. He developed cardiopulmonary insufficiency rapidly 
after birth, dying on day 1 of life. Subsequent analysis of respiratory chain function in 
patient muscle homogenate revealed a marked defect in complex II activity. The four 
affected individuals described here show phenotypic overlap with both these 
individuals (Table 5.1).  
 
This study extends the clinical spectrum and highlights the wide range of phenotypical 
features and severity across affected individuals, even those with the same SDHD 
genotype (Table 5.1). Hypertrichosis, a recognised feature of some forms of 
mitochondrial disease (most notably SURF1-associated Leigh syndrome) (377), was 
a noted feature in two Palestinian children. Hirschsprung disease diagnosed in a single 
affected individual (V:2) has not been previously reported in association with SDHD 
variants, and it remains unclear whether this is an associated or unrelated feature. 
Neurodevelopmental regression is a common characteristic of mitochondrial disease, 
particularly during physiologic stress through intercurrent infection, prolonged fasting 
or dehydration (378). It is thus unsurprising that this appears to be a common feature 
of complex II deficiency due to biallelic SDHD variants (Table 5.1). An accurate 
molecular diagnosis for complex II deficient patients would support avoidance of 




In addition to their role in primary mitochondrial disease, heterozygous germline 
variants in SDHD and other complex II subunits and assembly factors (including 
SDHA, SDHB, SDHC and SDHAF2) are associated with paragangliomas, 
phaeochromocytomas and gastrointestinal stromal tumours (369). Dominantly 
inherited hereditary cancer-associated SDHD variants exhibit a parent of origin effect; 
typically only paternally inherited mutations are associated with disease (379, 380). 
This was originally interpreted as evidence for sex-specific epigenetic modification of 
the maternal SDHD allele (381); however, the SDHD gene does not appear to be 
imprinted, being biallelically expressed in human brain, kidney and lymphoid tissue 
(379). Instead, the ‘Hensen Model’ suggests that tumour development only occurs 
following loss of function of both copies of SDHD as well as loss of an imprinted 
(paternally silenced and maternally active) tumour suppressor gene likely found within 
the chromosome 11p15 region, which contains several loci regulated by genomic 
imprinting as well as encompassing the candidate tumour suppressor genes HK19 
and CDKN1C (382, 383).  
 
None of the three SDHD variants associated with mitochondrial complex II deficiency 
have been previously linked to tumourigenesis, including in this extended Palestinian 
family, although a Dutch founder familial paraganglioma SDHD variant c.274G>T; 
p.(Asp92Tyr) affecting the same Asp92 amino acid residue as the p.(Asp92Gly) 
mitochondrial complex II deficiency-associated variant has been described (384). 
Additionally, SDHA and SDHB variants have been associated with both mitochondrial 
complex II deficiency in biallelic form, and hereditary cancer susceptibility in 
monoallelic form (371, 385). Therefore, routine surveillance of heterozygous SDHD 
carriers is suggested for early detection of paragangliomas and phaeochromocytomas 
facilitating appropriate intervention.  
 
Together the data presented here consolidate biallelic SDHD variants as a cause of 
mitochondrial disease due to mitochondrial complex II malfunction, and extend the 
variable clinical features associated with the condition.   
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5.3 Informing clinical care through genomic studies in Pakistani 




In Pakistan, blindness presents a significant public health issue with an estimated 
prevalence of 15 per 10,000 in children under the age of 15 years (386), and inherited 
eye diseases are an important contributor to this burden (183, 387). Due to regional 
geographical limitations or restricted local clinical resources, however, there is often 
limited access to ophthalmic equipment and expertise needed for performing and 
interpreting the detailed phenotyping studies needed for an accurate clinical diagnosis. 
In a setting where clinical information is limited, the application of next generation 
sequencing approaches may enable an accurate molecular diagnosis to be achieved, 
providing important clinical benefits to affected individuals and their families, as well 
as providing scientific insights into the genomic architecture of inherited eye diseases 
within local communities as well as globally. 
 
As part of an ongoing international collaboration, genomic studies were undertaken in 
17 families from Pakistan with a preliminary clinical diagnosis of anophthalmia, 
congenital cataracts, congenital blindness, nystagmus and OCA. This study identified 
14 likely disease-causing mutations in these families, leading to an accurate molecular 
diagnosis and subsequent refinement of the initial clinical diagnosis, with important 
treatment and prognostic implications for affected individuals and their families. 
 
5.3.2 Materials and methods 
 
Genetic and clinical investigations in 17 Pakistani families were undertaken with 
informed consent. Medical histories were taken to enable the initial clinical diagnosis. 
Following results of genetic analyses and identification of likely pathogenic variants, 
affected individuals were revisited, and a detailed medical history including 
documentation of symptoms was ascertained. Clinical features were documented with 
facial photographs and videos, as well as external ocular photographs. Visual acuity 
testing using Snellen charts, anterior and posterior segment examinations on a slit-
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lamp biomicroscope and B-scan ultrasonography was performed in a limited number 
of affected individuals.  
 
Blood sample collection and DNA extraction was performed as previously described 
(see section 2.3.2 
2.3.2 DNA extraction and quantification). WES (Exeter Sequencing Service, University of 
Exeter, UK) (families 50 - 52 and 59), or Illumina TruSightTM One clinical exome 
sequencing panel (families 56 - 58, 60 - 66) was performed as described in section 
2.3.5 in a single affected individual in each family (apart from family 59, where two 
affected individuals underwent WES). Bioinformatic analysis of exome data was 
performed as per section 2.3.5. Primer design, PCR and dideoxy sequencing 
(Appendix Tables D1 and D2) was performed as described in section 2.3.3 to 
genotype and confirm appropriate segregation of the candidate disease variant in all 
available affected and unaffected individuals. 
 
A literature review was performed as described in section 2.4 to retrieve all reported 
ALDH1A3, TDRD7 and ATOH7 inherited ocular disease-associated variants. Findings 
are summarised in Tables 5.6 – 5.8. 
 
5.3.3 Results: clinical and genetic findings 
 
Study subjects from 17 families with individuals diagnosed with ocular conditions 
alongside parents and unaffected siblings were enrolled from different provinces in 
Pakistan (Sindh, KPK, Punjab and Balochistan). Two families were initially diagnosed 
with anophthalmia (families 50 and 51) six families with non-syndromic congenital 
cataracts (families 52 - 55, 57, 58), five families with OCA (families 62 - 66), one family 
with congenital blindness (family 59) and three families with nystagmus (families 56, 
60, 61). Preliminary clinical findings are summarised in Table 5.2. 
 
Following molecular genetic findings, affected individuals underwent a further 
ophthalmic examination where possible, allowing confirmation of the initial clinical 
diagnosis in eight families (families 50 - 56 and family 60). In some individuals, 
additional ocular pathologies were identified, allowing a refinement of the initial clinical 
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diagnoses in the remaining nine families (families 57 - 59 and 61 - 66). These results 
are summarised in Table 5.2.
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Abbreviations: gnomAD, genome aggregation database (v2.1.1); hom, homozygous; HPS, Hermansky-pudlak syndrome; KPK, Khyber 
Paktunkhwa; MAF, minor allele frequency; OCA, oculocutaneous albinism; SAS, South Asia; RD, retinal detachment. 
 
Gene transcripts: ALDH1A3 (NM_000693.3); FYCO1 (NM_024513.3); TDRD7 (NM_014290.2), CYP1B1 (NM_000104.3), ATOH7 
(NM_145178.3), LRP5 (NM_002335.3), FRMD7 (NM_194277.2), PAX6 (NM_000280.5), HPS1 (NM_000195.3). 
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Novel variants in ALDH1A3 associated with autosomal recessive 
anophthalmia/microphthalmia 
 
Bilateral isolated anophthalmia was the major clinical finding in all affected 
individuals in families 50 and 51; affected individuals were all reported to be of 
normal intelligence with no signs of intellectual disability, and no other 
neurological and behavioural features were observed. WES performed in a 
single affected individual in each family (family 50, individual IV:7; family 61, 
individual II:1) identified homozygosity for novel ALDH1A3 variants in each 
family, summarised in Table 5.2. 
 
The novel c.1240G>C ; p.(Gly414Arg) variant identified in family 50 was absent 
in gnomAD (v2.1.1 and v3.1.1); there was however another genomic variant 
(c.1240G>A) resulting in the same p.(Gly414Arg) amino acid substitution that 
is present in only a single heterozygous non-Finnish European individual in 
gnomAD, with no homozygous individuals for this variant reported. In silico 
analysis of the ALDH1A3 p.(Gly414Arg) variant using PolyPhen-2, PROVEAN 
and SIFT all predict pathogenicity. In family 51, the novel c.172dupG; 
p.(Glu58Glyfs*5) variant is predicted to result in a frameshift followed by a 
premature stop codon [p.(Glu58Glyfs*5)], leading to loss of function via mRNA-
targeted degradation and nonsense-mediated decay. Both ALDH1A3 variants 
segregate as expected for an autosomal recessive condition in each family 
investigated (Figure 5.2). 
 
 
A FYCO1 c.2206C>T; p.(Gln736*) likely regional founder gene variant 
commonly underlies congenital cataracts in Pakistani families  
 
In family 52, WES in single affected individual (V:7) identified a single 
homozygous FYCO1 premature nonsense variant (GRCh38) c.2206C>T; 
p.(Gln736*) of relevance to the ocular phenotype. This variant has previously 
been described in association with congenital cataracts in Pakistani families 
(388, 389). The same FYCO1 variant was subsequently identified via targeted 
dideoxy sequencing in a further three congenital cataract families (families 53 -
55) residing in the same region (Agra Road, Sindh) as family 52 (Table 5.2). 
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This variant segregated as expected for an autosomal recessive condition in all 
families investigated (Figure 5.3). Further clinical details are summarised in 
Table 5.3. 
 
Distinct HPS1 gene variants are associated with albinism in five Pakistani 
families 
 
Affected individuals in families 62 - 66 all had a clinical diagnosis of OCA. 
TruSightTM One clinical exome sequencing of a single affected individual in 
each family (family 62, individual II:2; family 63, individual IV:1; family 64, 
individual IV:3; family 65, individual IV:2 and family 66, individual II:2) identified 
three novel and two previous reported HPS1 variants, summarised in Table 5.2.  
 
For the novel HPS1 c.1397+1G>A splice site variant, in silico analysis using the 
bioinformatics tool Human Splicing Finder predicts an effect on splicing via 
alteration of the wild-type donor site. The novel HPS1 p.(Leu670Pro) variant 
alters an evolutionary conserved leucine residue (Figure 5.5), with 
bioinformatics tools SIFT, PolyPhen-2 and PROVEAN all predicting 
pathogenicity. Missense variants located within the same Longin 3 domain as 
the p.(Leu670Pro) variant have previously been reported in association with 
Hermansky-Pudlak syndrome (HPS) (141, 348, 404-408). The novel HPS1 
p.(Trp146*) nonsense variant is predicted to result in loss of function via mRNA-
targeted degradation and nonsense-mediated decay. 
 
All HPS1 variants segregated as expected for an autosomal recessive condition 
in all families investigated (Figure 5.5) and were considered likely causative for 
HPS in all affected individuals. 
 
Defining sequence variants in six families with inherited ocular disease enables 
refinement of clinical diagnosis 
 
Illumina TruSightTM One clinical exome sequencing (family 56, individual II:2; 
family 57, individual V:1; family 58, individual IV:1; family 60, individual IV:2; 
family 61, individual IV:3) and WES (family 59, individuals IV:2 and IV:5) was 
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performed in six families with preliminary clinical diagnoses of nystagmus, 
congenital cataracts and congenital blindness. In all families investigated, novel 
and known likely pathogenic variants in inherited ocular disease genes that 
were of plausible relevance to the ocular phenotype were identified, allowing 
further refinement of the initial clinical diagnoses (summarised in Table 5.2). 
 
The novel TDRD7 c.2469delG; p.(Asn824Thrfs*27) and ATOH7 c.94delG; 
p.(Ala32Profs*55) variants are predicted to result in a frameshift. These 
variants, as well as the novel FRMD7 c.443T>A, p.(Leu148*) nonsense variant, 
are all predicted to result in loss of function via mRNA-targeted degradation and 
nonsense-mediated decay. The novel LRP5 c.1076C>G; p.(Thr359Arg) 
missense variant alters an evolutionary conserved threonine residue, with 
bioinformatics tools SIFT, PolyPhen-2 and PROVEAN all predicting 
pathogenicity.  
 
Following genetic investigations, a further limited ophthalmic examination was 
performed in affected individuals from families 58 and 59, with additional clinical 
findings remaining consistent with the molecular diagnoses obtained (Tables 
5.4 and 5.5).  
 
In family 60, the FRMD7 p.(Leu148*) variant segregated appropriately for an X-
linked condition (penetrant in the carrier female III:2). In family 61, the PAX6 
variant was found to occur de novo, and was not identified in either unaffected 
parent. In the remaining families (families 57 - 59), the variants segregated 
appropriately for an autosomal recessive condition. All identified variants were 
thought likely to be responsible for the inherited ocular disorder in the affected 








Figure 5.2 Pedigrees and ALDH1A3 genotype data for families 50 - 51 
(A-B) Pedigree diagrams of families 50 and 51 showing segregation of the ALDH1A3 
c.172dupG; p.(Glu58Glyfs*5) and c.1240G>C; p.(Gly414Arg) variants in family 51 (A) 
and family 50 (B) respectively, co-segregating appropriately for an autosomal 
recessive condition. Genotypes are shown beneath each family member investigated 
(+, variant; -, wild type).  
(C-D) Sequence chromatograms of a wild-type individual along with ALDH1A3 
c.172dupG in a homozygous affected individual (C), as well as the DNA sequence at 
position ALDH1A3 c.1240G>C in a homozygous affected individual (D). 
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(E) Schematic showing domain architecture of ALDH1A3 polypeptide [predicted 
domains described by Moretti et al (409)] and the location of the c.172dupG; 
p.(Glu58Glyfs*5) and c.1240G>C; p.(Gly414Arg) variants. OD, oligomerisation 
domain. 
(F) Photographs of two affected individuals in family 49 [F(i)] and family 50 [F(i)] with 
non-syndromic clinical anophthalmia. 
(G) Conservation analysis: multiple species alignments of partial amino acid 




Figure 5.3 Pedigrees and FYCO1 genotype data for families 52 - 55 
 (A) Pedigree diagrams in families 52 - 55 showing segregation of FYCO1 c.2206C>T; 
p.(Gln736*) variants, co-segregating appropriately for an autosomal recessive 
condition. Genotypes are shown beneath each family member investigated (+, variant; 
-, wild type).  
(B) Sequence chromatograms of the FYCO1 c.2206C>T; p.(Gln736*) variant in a 










Figure 5.4 Pedigrees and genotype data for families 56 - 61 
A) Pedigree diagrams of families 56 - 61 showing segregation of identified ocular 
disease variants. Genotypes are shown beneath each family member investigated (+, 
variant; -, wild type) alongside sequence chromatograms of the disease variant in a 
homozygous (families 56-59), hemizygous (family 60) and heterozygous (family 61) 
affected individual in each family. 
(B) Schematic showing domain architecture of LRP5 [adapted from UniProt (216)] and 
the location of the c.1076C>G; p.(Thr359Arg) variant. Low-density lipoprotein receptor 
repeat class A and B domains are denoted by the blue and green rectangles 
respectively, orange rectangle represents the signal peptide, red rectangles denote the 
coagulation Factor Xa inhibitory site, and the purple rectangle denotes the 
transmembrane domain. 
(C) Conservation analysis: multiple species alignments of partial amino acid 





Figure 5.5 Pedigrees and HPS1 genotype data for families 62 - 66 
 (A) Pedigree diagrams of families 62 - 66 showing segregation of identified HPS1 
variants, cosegregating appropriately for an autosomal recessive condition in each 
family investigated. Genotypes are shown beneath each family member investigated 
(+, variant; -, wild type) alongside sequence chromatograms of the HPS1 variant in a 
homozygous affected individual in each family. 
(B) Schematic showing domain architecture of HPS1 [adapted from UniProt (216)] and 
the location of the c.2009T>C; p.(Leu670Pro) variant within the Longin 3 domain. 
(C) Conservation analysis: multiple species alignments of partial amino acid 
sequences of HPS1 showing conservation of leucine at position 670. 
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Cornea AC Cataracts Cataract surgery Fundus 
52 (V:3) 21 6/12 14 Clear D&Q 
✓ 
BE present at birth 
✓  
IOL in situ RE, 
decentered LE 
RE: slight optic disc pallor, healthy 
retina 
LE: healthy optic disc & retina 
52 (V:6) 13 HM 13 Clear D&Q 
✓ 
BE present at birth 
✓  
IOL in situ 
Healthy optic disc & retina 
52 (V:6) 16 PL 15 Clear D&Q 
✓ 
BE present at birth  
RE lamellar cataract 
✓  
LE only, IOL in situ  
No fundal view 
52 (VI:3) 3 
RE: 6/18 
LE: 6/9 
15 Clear D&Q 
✓ 
BE present at birth 
✓  
Aphakic 
Healthy optic disc & retina 







BE present at birth 
✓  
IOL in situ with PC 
thickening 
Healthy optic disc, retina & macula 







BE present at birth 
✓  
IOL in situ with PC 
thickening 
Healthy optic disc & retina 
54 (V:1) 14 
RE: 6/12 
LE: 6/12 
10 Clear D&Q 
✓ 
BE present at birth 
✓  
IOL in situ with 
posterior capsulotomy 
Healthy optic disc & retina 
54 (V:3) 6 PL 8 Clear D&Q 
✓ 
BE present at birth  
Lamellar and posterior 




No fundal view, dense vitritis on B-
scan ultrasonography 
55 (III:3) 26 
RE: 6/9 
LE: 6/12 
9 Clear D&Q 
✓ 
BE present at birth 
✓  
IOL in situ with 
posterior capsulotomy 
Healthy optic disc & retina 







BE present at birth 
✓  
IOL in situ with PC 
thickening 
Healthy optic disc & retina 
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55 (III:5) 17 
RE: 6/12 
LE: 6/12 
13 Clear D&Q 
✓ 
BE present at birth 
✓  
IOL in situ 
Healthy optic disc & retina 





BE present at birth  




No fundal view 
 
Abbreviations: AC, anterior chamber; BCVA, best corrected visual acuity; BE, both eyes; D&Q, deep and quiet; HM, hand movement; ID, 
individual; IOL, intraocular lens; IOP, intraocular pressure; LE, left eye; NAD, no abnormalities detected; PC, posterior capsule; PL, perception of 
light; RE, right eye; yrs, years. 
 














Cornea AC Lens Fundus Ocular 
surgery 
58 (1V:1) 18 Birth Bilateral Stable HM 26 Cloudy, BK NA 
Cataract No view due to 
cataract & BK 
Nil 
58 (1V:3) 15 Birth Unilateral Progressing NPL Hypotony NA 
Shallow, 
phthisical 
Cataract No view Glaucoma 
surgery 













disc, retinal flat 
Cataract 
surgery 










Abbreviations: AC, anterior chamber; BCVA, best corrected visual acuity; BE, both eyes; BK, band keratopathy; CF, counting fingers; HM, hand 
movement; IOL, intraocular lens; IOP, intraocular pressure; NA, no information available; NPL, no perception of light; PI, peripheral iridotomy; 





Table 5.5 Ocular findings in affected individuals homozygous for LRP5 c.1076C>G; p.(Thr359Arg) 
 
Family (ID) Age examined 
(yrs) 
Age of onset  Progression Nystagmus VA Globe Cornea Iris adhesions Cataract 
59 (1V:2) 18 Early infancy Stable ✓ Blind Microphthalmia Central opacity ✓ ✓ 
59 (1V:5) 16 Early infancy Stable ✓ Blind Microphthalmia Central opacity ✓ ✓ 
59 (1V:7) 15 Early infancy Stable ✓ Blind Microphthalmia Central opacity ✓ ✓ 
59 (1V:9) 17 Early infancy Stable ✓ Blind Microphthalmia Central opacity ✓ ✓ 
59 (IV:13) 15 Early infancy Stable ✓ Blind Microphthalmia Central opacity ✓ ✓ 
 






Anophthalmia and microphthalmia are severe congenital developmental defects of the 
eye. In the clinical context, anophthalmia refers to a complete absence of the globe in 
the orbit, whilst microphthalmia refers to the presence of a small globe within the orbit. 
Both anophthalmia and microphthalmia are more commonly bilateral, although they 
can also present unilaterally. These are relatively rare defects, occurring with an 
estimated combined incidence of 1 in 10,000 live births (410). Anophthalmia and 
microphthalmia can occur as isolated malformations, or as part of a syndrome; both 
forms have been associated with autosomal recessive, autosomal dominant and X-
linked patterns of inheritance, and display extensive genetic heterogeneity (411). 
SOX2 variants are the major single-gene cause of anophthalmia and microphthalmia, 
accounting for ~10 - 15% of all cases (412). Variants in other genes have been shown 
to account for another ~25% of cases of anophthalmia and microphthalmia (413). In 
up to 50 - 60% of cases however, the underlying genetic cause remains undetermined 
(411, 414). 
 
Fares-Taie et al first provided evidence in 2013 for ALDH1A3 involvement in 
autosomal recessive anophthalmia and microphthalmia in humans (412). Since then, 
including the individuals reported in this study, ALDH1A3 variants have been identified 
as a cause of autosomal recessive anophthalmia and microphthalmia in 67 individuals 
from 28 families to date (Table 5.6). Among these, 56 individuals are from 19 
consanguineous families (412, 415-425) and even where consanguinity was not 
documented, most affected individuals were found to be homozygous for the disease-
causing ALDH1A3 variant, with only two reported individuals with anophthalma or 
microphthalmia associated with compound heterozygosity for pathogenic ALDH1A3 
variants (426, 427).  
 
ALDH1A3-associated anophthalmia and microphthalmia is frequently reported in 
association with other ocular and extraocular anomalies, such as the presence of short 
eyelids, blepharophimosis and reduced palpebral fissures (420, 421, 425, 426), 
entropion (425), conjunctival symblepharon (421), conjunctival discoloration (421), 
large eyebrows and synophrys (421, 423), coloboma (416, 417, 419, 421, 425), 
hypoplasia of the optic tracts and chiasm (412, 415, 421, 423, 425), hypoplastic extra 
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ocular muscles (415, 423), refractive errors including both myopia and hyperopia (416, 
417), and esotropia (416). There is a high variability observed in the phenotypic 
expression of dysmorphic or systemic features associated with anophthalmia and 
microphthalmia, even in individuals with the same ALDH1A3 gene variants (418, 423, 
424). Mild hypoplasia of the vermis (variant of Dandy-Walker malformation), as well 
as pulmonary stenosis and atrial septal defect, have previously been reported in 
association with ALDH1A3-associated anophthalmia and microphthalmia (412, 423). 
However, as these systemic findings have only been reported in a single individual 
each, it still remains unclear if these are associated or unrelated features of ALDH1A3 
variation. Occasionally, patients with ALDH1A3-associated anophthalmia and 
microphthalmia are also reported to have neurocognitive or behavioural features 
including intellectual disability, developmental delay and autism (412, 416, 417, 423). 
This association remains controversial due to the wide inter-familial variability in 
neurocognitive or behavioural outcomes (416, 417, 423), and the important 
confounding impact of visual impairment during development (428, 429). In addition, 
intellectual disability due to other genetic disorders may be more common in 
populations with high consanguinity (430). 
 
It has previously been suggested that the difference in phenotype between 
microphthalmia and anophthalmia may be the result of residual ALDH1A3 activity 
(421). However, a review of all known disease-causing mutations in ALDH1A3 (Figure 
5.6 and Table 5.6) does not seem to support this hypothesis, with no consistent 
correlation between a particular phenotype (anophthalmia or microphthalmia) and the 
nature of variation (missense, nonsense, frameshift or splice variants) or the protein 
domain affected (NAD-binding domain, catalytic domain or oligomerisation domain). 
This may partly be due to difficulties in distinguishing between anophthalmia from 
severe microphthalmia in routine clinical practice. True congenital anophthalmia can 
only be diagnosed radiologically or histologically, and most published cases of clinical 
anophthalmia probably include cases of severe microphthalmia, where residual ocular 
tissue may have been present in the orbit despite external appearances of an absent 
globe (410). Although systemic features have been reported in ALDH1A3-associated 
ocular disease, these are uncommon, and the associations are controversial, 
providing a relatively good prognosis for affected families when compared to other 




Figure 5.6 ALDH1A3 variants associated with anopthalmia and microphthalmia.  
(A) Schematic representation of ALDH1A3 NM_000693.3 transcript highlighting the position 
of all disease-causing variants associated with anophthalmia and microphthalmia identified to 
date.  
(B) Schematic showing domain architecture of ALDH1A3 [predicted domains described by 
Moretti et al (24)] and the locations of all disease-causing variants associated with 
anophthalmia and microphthalmia identified to date. OD, oligomerisation domain. 
Variants identified in this study are denoted by a red asterix (*).  
 
To date, there have only been six previously reported variants in TDRD7 associated 
with juvenile or congenital cataracts in homozygous form in six families (389, 431-
434), including a further frameshift deletion [c.1129delG; p.(Ala377Profs*2)] in one 
other consanguineous Pakistani family (389) (Table 5.7). The identification of a 
second TDRD7 variant in Pakistan as part of this study raises the possibility that 
TDRD7 variation is a potentially under-recognised cause of congenital cataracts in 
Pakistan. Additionally, there have been a small number of paediatric cataract cases 
associated with monoallelic TDRD7 variants (431, 435, 436), and there have also been 
reports of two families where homozygosity for TDRD7 variants in male individuals 
was associated with azoospermia in combination with congenital cataracts (434); the 
true causal relationship in these cases however still remains uncertain.  
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Although affected individuals in families 57 and 58 were initially diagnosed with 
congenital cataracts, genomic studies subsequently identified homozygous sequence 
variants in CYP1B1 and ATOH7 respectively as likely responsible for ocular disease 
in these families. Autosomal recessive mutations in CYP1B1 are the most common 
cause of primary congenital glaucoma, and the CYP1B1 c.1169G>A; p.(Arg390His) 
variant has been found to be particularly common in Pakistani, North Indian, Iranian 
and Chinese communities (392, 437-439), supporting a revised clinical diagnosis of 
primary congenital glaucoma in this family. The initial misdiagnosis of congenital 
cataracts could have been due to difficulties in differentiating between leukocoria 
caused by lenticular opacities, and corneal oedema and opacity resulting from raised 
intraocular pressures in primary congenital glaucoma. 
 
Disruption of ATOH7 function has been previously described to cause a spectrum of 
developmental eye disorders with overlapping phenotypes in only a small number of 
families (Table 5.8). Associated conditions include non-syndromic congenital retinal 
nonattachment (24, 440, 441), persistent hyperplasia of the primary vitreous (442), 
and FEVR (443), with common clinical features including poor vision from birth, 
nystagmus, microphthalmia, corneal opacities, cataracts, vitreous anomalies including 
persistent foetal vasculature or a retrolental fibrovascular mass, retinal vascular 
abnormalities and retinal detachment. ATOH7 variants have also been potentially 
implicated in optic nerve hypoplasia and aplasia (444, 445), although the true 
association remains unclear (442, 444, 446). Additionally, genome-wide association 
studies have implicated ATOH7 variants in association with adult-onset open-angle 
glaucoma (447, 448), and a heterozygous ATOH7 deletion has been associated with 
primary open angle glaucoma in a single individual (449); however the identification of 
two affected individuals (IV:1 and IV:4) in family 58 with features of congenital 
glaucoma (Table 5.2) represents the first time ATOH7 variants have been associated 
with this phenotype. This is of potential clinical relevance, as in contrast to the 
permanent visual field loss associated with glaucomatous optic neuropathy in adults 
with adult-onset glaucoma, optic neuropathy in infants and young children with 
congenital glaucoma is potentially reversible, especially in the early stages of the 
disease (450). Detailed clinical phenotyping in additional families will be helpful to 
clarify this potential genotype-phenotype correlation, and a prompt ophthalmic 
assessment in all individuals with ATOH7‐associated ocular disease may allow early 
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recognition and appropriate surgical management of congenital glaucoma if present, 
significantly improving a child’s visual prognosis. 
 
In family 59, identification of a homozygous LRP5 variant causing global ocular 
developmental defects has permitted a refined clinical diagnosis and improved 
understanding of disease in affected individuals who did not have a previous 
ophthalmic diagnosis. In addition to ocular findings, LRP5 variants are typically 
associated with reduced bone mineral density, osteopenia and osteoporosis (451, 
452), and appropriate clinical screening of affected individuals may enable early 
detection of skeletal co-morbidities and may prevent the development of secondary 
complications. 
 
Early onset nystagmus in an otherwise seemingly healthy child can be associated with 
a diverse range of ophthalmic conditions including achromatopsia, congenital 
stationary night blindness, inherited retinal dystrophies, aniridia and ocular albinism 
(144). In family 60, a novel FRMD7 variant was identified as likely responsible for X-
linked congenital idiopathic nystagmus in affected individuals. There are now over 90 
FRMD7 variants reported to cause congenital idiopathic nystagmus (453); this is 
however the first time FRMD7 has been identified as a cause of congenital idiopathic 
nystagmus in Pakistani communities. The FRMD7 molecular diagnosis in this family 
provided reassurance for the family regarding the good visual prognosis and non-
progressive nature of the condition, without the need for complex, invasive and 
expensive investigations to rule out an underlying ocular disease. In family 61, despite 
the consanguineous family structure, identification of a well reported PAX6 nonsense 
variant (6, 393-400) occurring de novo in the affected individual allowed accurate 
family counselling regarding recurrence risks. Additionally, this provided a molecular 
mechanism for the aniridia later identified on re-examination of the affected individual, 
and afforded reassurance by excluding a PAX6 deletion extending to the WT1 gene 
predisposing to Wilms tumour development (454). 
 
HPS is an autosomal recessive condition where defects in intracellular vesicle 
formation and trafficking result in OCA associated with a bleeding diathesis and ceroid-
lipofuscin lysosomal storage disease. This can result in life-threatening manifestations 
such as pulmonary fibrosis, granulomatous colitis, and immunodeficiency (405). 
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Awareness of this diagnosis and its associated systemic implications in families 62 - 
66 has enabled counselling about the risk of pulmonary fibrosis, and importance of 
smoking cessation and prompt treatment of respiratory infections to optimise 
pulmonary function. Clinicians caring for the family are also now aware of the risk of 
prolonged bleeding and increased need for platelet or red blood cell transfusions 
following surgical procedures. The five disease-causing HPS1 variants identified in 
this study also now doubles the number of HPS1 variants reported in Pakistani families 
(455). 
 
The families investigated in this study highlight the notable diagnostic difficulties 
encountered by clinicians in geographically isolated regions in Pakistan, who do not 
always have access to the specialised equipment for detailed ocular phenotyping 
necessary for an accurate ophthalmic diagnosis. Recognising these genes and 
variants as a cause of ocular disease within these communities will facilitate more 
accurate clinical diagnoses, early recognition and treatment for individuals with a 
similar clinical presentation in the region.
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Missense c.211G>A p.(Val71Met) Israeli 1 (9) Anophthalmia & 
microphthalmia 
Mory et al (415) Pathogenic 
(VCV000091908) 
 c.265C>T p.(Arg89Cys) Pakistani 1 (2) Anophthalmia & 
microphthalmia 
Fares-Taie et al (412) Pathogenic 
(VCV000040203) 
 c.287G>A p.(Arg96His) Chinese 1 (2) Anophthalmia Liu et al (426) Pathogenic 
(VCV000978214) 
 c.434C>T p.(Ala145Val) Saudi Arabian 1 (2) Microphthalmia Aldahmesh et al (416) Not present 
 c.521G>A p.(Cys174Tyr) Lebanese 1 (3) Anophthalmia & 
microphthalmia 
Roos et al (417) Not present 
 c.709G>A p.(Gly237Arg) Chinese & 
Iranian 
3 (5) Anophthalmia Liu et al (426); 
Dehghani et al (418) 
Pathogenic 
(VCV000978215) 
 c.845G>C p.(Gly282Ala) Arabic 1 (2) Microphthalmia Alabdullatif et al (419) Not present 
 c.874G>T p.(Asp292Tyr) Asian British - 
Bangladeshi 
1 (2) Anophthalmia Patel et al (427) Not present 
 c.964G>A p.(Val322Met) Indian 1 (1) Anophthalmia Ullah et al (420) Uncertain 
significance 
(VCV000653567) 
 c.1064C>G p.(Pro355Arg) Egyptian 1 (1) Anophthalmia Abouzeid et al (421) Not present 
 c.1105A>T p.(Ile369Pro) Saudi Arabian 1 (3) Microphthalmia Aldahmesh et al (416) Not present 
 c.1144G>A p.(Gly382Arg) Egyptian 1 (4) Anophthalmia Abouzeid et al (421) Not present 
 c.1231G>A p.(Glu411Lys) Swiss - Sri 
Lankan 
1 (1) Microphthalmia Abouzeid et al (421) Not present 
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 c.1240G>C p.(Gly414Arg) Pakistani 1 (5) Anophthalmia Lin et al (422) – this 
study 
Not present 
 c.1393A>T p.(Ile465Phe) Asian British - 
Bangladeshi 
1 (2) Anophthalmia Patel et al (427) Not present 
 c.1398C>A p.(Asn466Lys) Turkish 1 (2) Anophthalmia & 
microphthalmia 
Semerci et al (423) Not present 
 c.1477G>C p.(Ala493Pro) Turkish 1 (1) Anophthalmia & 
microphthalmia 
Fares-Taie et al (412) Pathogenic 
(VCV000040204) 
Nonsense c.568A>T p.(Lys190*) Egyptian 1 (2) Anophthalmia & 
microphthalmia 
Yahyavi et al (425) Not present 
 c.898G>T p.(Glu300*) Swiss - 
Spanish 
1 (1) Microphthalmia Abouzeid et al (421) Not present 
 c.1165A>T p.(Lys389*) Hispanic 1 (1) Anophthalmia & 
microphthalmia 
Yahyavi et al (425) Not present 
Splicing c.204+1G>A Alteration of WT 
donor site 
Egyptian 1 (2) Anophthalmia & 
microphthalmia 
Abouzeid et al (421) Not present 
 c.475+1G>T Skipping of exon 
5 
Moroccan 1 (1) Anophthalmia & 
microphthalmia 
Fares-Taie et al (412) Pathogenic 
(VCV000040205) 
 c.666G>A Skipping of exon 
6 
Turkish 1 (7) Anophthalmia & 
microphthalmia 
Semerci et al (423); 
Plaisancié et al (424) 
Not present 
 c.1391+1G>T Alteration of WT 
donor site 





Pakistani 1 (4) Anophthalmia Ullah et al (420) Not present 




Abbreviations: WT, wild type. Variants identified in this study are highlighted in yellow 
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Table 5.7 Summary of all reported TDRD7 variants associated with inherited ocular disease 








Associated phenotype Reference ClinVar 
(Accession) 
Missense Monoallelic c.83A>C p.(Gln28Pro) Han 
Chinese 
1 (1) Bilateral posterior polar 
cataract 
Li et al (435) Not present 
 Biallelic 
(hom) 
c.2539G>A p.(Asp847Asn) Saudi 
Arabian 






c.689dupA p.(Tyr230*) Chinese 1 (2) AR congenital cataracts + 
azoospermia in males 




 Monoallelic   Chinese 1 (1) Cataract 
(Also CRYBA2 variant het 
carrier) 











c.2469delG p.(Asn824Thrfs*27) Pakistani 1 (2) AR congenital cataracts This study Not present 
 Biallelic 
(hom) 
c.328dupA p.(Thr110Asnfs*30) Chinese 1 (3) AR congenital cataracts + 
azoospermia in males 













  NA 1 (1) NA Maddirevula 
et al (433) 
 




Monoallelic 46,X,Y,inv(9)(q22.33q34.11) NA 1 (1) Juvenile cataract and 
hypospadias  
(NR5A1 disruption thought 
responsible for hypospadias) 








Table 5.8 Summary of all reported biallelic ATOH7 variants associated with inherited developmental ocular disease 
Type of variant Nucleotide 
variant 




Associated phenotype Reference ClinVar 
(Accession) 
Missense c.125G>C p.(Arg42Pro) Pakistani 1  Non-syndromic congenital retinal 
nonattachment 
Keser et al (440) Not present 
 c.136A>C p.(Asn46His) Pakistani 1 (3) Persistent hyperplasia of the 
primary vitreous 
Prasov et al (442) Pathogenic 
(VCV000144067) 
 c.146A>T p.(Glu49Val) Pakistani 1 (5) Ocular developmental defect: 
features include nystagmus, 
reduced vision, dense corneal 
opacity, microphthalmia, 
microcornea, retrolental mass 
Khan et al (443) Pathogenic 
(VCV000144065) 
 c.175G>A p.(Ala59Thr) Swiss 1 (2) Optic nerve hypoplasia, foveal 
hypoplasia and vascular 
abnormalities 
Atac et al (444) Pathogenic 
(VCV000812672) 
 c.176C>T p.(Ala59Val) Swiss 1 (2) Optic nerve hypoplasia, foveal 
hypoplasia and vascular 
abnormalities 
Atac et al (444) Uncertain 
significance 
(VCV000812673) 
Frameshift c.53delC p.(Pro18Argfs*69) Turkey 1 (2) Familial exudative 
vitreoretinopathy 
Khan et al (443) Pathogenic 
(VCV000144066) 
 c.94delG p.(Ala32Profs*55) Pakistani 1 (5) Global ocular developmental 
defect: features include cataracts, 
congenital glaucoma, retinal 
detachment 
This study Not present 
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Inframe deletion c.121_144del24 p.(Arg41_Arg48del) Japanese 1(1) Non-syndromic congenital retinal 
nonattachment 










Kurdish 1 (4) Non-syndromic congenital retinal 
nonattachment 




   Pakistani 2 (2) Non-syndromic congenital retinal 
nonattachment 
Keser et al (440)  
 
Abbreviations: hom, homozygous. Variant identified in this study is highlighted in yellow 
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5.4 Conclusions and future work 
 
Studies of families with inherited ocular diseases in Pakistani and Palestinian 
communities have helped clarify the phenotypic characterisation and genetic 
associations of rare and ultra-rare inherited eye diseases, and provide much-
needed scientific insight into the spectrum, nature and causes of ocular disease 
within these communities and globally. 
 
Mitochondrial complex II deficiency is a rare inborn error of metabolism, 
accounting for approximately 2% of mitochondrial disease diagnoses. Only 61 
patients have been described to date, associated with pathogenic variants in 
four complex II genes (SDHA, SDHB, SDHD and SDHAF1); of these, only two 
affected individuals have been reported with candidate biallelic variants in the 
SDHD gene (456). The three additional affected individuals described in this 
study further consolidate recessive SDHD variants as contributing to 
mitochondrial complex II deficiency. There is unfortunately no cure for complex 
II deficiency, although some therapeutic interventions may be associated with 
symptomatic improvements in these patients, including riboflavin, l-carnitine 
and ubiquinone (456). Further studies integrating detailed clinical phenotyping 
and metabolic investigations, molecular genomic analyses combined with in 
silico pathogenicity prediction and structural modelling, histological and 
histochemical studies of muscle biopsy specimens, spectrophotometric 
assays of OXPHOS respiratory chain function, BN-PAGE and SDS-PAGE 
followed by Western blot analysis to study physiological mitochondrial complex 
protein-protein interactions, and complementation studies in patient and yeast 
cells will be useful in developing a better understanding of the molecular basis 
of these conditions, which may lead to the development of more effective 
therapies. 
 
TDRD7 (389, 431-434) and ATOH7 (24, 440-443) are uncommon causes of 
developmental eye disorders. ATOH7 dysfunction is associated with a wide 
spectrum of developmental ocular phenotypes including non-syndromic 
congenital retinal nonattachment (24, 440, 441), persistent hyperplasia of the 
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primary vitreous (442), and FEVR (443), and potentially implicated in optic 
nerve hypoplasia and aplasia (444, 445). ATOH7 is known to function as an 
early retinal transcription factor crucial for RGC development and specification 
(441), and further functional characterisation in animal models or iPSC-derived 
retinal organoids may be useful in assessing the impact of pathogenic ATOH7 
variants on RGC morphology, and delineate the mechanisms by which ATOH7 
dysfunction leads to the diverse developmental ocular phenotypes described.  
 
TDRD7 is a component of ribonucleoprotein complexes and RNA granules in 
differentiating lens cells, suggesting that post-transcriptional regulation of gene 
expression plays an important role in lens homeostasis (431). TDRD gene 
polymorphisms have potentially been associated with susceptibility to age-
related cataracts (457), and there is also increasing evidence for additional 
genes implicated in the development of both congenital and adult-onset 
cataracts, such as LIM2, EPHA2, and CRYAA (458, 459). Understanding the 
genetic basis and molecular pathogenesis of congenital cataracts may lead to 
the development of strategies that prevent or delay the development of age-
related cataracts, hence reducing the enormous global burden for cataract 
surgery. Studies of RNA and protein-binding targets of TDRD7, coupled with 
bioinformatics strategies, have identified several potential interacting partners 
of TDRD7, including HSPB1, NRAS and ACTN2 (460-462). Further 
investigation into these molecular pathways, including subcellular localisation 
studies in lens fiber and epithelial cells, characterising gene expression in the 
lens during development, and studying ocular and lens development in 
xenopus, zebrafish or mouse gene-perturbation models (463-465), may yield 
new insights into cataractogenesis. 
 
There is a wide phenotypic variation in ALDH1A3-associated ocular disease. 
Individuals with the same ALDH1A3 variant can display both anophthalmia and 
microphthalmia in different eyes (419, 421, 425), and affected individuals with 
the same variant within the same family have been found to have clinical 
phenotypes of differing severity (417, 421, 423-425). Epidemiological studies 
have predicted the contribution of both genetic and environmental factors in the 
pathogenesis of congenital eye defects including anophthalmia and 
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microphthalmia (466), and the wide phenotypic spectrum seen may result from 
the impact of modifying genes or environmental influences affecting the 
ALDH1A3-associated eye disease phenotype. Further studies including DNA-
methylation studies in animal models investigating epigenomic influences, 
transcriptomic analyses in patients linking altered gene expression to 
differential phenotypic outcomes, and co-immunoprecipitation and pull-down 
assays to investigate ALDH1A3 protein interactions, would be useful to define 
this interaction and elucidate underlying pathways. Given that ALDH1A3 gene 
mutations appear to be the most common cause of anophthalmia and 
microphthalmia in consanguineous families (412, 415-425), screening for 
variants in this gene before exome analysis in populations with high rates of 







6 CONCLUDING COMMENTS 
 
This thesis documents the results of clinical and genetic analyses in a total of 
66 Amish, Pakistani and Palestinian families, with a range of genetically 
undiagnosed syndromic and non-syndromic inherited ocular diseases. The 
work described in this thesis entails the identification of 18 novel pathogenic 
variants in 10 genes associated with a variety of inherited ocular disorders, 
including OCA (TYR, OCA2, HPS1), congenital nystagmus (FRMD7), ocular 
developmental disorders (ALDH1A3, TDRD7, ATOH7 and LRP5) and 
ciliopathies (BBS5, SCAPER). This knowledge significantly expands on the 
molecular spectrum of inherited eye diseases in communities and globally. In 
many families investigated, the molecular diagnosis enabled a subsequent 
confirmation or refinement of the initial clinical diagnosis, as detailed in chapter 
5.3, with important treatment and prognostic implications for affected individuals 
and their families.  
 
In the Amish, Pakistani and Palestinian communities, geographical isolation, 
common ancestry and endogamy, combined with the often large family sizes 
typical of families in these regions, often results in an enrichment of disease-
causing founder variants. These often represent important causes of disease 
in a particular region, and identification of the INPP5E c.1879C>T; p.(Gln627*) 
founder variant associated with MORM syndrome in the Punjab region in 
Pakistan (described in chapter 4.2), as well as the SCAPER c.2236dupA, 
p.(Ile746Asnfs*6) founder variant in the Ohio Amish community (described in 
chapter 4.4), allows targeted genetic testing for these variants, permitting a 
more rapid and cost-effective means of achieving a molecular diagnosis, 
shortening the diagnostic odyssey for affected individuals within the community.  
 
There is a relative lack of knowledge regarding the specific nature and causes 
of inherited ocular diseases particularly in developing nations such as Pakistan. 
Literature reviews were conducted, compiling the most comprehensive and 
curated reports of genes and variants associated with BBS and OCA in 
Pakistan to date (presented in Appendices B and C respectively). This work 
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highlights the OCA2 c.1045-15T>G and p.(Asp486Tyr) founder variants, as well 
as the TYR p.(Arg278*) recurrent variant as contributing significantly to OCA in 
Pakistan. These reviews will enhance knowledge of the genomic architecture 
pertaining to these inherited eye diseases in Pakistan, and facilitate the 
development of community-relevant disease databases correlating allele 
frequencies with geographical localisation and ethnicity. This is of enormous 
value for local healthcare resource planning, enabling the design of community-
specific hierarchical strategies for rapid and cost-effective genetic testing arrays 
to enable an accurate disease diagnosis to be achieved more rapidly, thus 
aiding the development of diagnostic and clinical care pathways and policies 
throughout Pakistan. 
 
This thesis also details comprehensive clinical and genetic studies of a number 
of rare inherited ocular disorders, described in only small numbers of affected 
individuals to date. This includes MORM syndrome and SCAPER syndrome 
(described in chapters 4.2 and 4.4), mitochondrial complex II deficiency 
associated with biallelic SDHD variation (chapter 5.2), TDRD7-associated 
congenital cataracts (chapter 5.3), and developmental eye defects associated 
with ALDH1A3 and ATOH7 (chapter 5.3). The deep phenotypic characterisation 
performed in these study families allowed a more comprehensive clinical 
comparison to be made with the previously reported cases, expanding on the 
disease-associated clinical spectrum, delineating the core and variable 
phenotypic features, and clarifying the presence (or indeed absence) of any 
genotype-phenotype correlation associated with variants in these genes. 
 
The work of this thesis also provides novel insights into known inherited eye 
disease genes. The role of two common TYR variants p.(Ser192Tyr) and 
p.(Arg402Gln) in OCA, previously considered to represent non-pathogenic 
polymorphic alleles although subsequently contested, has been debated over 
the last 10 years. Chapter 3.2 now provides strong evidence that the TYR 
p.(Ser192Tyr)/p.(Arg402Gln) in cis haplotype may cause disease both when 
occurring in compound heterozygous fashion with a second deleterious allele, 
or in doubly homozygous state. The increased frequency of the BBS1 
p.(Met390Arg) variant in the Pennsylvania Amish community will similarly 
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permit empowered genetic and co-segregation studies able to determine 
phenotypic penetrance of this hypomorphic variant, which has important 
diagnostic implications given that this common founder variant is responsible 
for ~80% of BBS1 cases in European populations (297). Alongside detailed 
phenotypic assessments, this will allow clarity into the potential contribution of 
any additional BBS modifier variants, and may provide evidence supporting or 
disputing the controversial triallelic hypothesis in BBS. To this end, recruitment 
of additional family members in the extended Amish family with BBS studied in 
chapter 4.3 is ongoing, and detailed phenotype information is being obtained in 
collaboration with local ophthalmologists and clinicians. 
 
Within this thesis, several sequencing techniques were employed, often in a 
hierarchical fashion, in the genomic investigation of families with inherited eye 
diseases. For instance, albinism families often first underwent TYR gene 
screening, followed by Illumina TruSightTM One clinical exome sequencing, in 
order to detect causative variants in known albinism genes, whilst 
consanguineous families with complex ocular phenotypes were instead 
investigated with genome-wide SNP genotyping and WES in the first instance, 
which would facilitate the detection of rare or even novel disease genes 
involved in hereditary eye diseases. Each genomic technique has recognised 
limitations and advantages, balancing a more comprehensive analysis against 
the difficulties in interpreting large numbers of variants; and the tailored 
approach adopted in this study enabled a pragmatic, efficient and cost-effective 
means of achieving a molecular diagnosis in many affected families, reflecting 
the likely real-word application of genomic technologies in these resource-
scarce communities. 
 
Studies in this thesis have contributed to a recent development of a new 
microarray platform diagnostic testing panel, led by the WoH project and now 
available in the Wisconsin Clinical Laboratory Improvement Amendments 
(CLIA) - certified regional testing laboratory. This flexible platform offers a rapid 
and cost-effective means of targeting the specific gene mutations of >150 
genetic disorders identified across the Amish communities, and can be readily 
expanded to incorporate new disease-associated variants as they are identified 
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within the community. Testing via the platform is offered at cost to the Amish 
community, and has particular utility as part of a molecular-based newborn 
screening program, allowing affected individuals and families to benefit from 
early diagnosis and intervention. One particular benefit will be in the early 
diagnosis of propionic acidemia, an inborn error of metabolism occurring at an 
increased frequency in the Amish-Mennonite communities due to a founder 
missense variant in PCCB [c.1606A>G; p.(Asn536Asp)] (467). This is a 
condition where early diagnosis and intervention is shown to improve long-term 
neurological outcomes (468), however, cases may be missed using standard 
newborn screening metabolic assays. This genetic testing platform may also be 
of use as a carrier screening assay as the communities grow more receptive 
towards this, permitting anticipatory health care to prevent or mitigate the 
devastating effects of genetic diseases that may occur in the newborn. 
 
In recent years, advances in NGS technologies and bioinformatics processing 
algorithms, tools, and pipelines, have led to improvements in the diagnosis of 
Mendelian disorders. Despite this, overall diagnostic rates for exome 
sequencing, the primary genomic technique employed in this study, is limited 
to ~25 - 50% (433). Some of these molecularly undiagnosed individuals may 
harbour variants in genes yet to be associated with human disease. Studies of 
inherited eye diseases in genetically isolated populations such as the Amish 
communities of the USA, or rural Pakistani and Palestinian communities, where 
the unique genomic architecture of these communities enables the application 
of empowered genomic approaches for disease gene identification (60, 469, 
470), together with genomic matchmaking initiatives (471), will facilitate the 
identification of novel gene-disease associations, whilst also providing 
desperately required healthcare benefits for the families and populations 
involved. 
 
The relatively low diagnostic rate of exome sequencing may also reflect the 
restricted focus, limited to coding sequences and intronic sequences flanking 
the exon-intron boundaries, representing only ~1.5% of the human genome. 
The application of whole genome sequencing approaches, which enable the 
detection of structural variants, deep intronic and regulatory variants in non-
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coding regions, may lead to further improvements in diagnostic yield, and is an 
option being considered for any remaining molecularly undiagnosed individuals 
recruited through the established collaborative research consortium involving 
the community genomics research group at the University of Exeter, and 
collaborating scientists and clinicians within the Amish communities and at 
research centres in Pakistan and Palestine. 
 
Interestingly, it has been suggested that genome sequencing only offers a 
minimal uplift in diagnostic yield compared to exome sequencing, and that the 
primary limitation to molecular diagnostic rates may relate not to the capture or 
calling of causal variants at the sequencing stage, but rather in the interpretation 
of the genomic variants identified (433). Current strategies for variant 
interpretation include family segregation, computational variant effect 
prediction, and functional assays (472), and are fairly reliable when applied to 
protein-coding regions of the genome, although predicting the pathogenicity of 
missense variants can be challenging (473), as demonstrated by the uncertain 
significance of the novel OCA2 p.(Arg588Trp) variant identified in family 38 
(chapter 3.3). Other sequence variants, such as deep intronic, enhancer or 
promoter region variants, as well as coding sequence variants with splice-
disrupting potential, remain difficult to interpret, despite their clear contribution 
to Mendelian disease. Whole transcriptome sequencing approaches (RNA-seq) 
allowing quantification of gene expression levels and detection of alternative 
splicing (474), as well as multiplexed functional assays for variant effect (475), 
show promising potential in empowering variant interpretation and resolving the 
variants of uncertain significance “trapped in the interpretative void between 
benign and pathogenic” (476). These approaches are currently largely 
restricted to research environments, but their validation and integration into 
mainstream clinical practice may bring about transformative benefits in rare 
disease diagnostics.  
 
Together, the work presented in this thesis provides an improved knowledge of 
the clinical and molecular spectrum of hereditary eye diseases in the Amish, 
Pakistan and Palestinian communities. These findings enabled targeted 
changes in clinical management and accurate prognostic information to be 
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provided to affected individuals and families, with communities benefitting from 
targeted genetic testing strategies that permit cost-effective disease diagnosis 
and improved carrier detection. This new knowledge may also enable 
experimental approaches for restoration of protein function through gene 
therapy, such as Luxturna® (voretigene neparvovec), the first ever licensed 
gene replacement therapy for the treatment of a genetic disease in humans, 
approved for the treatment of patients with RPE65-associated retinal dystrophy 
(12). In this way, an improved understanding of disease pathways arising from 
the discovery of novel disease genes identified in a community setting may thus 
ultimately also be applied to genetically diverse populations such as the UK and 
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APPENDIX A: NGS AND AUTOZYGOSITY MAPPING 
A.1 NGS 
 
The traditional approach to disease gene identification in Mendelian diseases involved 
dideoxy sequencing of candidate genes selected based on their predicted relevance 
to disease pathophysiology, their location within a disease locus identified through 
positional mapping, or a combination of both. This approach however is reliant on prior 
knowledge of the predicted protein structure or function and molecular pathway of 
disease.  
 
The advent, widespread availability and decreasing costs of high throughput NGS 
technologies now provide an efficient and cost-effective approach for the unbiased 
interrogation of an individual’s genome. This includes exome sequencing, which 
investigates the protein-coding regions (exons and splice sites) of the genome, where 
approximately 85% of Mendelian disease-causing variants are found (477), as well as 
genome sequencing, which will also allow the detection of variants in non-coding and 
regulatory genomic regions. 
 
NGS approaches have dramatically accelerated the discovery of novel disease genes 
for rare Mendelian disorders (478) and have a transformative potential in disease 
diagnosis and personalised medicine, with genomic medicine initiatives currently 
being integrated into healthcare systems across the world (86). NGS approaches 
however often result in large numbers of genomic variants identified [over 20,000 
variants in each exome (479) and several million in each genome (480)], and the 
challenge therefore now shifts from disease gene identification to variant 
interpretation. This has been aided by the development of population variant 
databases such as the gnomAD (481), disease variant databases such as ClinVar 
(482) and HGMD (483), and in silico variant pathogenicity prediction tools such as 
SIFT (484), Polyphen-2 (485) and MaxEntScan (486).  
 
There is however still a need for robust and efficient variant prioritisation strategies to 
identify the pathogenic variant and prove disease causality. One such strategy 
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combines a gene sequencing method such as exome or genome sequencing with a 
genome scanning method such as autozygosity mapping, allowing the rapid 
identification of potential disease-causing sequence alterations within a disease locus 
that can be prioritised for further investigation (44).  
 
A.2 Autozygosity mapping 
 
Autozygosity mapping is a powerful technique used to identify candidate loci for 
autosomal recessive disease genes in populations where there is a significant founder 
effect due to unions between closely related (consanguineous) or more distantly 
related individuals (such as endogamous populations with a high frequency of inter-
community marriage). This approach relies on the principle that affected individuals in 
these populations will be homozygous for the same disease variant within a genomic 
segment or haplotype inherited from a common ancestor, referred to as autozygosity 
or ‘identity by descent’ (487). The genome is scanned to identify or ‘map’ the 
autozygous regions shared exclusively and consistently by affected individuals, 
signposting the location where the pathogenic variant is likely to be discovered (Figure 
A1).  
 
Figure A1 Principles of autozygosity mapping 
Red boxes across chromosomes indicate regions of homozygosity in affected individual, with 
the common autozygous region shared across all affected individuals indicating the most 
probable location of the disease-causing gene. Image created with BioRender. 
 
Historically, autozygosity mapping was dependent on the analysis of microsatellite 
markers, however, this has largely been superseded by SNP genotyping panels and 
microarray technology. SNPs, being diallelic, are less informative than the highly 
polymorphic microsatellites, but are dispersed more equally throughout the genome 
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at a higher density, allowing the detection of smaller autozygous regions (488). 
Additionally, SNP genotyping platforms are easily automated, permitting higher 
throughput and lower costs, and can also be used to detect CNV (489). 
 
There are important pitfalls to be aware of in the interpretation of autozygosity mapping 
results, particularly in the study of rare diseases in community settings. Successful 
identification of disease loci using this technique relies on correct ascertainment of 
affectation status in family members for accurate inheritance models and interpretation 
of results. In ophthalmology, this often relies on specialist equipment and expertise 
that is usually based in the larger teaching hospitals, whilst affected families in 
communities often reside in more rural and geographically isolated locations with 
limited accessibility. Additionally, given the enrichment of disease-causing mutations 
within communities due to a founder effect, a situation may arise where a disease may 
be caused by compound heterozygous mutations (490, 491), or two phenotypically 
similar conditions may segregate independently in a single family (especially taking 
into account the clinical and genetic heterogeneity inherent in many inherited eye 
diseases) (331, 491, 492), further complicating the interpretation of results generated 
using autozygosity mapping techniques. Despite these considerations, the combined 
approach of autozygosity mapping with NGS can helpful in clarifying molecular 
diagnoses in conditions that are diagnostically challenging due to genetic and 
phenotypic heterogeneity, such as inherited retinal dystrophies (493, 494). 
 
With the increasingly widespread use of exome and more recently genome 
sequencing in both diagnostic and research environments, the large volume of 
sequence data information generated by these NGS technologies raises the possibility 
of analysing the exome or genome sequence data itself to simultaneously map 
autozygous regions (without the need for the genome-wide SNP-genotyping 
microarrays that were previously used for this purpose) and concurrently identify all 
potentially deleterious sequence variants within these candidate disease loci. This 
one-step experimental approach is attractive in principle, and several bioinformatic 
tools have been developed for this purpose (495-497). However, these analyses do 
have their limitations; with exome data, the coverage can be poor with numerous gaps 
due to the uneven distribution of coding regions across the genome, and there is the 
potential for shorter autozygous regions located within gene-poor regions to be missed 
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(495), whilst the lower read depth of genome sequencing can result in erroneous SNP 
calls due to errors in sequencing or chance sampling of only one allele at a genuinely 
heterozygous position (498). With an awareness of these limitations however, 
adopting a cautious approach to analysis with a greater level of thought and subjective 
data interpretation, the use of exome or genome data for detecting regions of 
autozygosity can still be an effective adjunct in the detection of novel disease genes, 
and for rapid screening for deleterious variants in known disease genes. 
 
A.3 Advances in sequencing technologies  
 
Whilst NGS technologies have facilitated significant advances in medical research, 
they are not without their limitations. NGS methods are reliant on PCR, which is 
inefficient in amplifying genomic regions with a high GC content (499). NGS platforms 
are also dependent on clonal amplification to create clusters of molecules, with the 
potential for base incorporation errors in individual molecules within a cluster, thereby 
increasing the noise within samples, and limiting the reads to short lengths of 50-500 
bp (500). Numerous short reads require extensive assembly, and genomes often 
contain repeat sequences that are longer than the NGS reads, resulting in 
complexities in alignment that can lead to mis-assemblies and gaps (501). Some areas 
of the genome, such as areas of repetitive DNA, high sequence homology, or even 
extreme GC content, are therefore still difficult to analyse with current NGS platforms 
(500). 
 
There are further limitations to the use of NGS technologies for variant analysis in rare 
diseases. Whilst short reads allow accurate detection of smaller variants such as 
single-nucleotide variations and short indels, the detection and characterisation of 
larger structural variants is challenging, and there is limited capacity to link 
independent variants on the same gene for phasing of alleles and discrimination of 
parental origin, which is important in situations where compound heterozygosity is 
identified (233). 
 
The advent of third-generation sequencing, also known as long-read sequencing, may 
provide a solution to the aforementioned issues. Third-generation sequencing 
platforms work by single-molecule sequencing in real time with no amplification, 
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directly providing long linear read lengths (1 – 100 kb) and fast sequencing times (2-
10 hours) (500). Two commercially available third-generation sequencing 
technologies include the single-molecule real-time (SMRT) sequencing by Pacific 
Biosciences (PacBio) and nanopore sequencing by Oxford Nanopore Technologies 
(ONT). PacBio utilises a sequencing-by-synthesis approach, with real-time acquisition 
of signals from fluorescently-labelled nucleotides as they are being incorporated into 
single DNA molecules (502). Nanopore sequencing instead identifies nucleotides by 
measuring their electrical conductivity as they pass through the nanopore membrane 
(503). Both techniques have drawbacks compared to standard NGS platforms, 
including higher sequencing error rates, lower throughput and higher costs (504), and 
developments to address these will be needed before these third-generation 
sequencing technologies can be widely adopted in clinical diagnostic and research 
settings. 
 
There is also a need for additional biological knowledge that can highlight the 
molecular signature of the disease. This can aid in the identification of candidate 
disease genes and variants, particularly for non-coding and regulatory variants, and 
enable a better understanding of their disease mechanism. One potential route is 
through functional genomic assays via broad-based ‘omics’ approaches, which study 
the impact on different cellular products including gene transcripts (transcriptomics), 
proteins (proteomics) or metabolites (metabolomics), in affected individuals compared 
to unaffected controls, allowing the identification of aberrant cellular products or 
activities. One such technique is RNA-sequencing (RNA-seq), which measures 
transcript levels and diversity in individual tissue types (505), and can be used to 
highlight the consequences of both coding and non-coding variants on gene 
expression levels or alternative splicing. Recent applications of this technique have 
aided in the diagnosis of several rare diseases, with particular success for conditions 
with a neuromuscular or mitochondrial phenotype (506, 507). 
 
Recent advances in sequencing technologies and bioinformatics have greatly 
improved our diagnosis and understanding of rare Mendelian disorders. Future efforts 
are likely to focus on combining the current and developing technologies into a single 
streamlined workflow for disease variant identification, prioritisation and 
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characterisation, which will hopefully improve the diagnostic yield in monogenic 
disorders and shed further light on the complexities of oligogenic diseases. 
 
A.4 Glossary of terms 
 
ClinVar: This is a freely accessible public database that archives and aggregates 
reports with supporting evidence about relationships between human variation, 
phenotypes and clinical significance (482). 
 
Genome Aggregation Database (gnomAD): This database was developed by an 
international coalition of investigators, and aggregates and harmonises both exome 
and genome sequencing data from a wide variety of large-scale sequencing projects 
(481). The v2.1.1 dataset (GRCh37) contains 125,748 exome sequences and 15,708 
whole-genome sequences from unrelated individuals sequenced as part of various 
disease-specific and population genetic studies. The v3.1.1 dataset (GRCh38) spans 
76,156 genomes as selected in v2. 
 
Human Gene Mutation Database (HGMD): This is a database collating germ-line 
variants in nuclear genes reported in the literature in association with human inherited 
diseases, and includes both disease-causing variants as well as functional 
polymorphisms (483). 
 
Minor allele frequency (MAF): the frequency of the alternative allele(s) in a given 
population. 
 
Mapping quality (MQ): This is the root mean square of the mapping quality of reads 
across all reads at the site, and provides an estimation of the overall mapping quality 
of reads supporting a variant call. 
 
MaxEntScan: This in silico algorithm is based on the ‘maximum entropy principle’ 
(486). The splice signal given by a wild-type sequence is compared to the splice site 
signal given by a mutated sequence, and a change in splice site signal of ≥10% is 




Polymorphism Phenotyping v2 (Polyphen-2): This in silico algorithm applies to non-
synonymous variants, and predicts the functional significance of an amino acid 
substitution using sequence-based and structure-based predictive features (485). 
Scores range from 0.0 (tolerated) to 1.0 (deleterious). 
 
Protein Variation Effect Analyser (PROVEAN): This in silico algorithm applies to non-
synonymous and indel variants, and predicts whether an amino acid substitution or 
indel has an impact on the biological function of a protein based on the degree of 
conservation of amino acid residues in sequence alignments derived from closely-
related sequences (508). If the generated score is ≤ -2.5, the protein variant is 
predicted to have a deleterious effect; if the score is above the threshold, the variant 
is predicted to have a neutral effect. 
 
Read depth (DP): This is the number of reads that have passed the variant caller’s 
internal quality control metrics. 
 
Sorting Intolerant From Tolerant (SIFT): This in silico algorithm applies to non-
synonymous variants, and predicts whether an amino acid substitution affects protein 
function based on sequence homology and the physical properties of amino acids 
(484). Scores range from 0.0 (deleterious) to 1.0 (tolerated). 
 
SpliceSiteFinder-like (SSF): This prediction program uses an algorithm based on 
Shapiro and Senapathy et al (509) using position weight matrices computed from a 
set of human constitutive exon/intron junctions for donor and acceptor sites. The splice 
signal given by the wild-type sequence is compared to the splice site signal given by 
the mutated sequence. A change in splice site signal of ≥10% is considered to predict 
a pathogenic effect. 
 
Splice Site Prediction by Neural Network (NNSplice): This prediction algorithm is 
based on neural networks, and analyses the structure of donor and acceptor sites 





APPENDIX B: A NOVEL BBS5 VARIANT ASSOCIATED WITH 
BBS IN A PAKISTANI FAMILY  
 
Clinical and genomic investigations were undertaken in a Pakistani family (family 42) 
where affected individuals displayed phenotypic features that were highly suggestive 
of BBS, in order to aid diagnosis and clinical management. 
 
B.1 Materials and methods 
 
 
Family recruitment, clinical assessment, blood sample collection and DNA extraction 
was performed as previously described (see section 4.2.2). WES was undertaken 
using DNA from a single affected individual in family 42 (individual IV:1) at BGI Hong 
Kong, as described in section 2.3.5. Bioinformatic analysis with additional virtual gene 
panel analysis and filtering to retain heterozygous variants compatible with triallelism 
was performed as described in section 4.2.2. Primer design, PCR and dideoxy 
sequencing (Appendix Table D2) was also performed as previously described in 
section 2.3.3 to genotype and confirm appropriate segregation of the candidate 
disease variant in all available affected and unaffected individuals. 
 
A literature review was performed as described in section 2.4 to retrieve all BBS-
associated variants reported in Pakistani families. Findings are summarised in Table 
B2 and Figure B2. 
 
B.2 Results: clinical and genetic findings 
 
A multigenerational family (family 42) with two affected individuals (IV:1 and IV:4) 
residing in a remote village in the KPK province of Pakistan was investigated. Both 
affected individuals were described to have moderate developmental delay/intellectual 
disability, visual impairment, truncal obesity, postaxial polydactyly, and renal 
anomalies. A single affected male was also reported to have hypogonadism (individual 




Table B1 Summary of clinical features observed in affected individuals in family 
42 with BBS and homozygous for the BBS5 c.196delA variant 
 
 
Abbreviations: F, female; M, male; yrs, years; (S), severe/profound; (M), mild/moderate. The 




After filtering of variants for zygosity, call quality, population frequency and predicted 
outcome in WES data in a single affected individual (IV:1), only a single plausible 
candidate disease variant of potential relevance to the phenotype was identified, a 
homozygous novel BBS5 frameshift variant (GRCh38) chr2:g.169487122delA; 
NM_152384.2:c.196delA; p.(Arg66Glufs*12). This variant was absent in gnomAD 
(v2.1.1 and v3.1.1) and from a control exome dataset of 100 ethnically matched 
controls undertaken in the Human Molecular Genetics laboratory in Pakistan. This 
variant segregated appropriately for an autosomal recessive condition in the family 
(Figure B1). 
 
Additional analysis of exome data undertaken using the “rare multisystem ciliopathy 
disorders v1.84” PanelApp virtual gene panel did not identify any homozygous or 
compound heterozygous candidate variants compatible with the phenotype. No 





Figure B1 Family 42 pedigree showing BBS5 c.196delA genotype data 
(A) Pedigree diagram of family 42 showing segregation of the BBS5 c.196delA; 
p.(Arg66Glufs*12) variant, co-segregating appropriately for an autosomal recessive 
condition.. Genotypes are shown beneath generations III and IV (+, c.196delA; -, wild type).  
(B) Sequence chromatogram of BBS5 c.196delA in a homozygous affected individual. 
(C) Schematic showing domain architecture of BBS5 [adapted from Nachury et al (287) and 
the location of the c.196delA; p.(Arg66Glufs*12) variant. This variant is located within the first 




BBS5, located on chromosome 2q31.1, encodes the BBS5 protein, one of eight 
proteins that form the stable core of the BBSome protein complex. BBS5 is structurally 
and functionally unique among the BBSome components in that it has two Pleckstrin 
Homology-like (PH-like) domains that are capable of binding to phosphoinositides 
(Figure B1), with this interaction predicted to play a critical role in ciliogenesis (287). 
Bbs5 knockout or mutant mice develop a complex phenotype consisting of increased 
pre-weaning lethality, craniofacial and skeletal defects, ventriculomegaly, pituitary 
anomalies, obesity, retinal degeneration and male infertility; recapitulating features 
previous described in ciliopathy syndromes (511, 512).  
 
Here, WES analysis identified a novel homozygous variant in BBS5, confirming a 
diagnosis of BBS as likely underlying the clinical features in the affected family (family 
42) investigated. This BBS5 c.196delA variant is predicted to result in a frameshift 
[p.(Arg66fsGlufs*12)] and nonsense‐mediated mRNA decay. The two affected 
individuals demonstrate classical features of BBS, including postaxial polydactyly, 
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learning difficulties, retinitis pigmentosa, and truncal obesity (284). Intra-familial 
phenotypic variability was noted, with individual IV:1 displaying more significant visual 
impairment and intellectual disability compared to his affected sister. Bilateral 
postaxial polydactyly of the lower limbs and clinodactyly of the hands was identified 
on examination in individual IV:1, whereas his sister IV:4 had bilateral postaxial 
polydactyly in both upper and lower limbs and short toes. This intra-familial phenotypic 
variability is well described in BBS, and “triallelism” has been proposed as a possible 
mechanism for this, where affected individuals carry homozygous or compound 
heterozygous variants at one BBS locus with a third heterozygous variant in a second 
BBS gene that interacts to cause or modify the disease phenotype (254). However, 
virtual gene panel analysis of BBS genes undertaken in the present study did not 
identify any candidate variants that could plausibly be compatible with triallelism.  
In populations of Northern European descent, BBS1 and BBS10 are the most 
commonly mutated genes, responsible for approximately 23% and 20% of BBS cases 
respectively (300, 513), with the BBS1 p.(Met390Arg) (297) and BBS10 
p.(Cys91fsLeufs*5) variants (307) being the most common pathogenic alleles for each 
of the two genes. In Pakistan, variants in ten out of the 21 BBS-associated genes have 
been identified in 74 affected individuals from 28 BBS families (Table B2) (61, 80, 511, 
514-528), including two individuals from the current study family (Figure B2). Although 
ARL6 and TTC8 are minor contributors to BBS globally, within the Pakistani 
community, they account 13.3% and 12.0% of all BBS cases respectively, and are the 
two most commonly mutated genes associated with BBS in Pakistan (Figure B2). 
To date, there have only been two BBS5 variants associated with BBS in Pakistani 
families: a homozygous missense variant of the start codon [c.2T>A; p.(M1?)] likely 
resulting in either failure of protein translation or in the translation of an illegitimate 
transcript reported in two families (520), and a 11‐bp deletion [c.743_744del11; 
p.(Glu245Glyfs*18)] frameshift mutation likely resulting in loss of function in a further 
two families (524) (Table B2). The novel BBS5 variant identified in this study therefore 





Figure B2 Contribution of BBS genes to BBS globally and within Pakistani 
families  
Global figures derived from (529)  
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Table B2 Summary of all reported variants associated with BBS in Pakistan 










c.47+1G>T Affects splicing 1 (2) Central Punjab Ajmal et al (515) Not present 
 c.442G>A p.(Asp148Asn) 1 (2) Central Punjab Ajmal et al (515) Likely pathogenic 
(VCV000645579) 
 c.887delT p.(Ile296Thrfs*7) 1 (1) NA Billingsley et al (517) Pathogenic 
(VCV000193740) 
BBS2 c.443A>T p.(Asn148Ile) 1 (2) Bagh, AJ&K Ali et al (516) Not present 
(NM_031885.5) c.1237C>T p.(Arg413*) 2 (2) NA Harville et al (520); 




ARL6 c.123+1131_*25296del53985 53985bp deletion 1 (1) NA Chen et al (518) Not present 
(NM_177976.3) c.281T>C p.(Ile94Thr) 1 (7) Remote regions Khan et al (522) Likely pathogenic 
 c.534A>G p.(Gln178Gln) 1 (2) NA Maria et al (524) Not present 
BBS4 
NM_033028.5 
c.221-1G>A Affects splicing 1 (2) Quetta, 
Balochistan 
Personal 





c.2T>A p.(Met1Lys) 2 (2) NA Harville et al (520) Pathogenic 
(VCV000812118) 
 c.196delA p.(Arg66Glufs*12) 1 (2) Bannu, KPK Khan et al (61) – this 
study 
Not present 
 c.734_744del11 p.(Glu245Glyfs*18) 2 (3) NA Maria et al (524) Not present 
MKKS 
(NM_018848.3) 
c.119C>G p.(Ser40*) 1 (3) Nawab Shah 
City, Sindh 
Ullah et al (a) (528) Likely pathogenic 
(VCV000549478) 
 c.287C>T p.(Ala96Val) 1 (3) NA Ullah et al (b) (527) Not present 
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 c.775delA p.(Thr259Leufs*21) 1 (2) NA Ullah et al (b) (527) Pathogenic 
(VCV000866319) 
 
BBS7 c.580_582delGCA p.(Ala194del) 1 (3) KPK Ullah et al (a) (528) Not present 
(NM_176824.3) c.719G>T p.(Gly240Val) 1 (2) Peshawar, KPK Hayat et al (521) Not present 
 c.1592_1597delTTCCAG p.(Val531_Pro532del) 1 (3) AJ&K Ullah et al (a) (528) Pathogenic 
(VCV000030680) 
TTC8 c.235+1G>A Affects splicing 1 (2) NA Deveault et al (519) Not present 
(NM_198309.3) c.1019+2_1019+4del Affects splicing 2 (4) NA Harville et al (520); 
Ansley et al (80) 
Pathogenic 
(VCV000002529) 




c.299delC p.(Ser100Leufs*24) 3 (6) DI Khan, KPK Khan et al (523); 
Muzammal et al (525) 
Not present 
 c.1789C>T p.(Gln597*) 1 (1) NA Maria et al (524) Not present 
BBS10 
(NM_024685.4) 
c.271dupT p.(Cys91Leufs*5) 1 (2) AJ&K Ullah et al (a) (528) Pathogenic 
(VCV000001328) 
 c.1075C>T p.(Gln359*) 1 (5) Remote regions Khan et al (522) Not present 
 c.1958_1967del p.(Ser653Ilefs*4) 1 (2) Punjab Agha et al (514) Not present 
BBS12 c.1438delG p.(Arg480Metfs*3) 1 (3) NA Billingsley et al (517) Not present 
(NM_152618.3) c.1589T>C p.(Leu530Pro) 2 (2) NA Harville et al (520) Not present 
 c.2102C>A p.(Ser701*) 1 (3) NA Pawlick et al (526) Not present 
 
Abbreviations: AJ&K, Azad Jammu and Kashmir; BBS, Bardet-Biedl syndrome; KPK, Khyber Pakhtunkhwa; NA, not available. The novel BBS5 




APPENDIX C: GENETIC VARIANTS AND MAPPED LOCI ASSOCIATED WITH NON-
SYNDROMIC AND SYNDROMIC OCA IN PAKISTANI POPULATIONS  
Appendix Table C includes a summary of ClinVar entries and PubMed reports defining possible pathogenicity of each variant, as 
well as other genetic information including the number of families and affected individuals reported 
Gene Nucleotide 
variant 











TYR c.62C>T p.(Pro21Leu) Jaworek et al (193) Punjab  
[Sayyid] 
1 (15) No Not present 
TYR c.103T>C p.(Cys35Arg) Jaworek et al (193) Punjab  
[Malik; Malik Jutt] 
2 (10) No Not present 
TYR c.132T>A p.(Ser44Arg) Shaha et al (530);  
Ullah et al (531);  
Arshad et al (532); 
Unpublished 
KPK (Peshawar) 4 (13) No Not present 
TYR c.164G>C p.(Cys55Ser) Shahzad et al (186) Punjab  
[Sidhu jut] 
1 (3) No VUS 
(VCV000617794) 
TYR c.223G>T p.(Asp75Tyr) Shahzad et al (186) Punjab  
[Qureshi] 
1 (3) No Likely pathogenic 
(VCV000617795) 
TYR c.230G>A p.(Arg77Gln) Shaha et al (530) AJ&K 
[Khokar; Rajput] 
5 (20) Japanese (201, 223, 
226, 533-535); Korean 
(536, 537); Chinese 
(162, 189, 229); Iran 
(538); Caucasian 
(129); North European 
(131); Scottish (131); 
Italian (131); German 








TYR c.248T>G p.(Val83Gly) Gula et al (188) KPK (Swat) 
[Pashto] 
1 (1) No Not present 
TYR c.272G>A p.(Cys91Tyr) Shakil et al (540) Punjab (RYK) 
[Somro] 




TYR c.308G>A p.(Cys103Tyr) Shakil et al (540) Punjab (Sahiwal) 
[Khokar] 
1 (4) France (141) Not present 
TYR c.346C>T p.(Arg116*) Gulb et al (192);  
Shakil et al (540) 
Punjab (Lahore) 
[Pukhtun; Mughal] 
2 (3) Chinese (131, 162, 




TYR c.585G>A p.(Trp195*) Shahzad et al (186) Punjab  
[Gondal] 
1 (6) Indian (541) Likely pathogenic 
(VCV000617796) 
TYR c.593T>C p.(Ile198Thr) Shahb et al (542) NA 1 (4) No Not present 
TYR c.649C>T p.(Arg217Trp) Shahzad et al 
(186); Sajid et al 






8 (41) Caucasian (198) Pathogenic/ likely 
pathogenic/ VUS 
(VCV000003795) 
TYR c.667C>T p.(Gln223*) Unpublished KPK (Bunar) 
[Pashton] 
1 (2) No Not present 
TYR c.715C>T p.(Arg239Trp) Shaha et al (530);  
Shakil et al (540) 
Punjab (RYK) 
[Turk] 
2 (6) Japanese (199); South 
Indian (200); Chinese 
(189) 
Not present 
TYR c.826T>C p.(Cys276Arg) Bibi et al (205) KPK 1 (3) No Not present 
TYR c.832C>T p.(Arg278*) Shahzad et al 
(186); Jaworek et al 
(193);  
Bibi et al (205);  
Sajid et al (191); 
Forshew et al 
(543); Arshad et al 
(532); Shakil et al 





Rajput; Mula khel; 





22 (99) Guyana (194); 
Japanese (201, 226, 
227); Chinese (162, 
171, 189, 197, 202, 
228-230); Korean 
(231); Indian (131, 
215, 223-225); 
Canada (203); Irish 
(131); Italian (131); 
Mexican (131); South 
European (131); 









TYR c.895C>T p.(Arg299Cys) Gula et al (188) Punjab (Ranwal) 
[Saraiki] 
1 (2) Danish (146); Chinese 
(197);  
Not present 
TYR c.896G>A p.(Arg299His) Shahzad et al 
(186); Jaworek et al 





4 (15) Caucasian (198); 
Chinese (189, 197, 
230, 544, 545); Israeli 




TYR c.982G>C p.(Glu328Gln) Tripathi et al (194) NA 1 (1) No Not provided 
(VCV000099591) 
TYR c.1037G>T p.(Gly346Val) Sajid et al (191) Sindh 1 (4) Indian (223) Likely pathogenic 
(VCV000437986) 
TYR c.1037G>A p.(Gly346Glu) Shahzad et al (186) Punjab  
[Sahoo] 




TYR c.1147G>A p.(Asp383Asn) Shahzad et al (186) Punjab 
[Bangulzai] 
1 (4) Japanese (534); North 
European (131); 
French (131); German 
(131, 539); Norwegian 
(131); Irish (131); 
Caucasian (134, 547); 
Korean (536)  
Pathogenic 
(VCV000003775) 
TYR c.1204C>T p.(Arg402*) Shahzad et al (186) Punjab  
[Gujjar] 
1 (5) Israeli Arab Christian 
(232); East Indian 
(215); Chinese (189); 
France (153); English 
(131); Scottish (131); 
German (131, 539); 
Italian (131); Lebanese 
(131, 546); Hungarian 
(131); Irish (131); 
Polish (131); 





TYR c.1217C>T p.(Pro406Leu) Jaworek et al (193) Punjab  
[Malik Jutt] 
1 (6) France (153); Amish 
(548); Ashkenazi 




TYR c.1231T>C p.(Tyr411His) Jaworek et al (193) Punjab  
[Arain] 
1 (6) No Not present 
TYR c.1255G>A p.(Gly419Arg) Shahzad et al 
(186); Gula et al 
(188); Jaworek et al 
(193); 
Gulb et al (192); 
Tripathi et al (194); 
Sajid et al (191);  
King et al (131); 
Arshad et al (532); 























26 (94) Indian (207, 215, 224); 
Egyptian (131); 
German (539); 
Caucasian (547)  
Pathogenic 
(VCV000003792) 
TYR c.1424G>A p.(Trp475*) Gula et al (188) Punjab (Bhakkar) 
[Saraiki] 
1 (5) No Not present 
TYR c.1037-18T>G Affects splicing Shahzad et al (186) Sindh  
[Urdu-speaking] 
1 (4) No Likely pathogenic 
(VCV000617798) 
TYR c.1037-7T>A Affects splicing Shahzad et al 





6 (22) Chinese (189); France 
(153); Danish (131); 
North European (131); 









(131); German (131); 
















Shahzad et al 




2 (14) No Likely pathogenic 
(VCV000617797) 
TYR c.1002delA p.(Ala335Leufs*20) Unpublished Punjab (Lahore) 
[Mayo] 
1 (3) No Not present 
TYR Exon 4-5 del Frameshift Shahzad et al (186) Punjab  
[Jutt; Chakotaray] 
2 (23) South Indian (Vysya) 
(224) 
- 
OCA2 c.827T>A p.(Val276Glu) Sajid et al (191) AJ&K 1 (2) No Not present 
OCA2 c.877G>C p.(Glu293Gln) Sajid et al (191) AJ&K 1 (2) No Not present 
OCA2 c.954G>A p.(Met318Ile) Jaworek et al (193) Punjab  
[Warraich] 
1 (23) No Not present 
OCA2 c.1056A>C p.(Arg352Ser) Shahzad et al (186) Sindh  
[Sindhi-speaking] 
1 (11) No Not present 
OCA2 c.1064C>T p.(Ala355Val) Shahzad et al (186) Punjab  
[Chandia] 
1 (5) No Likely pathogenic 
(VCV000617804) 
OCA2 c.1075G>C p.(Gly359Arg) Shahzad et al (186) KPK  
[Saraiki-speaking] 
1 (11) No Likely pathogenic 
(VCV000452941) 
OCA2 c.1211C>T p.(Thr404Met) Shahzad et al (186) Punjab  
[Sayyid] 
1 (5) Nigerian (553) Likely pathogenic 
(VCV000211766) 
OCA2 c.1322A>G p.(Asp441Gly) Shahzad et al (186) Sindh  
[Sindhi-speaking] 
1 (4) No VUS 
(VCV000502704) 
OCA2 c.1327G>A p.(Val443Ile) Mauri et al (140); 
Arshad et al (532) 
Punjab  
[Saraiki] 









OCA2 c.1456G>T p.(Asp486Tyr) Shahzad et al 
(186); Jaworek et al 
(193); Sajid et al 










12 (61) No VUS 
(VCV000617806) 
OCA2 c.1580T>G p.(Leu527Arg) Jaworek et al (193); Punjab  
[Warraich] 
1 (23) No Not present 
OCA2 c.1762C>T p.(Arg588Trp) Arshad et al (532) Punjab  
[Saraiki] 
1 (1) No VUS 
(VCV000885235) 
OCA2 c.1922C>T p.(Ser641Leu) Shahzad et al (186) Punjab  
[Mughal] 
1 (4) No Likely pathogenic 
(VCV000617807) 
OCA2 c.2020C>G p.(Leu674Val) Arshad et al (532) KPK  
[Yousafzai] 
1 (2) East Indian (215) Pathogenic/ VUS 
(VCV000194918) 
OCA2 c.2207C>T p.(Ser736Leu) Unpublished NA 1 (1) Caucasian (208); 





OCA2 c.2228C>T p.(Pro743Leu) Shahzad et al 










OCA2 c.2359G>A p.(Ala787Thr) Jaworek et al (193) Punjab  
[Chohan] 









2 (6) Yes (210) Pathogenic/ likely 
pathogenic 
(VCV000617810) 
OCA2 c.2360C>A p.(Ala787Glu) Shahzad et al (186) Punjab  
[Langah Jutt] 
1 (9) No Likely pathogenic 
(VCV000617809) 
OCA2 c.2458T>C p.(Ser820Pro) Arshad et al (532) Punjab  
[Niaz] 
1 (2) No Not present 
OCA2 c.1045-15T>G Affects splicing Shahzad et al 








(193); Arshad et al 
(532); Unpublished 







OCA2 c.1182+2dupT Affects splicing Shahzad et al (186) Punjab  
[Arain] 
1 (3) No Likely pathogenic 
(VCV000617805) 
OCA2 c.1951+4A>G Affects splicing Shahzad et al (186) Sindh  
[Urdu-speaking] 









2 (4) No Not present 
OCA2 c.987delCins 
AGA 
p.(Gln330Aspfs*2) Shahzad et al (186) Sindh 1 (5) No Likely pathogenic 
(VCV000617801) 
OCA2 c.1960delG p.(Ala654Leufs*8) Lee et al (212) NA 1 (3) No Pathogenic 
(VCV000000957) 
OCA2 Exon 3-14 del Frameshift Shahzad et al (186) Punjab  
[Machi] 
1 (3) No - 
OCA2 Exon 7-8 del Frameshift Shahzad et al 




2 (8) No - 
OCA2 Exon 19 del Frameshift Shahzad et al 




4 (18) No - 
OCA2 Exon 20-24 
del 
Frameshift Shahzad et al (186) Punjab  
[Achakzai] 
1 (5) No - 
OCA2 Exon 22-24 
del 
Frameshift Shahzad et al (186) Punjab  
[Rajput] 
1 (3) No - 
TYRP1 c.256G>T p.(Asp86Tyr) Kausara et al (555) Punjab  
[Bhutta] 
1 (3) No Likely pathogenic 
(VCV000617811) 
TYRP1 c.1067G>A p.(Arg356Gln) Shahzad et al (186) Punjab  
[Langah; Haraaj; 
Matam] 







TYRP1 c.1120C>T p.(Arg374*) Forshew et al (543) NA 1 (8) No Pathogenic 
(VCV000017595) 
TYRP1 c.1534C>T p.(Glu512*) Shahzad et al (186) Punjab  
[Shaikh] 
1 (7) No Likely pathogenic 
(VCV000617812) 
TYRP1 c.647_668del p.(Glu216Glyfs*42) Kausara et al (555) Punjab  
[Ladd] 
1 (5) No Not present 
TYRP1 ~1 Mb del including whole gene Gula et al (188) KPK (Lakki 
Marwat)  
[Pashto] 
1 (2) No - 
SLC45A2 c.251T>C p.(Leu84Pro) Kausara et al (555) Punjab 
[Lakhat] 
1 (4) No Not present 
SLC45A2 c.1532C>T p.(Ala511Val) Shahzad et al 
(186); Gula et al 






4 (17) No Likely pathogenic 
(VCV000617813) 
SLC45A2 c.889-6T>G Affects splicing Kausara et al (555) Punjab 
[Rehmani] 
1 (3) No Not present 
SLC45A2 c.1331_dupA p.(Asn444Lysfs*5) Bibi et al (205) KPK 1 (2) No Not present 
OCA5 Mapped locus Kausarb et al (117) Punjab 1 (6) No - 








NA 1 (3) No Pathogenic 
(VCV000180629) 
HPS1 c.437G>A p.(Trp146*) Unpublished Punjab (Shadra) 
[Bhatti Rajpoot] 
1 (2) No Not present 
HPS1 c.517C>T p.(Arg173*) Unpublished KPK (Swabi) 
[Pashton, 
Yousafzai] 
1 (1) Chinese (402) Pathogenic 
(VCV000937794) 
HPS1 c.1342T>C p.(Trp448Arg) Yousaf et al (560) Punjab 1 (5) No Likely pathogenic 
(VCV000690341) 
HPS1 c.2009T>C p.(Leu670Pro) Unpublished KPK (Peshawar) 
[Pashton] 
1 (3) No Not present 




HPS1 c.1397+1G>A Affects splicing Unpublished Balochistan 
[Baloch] 
1 (1) No Not present 
HPS1 c.972delC p.(Met325Trpfs*6) Unpublished Puunjab (RYK) 
[Bukhari Sayyed] 




p.(Leu40Thrfs*7) Yousaf et al (560) Punjab 1 (5) No - 
HPS3 c.1509G>A p.(Met503IIe) Yousaf et al (560) Punjab 1 (4) No Likely pathogenic 
(VCV000627005) 
HPS4 c.276+5G>A Affects splicing Yousaf et al (560) Sindh 1 (5) No Not present 
HPS6 c.823C>T p.(Pro275Ser) Yousaf et al (560) Punjab 1 (5) No Likely pathogenic 
(VCV000690344) 
BLOC1S3 c.448delC p.(Gln150Argfs*75) Morgan et al (561) NA 1 (6) No Pathogenic 
(VCV000001489) 
BLOC1S6 c.232C>T p.(Gln78*) Yousaf et al (560) Sindh 1 (2) North Italian (562) Pathogenic 
(VCV000030412) 
 
Abbreviations: AJ&K, Azad Jammu and Kashmir; del, deletion; KPK, Khyber Pakhtunkhwa; NA, not available; RYK, Rahim Yar Khan; VUS, 





APPENDIX D: PRIMER PAIRS AND PCR CONDITIONS 
 
Table D1 Primer pairs used for sequencing the TYR coding exons and 
associated intron-exon junctions 
 




TYR_Exon 1_F TCAGCCAAGACATGTGATAATCA 60 992 
TYR_Exon 1_R TTATACCCTGCCTGAAGAAGTG 
TYR_Exon 2_F CAACATTTCTGCCTTCTCCTA 55 888 
TYR_Exon 2_R CTGCCTAGAATATTTTAAACAGG   
TYR_Exon 3_F GAATGAACAGGAGGGAACAC 58 470 
TYR_Exon 3_R TCTATTTAAATCCAATGAGCACGTT   
TYR_Exon 4_F TTCTGGAGGTTCAAAACTCAATG 58 675 
TYR_Exon 4_R ACAAAATGGCCTATGTTAAGCAA   
TYR_Exon 5_F TGTCTACTCCAAAGGACTGT 54 921 
TYR_Exon 5_R GGCACTTAGCTGGATGTGTT   
 
 
Table D2 Primer pairs used for sequencing the inherited eye disease gene 
variants identified in the study  
 




ALDH1A3_G414R_F CAGTCTCCAATGGCAATGCA 60 359 
ALDH1A3_R414R_R CACACACAGTCAACTCACCA 
ALDH1A3_c172dupG_F GGTGGACAAGATGGATAAGACG 58 300 
ALDH1A3_c172dupG_R GGCCAGTTCTGTCTTATAGCT   
ATOH7_c94delG_F GGAAGCCGAAGAGTCTCTGG 57 592 
ATOH7_c94delG_F GCACTCCCCCACTGTAAACT   
BBS1_M390R_F TTCCCCAGGCCTGTCTCTAT 60 539 
BBS1_M390R_R TCCGTCTTCCAGACGAGACT   
BBS5_ c196delA_F ACACATATGACTTGCTGGGAC 56 676 
BBS5_ c196delA_R TGGGATTAATCAAAACAGGGGA   
CYP1B1_R390H_F TCATCACTCTGCTGGTCAGG 58 388 
CYP1B1_R390H_R GAATTTTGCTCACTTGCTTTTC   
FRMD7_L148*_F ATCTCAGCGTTTCATGGAGC 57 237 
271 
 
FRMD7_L148*_R TGCAGCAGAACTTGGAGACT   
FYCO1_Q736*_F CTTAGCTGGCTCTGCACCTT 58 363 
FYCO1_Q736*_R CCAGATGGCAGAGAAGAAGG   
HPS1_W146*_F TGCTTGTGCCTTCATTCATT 56 388 
HPS1_W146*_R CCCCACTCCACAGTTAGAGC   
HPS1_R173*_F AGAGTAGAATGCCAGCAGCTT 64 243 
HPS1_R173*_R AGTGAATGTCCCCACTAGCC   
HPS1_L670P_F ACAGGATGCAAAGGCAGACT 60 240 
HPS1_L670P_R CCACAGCCTCACTCCTGAAT   
HPS1_c972delC_F ACAATGGAGCTGAGGGACAG 58 468 
HPS1_c972delC_R TTAGGATGAAGGGGTGTTGC   
HPS1_c1391+1_F GGGCATTACAGCAGAAGGGA 61 435 
HPS1_c1391+1_R CAAAAGTGAGCCCGGATCCT   
INPP5E_ Q627*_F AGGGTTGGCTTCCTTCCTG 58 392 
INPP5E_ Q627*_R GCCCTGGGTGTCCTCTTAAA   
LRP5_T359R_F GCCTGGCTGAGTATTTCCCT 58 580 
LRP5_T359R_R CCAGAATGACAGGTCCAGGT   
MKKS_H84Y_F TCGACAACCACAGGTCTCAG 60 240 
MKKS_H84Y_R TCCTCAGCTCTGCTCAGTCA   
OCA2_ V443I_F GGACTGGAATGCAGTGAGCT 64 321 
OCA2_ V443I_R TCTACGAGCCTGCTCACTCT   
OCA2_ D486Y_F CTTCCTCAGCTCTTGGTTGG 60 230 
OCA2_ D486Y_R ATACGAGCAAGCGCCTTAAA   
OCA2_ R588W_F TGGTTTTTGTCGTGCAACAA 64 578 
OCA2_ R588W_R CATCGACTGTGTGGGGAACA   
OCA2_ L674V_F ACAAATACGCAGTGCTGTCAG 62 320 
OCA2_ L674V_R TTCTGGGTGCCATCTGGTTG   
OCA2_ S736L_F TACACCTGTGAGTGCAGCAG 56 567 
OCA2_ S736L_R GTAAATGAGTGCTGCAGGCG   
OCA2_ Ala787V_F CCTGAAAAATTCCATGAAGGAG 58 196 
OCA2_ Ala787V_R CAAATCAAAGCCTGTGAGATGA   
OCA2_ S820P_F TCTGGAGGGGAATCTTGAGT 56 551 
OCA2_ S820P_R TGCACACAATGGAGGATGTC   
OCA2_c1045-15_F  AGTTCTGTGCACGATCTGGA 58 184 
OCA2_c1045-15_R TATGTGTCTGTGGGGTGTCC   
OCA2_c408delAA_F GTCTCCCTAGGCCCAGGTAA 62 501 
OCA2_c408delAA_R AGAGTGCACCACTGTCTGTG   
PAX6_R240*_F TGAATCACAAAGTGTGAAACTGC 64 206 
PAX6_R240*_R AGGTGGGAACCAGTTTGATG   
272 
 
SCAPER_c2236dup_F TTTGATCTCATGCTCCACTGT 56 401 
SCAPER_c2236dup_R AGCCCTTTAGACTATATGACCCT   
SDHD_E69K_F CTGCCTGTCAGTTTGGGTTA 58 243 
SDHD_E69K_R TTGCCAGTGACCATGAAGAG   
TDRD7_c2469delG_F GGATTTTAGCAAGGGTTTTGG 60 396 
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